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Various animal models of Alzheimer’s disease (AD) have been created to assist our appreciation of AD pathophysiology, as well
as aid development of novel therapeutic strategies. Despite the discovery of mutated proteins that predict the development of AD,
there are likely to be many other proteins also involved in this disorder. Complex physiological processes are mediated by coherent
interactions of clusters of functionally related proteins. Synaptic dysfunction is one of the hallmarks of AD. Synaptic proteins
are organized into multiprotein complexes in high-density membrane structures, known as lipid rafts. These microdomains
enable coherent clustering of synergistic signaling proteins. We have used mass analytical techniques and multiple bioinformatic
approaches to better appreciate the intricate interactions of these multifunctional proteins in the 3xTgAD murine model of AD.
Our results show that there are signiﬁcant alterations in numerous receptor/cell signaling proteins in cortical lipid rafts isolated
from 3xTgAD mice.
1.Introduction
Alzheimer’s disease (AD) is one of the most prevalent
neurodegenerativedisordersamongstadultsofadvancedage,
and it is the most common form of dementia and cognitive
impairment[1,2].ThebehavioralabnormalitiesinADresult
from dysfunction and death of neurons in brain regions
involved in cognition and mood, such as the hippocampus,
amygdala, and cortical regions. Progressive short-term and
eventual long-term memory loss and reduced cognitive
capacity are associated with two primary neurodegenerative
lesions, that is, extra- and intracellular β-amyloid plaques,
as well as neuroﬁbrillary tangles (NFTs) composed of the
microtubule protein tau [3–5]. In addition to the eﬀects of
amyloid plaques and NFTs, the lipid traﬃcking molecule,
apolipoprotein E4 (apoE4), has also been demonstrated to
be a genetic risk factor for AD [6, 7] .T h eA Dc h a r a c t e r i s t i c
extracellular plaques, found in both the hippocampus and
cortex of AD patients, consist of 39–42 amino acid long
amyloid-β (Aβ) peptides. These extracellular peptides are
generated by digestion of a transmembrane amyloid precur-
sor protein (APP). Proteolysis of the transmembrane APP by
a set of intramembrane enzymes, β- (also known as BACE-
1) and γ-secretases, is thought to be responsible for toxic
Aβ creation [5]. The discovery of familial mutations in the
APP gene that were strongly correlated with the presentation
of AD reinforced the importance of Aβ processing in
this disorder. A growing body of evidence indicates that
changes in lipid and cholesterol homeostasis can inﬂuence
AD progression and speciﬁcally Aβ production. One of
the prime sub cellular regions of amyloidogenic APP pro-
cessing is thought to be cholesterol-enriched membrane
microdomains, termed lipid rafts [8]. Cellular organization
of protein signaling complexes, to enhance the magnitude
and ﬁdelity of transmembrane signaling receptors, is facil-
itated by variations in the lipid constituents of the plasma
membrane. Lipid rafts represent discontinuous regions of
the plasma membrane that form functional microdomains,2 International Journal of Alzheimer’s Disease
which constrain the association of proteins in a coherent
and advantageous manner with respect to neurotransmissive
signaling [9]. Disruption of the correct stoichiometry of
signaling complexes within lipid rafts may underpin the
etiology of many diﬀerent neurodegenerative disorders [10–
12]. The hypothesis that changes in the lipid composition
of rafts contribute to AD pathology has gained considerable
support. For example, ApoE4 has been strongly correlated
with the generation of AD symptomatology. Both of the
amyloidogenic processing enzymes (β-a n dγ-secretase),
as well as APP, are all enriched in lipid raft membranes
[13, 14]. Reinforcing the connection between lipid density
levelsandAβproduction,increasingcholesterollevelselevate
the activity of both β-secretase (BACE-1) and γ-secretase
[14, 15]. In addition, ganglioside lipids, which are also
enriched in lipid rafts, can control the assembly of amyloid-
β proteins [16, 17]. Changes in ganglioside composition,
similar to those noted in human AD patients, are also
observed in diﬀe r e n tt r a n s g e n i cm o u s em o d e l so fA D[ 18].
In addition to a role of the lipid components of lipid rafts
in controlling amyloidogenesis, these raft environments may
also aﬀect NFTs as well. It has been demonstrated that
Aβ can induce activation of the tyrosine kinase Fyn in
neuronal cells, that is then recruited to lipid rafts which
catalyzes phosphorylation of tyrosine residue 18 on tau [19,
20]. Association of Aβ plaques to lipid rafts can mediate
recruitment of excess Fyn to the rafts, as well as further
recruitment and phosphorylation of tau. These activities are
thoughttoinduceneurotoxicityviatheeﬀectsoftau-induced
changes in the actin cytoskeleton and receptor/cellular
signaling pathways [21]. Therefore, the potential changes in
the lipid composition of lipid rafts, caused by exposure to
cytotoxicactivitiescharacteristictoAD,caninduceprofound
changes in cellular signal transduction and thereby induce
intracellular changes that lead to the development of AD.
The complexity of protein complexes within the lipid raft
environments raises considerable challenges to understand-
ing the molecular mechanisms of AD pathophysiology in
both the hippocampus and cortex of animals. Therefore,
we have employed a shotgun proteomics approach, allied to
advanced bioinformatic functional proﬁling, to gain a broad
and detailed appreciation of the alterations in signaling
proteins in lipid rafts in the triple-transgenic (3xTgAD)
model of AD [22]. Our study demonstrates that cortical lipid
rafts are profoundly aﬀected in the 3xTgAD mice and that
many of the neurophysiological deﬁcits characteristic of AD
(impaired synaptic strength, impaired learning and memory,
and increased oxidative stress) can be strongly linked to
changes in receptor and cell signaling events in the lipid rafts
in these animals. Therefore, the lipid raft environments can
be seen as one of the most important pathophysiological loci
of this disorder.
2. Methods
2.1. Animals and Morris Water Maze Testing. Animal care
and experimental procedures followed NIH guidelines and
were approved by the National Institute on Aging Animal
Care, and Use Committee. Experiments were performed
using male 3xTgAD [22–24] and control male C57-BL6
mice that were maintained under a 12-hour light/12-hour
dark cycle with continuous access to food and water. Water
maze testing took place using a modiﬁed version of the
methodologydescribedpreviously[25].Brieﬂy,animals(n =
10 per group, control male C57-BL6 or male 3xTgAD,
on a C57-BL6 background) received 8 days of acquisition
trainingusinganonvisibletargetplatform,consistingoffour
trials per day, with an intertrial interval of approximately
10 minutes. Each trial lasted until the animal found the
platform, or for a maximum of 60 seconds; animals that
failed to ﬁnd the platform within 60 seconds were guided
there by the experimenter. On each trial, mice were placed
into the pool, facing the wall, with start locations varied
pseudorandomly. Distance swam to escape the water, escape
time, and swim speed were measured for either control or
3xTgAD mice using a HVS2020 automated tracking system
(HVS Image, UK).
2.2. Isolation of Lipid Raft Detergent-Resistant Membranes.
The mice were anesthetized with isoﬂurane, decapitated, and
the brain was microdissected on ice. After removal of the
cortex,thetissuewassplitintoleftandrighthemisphere,half
for mass spectrometry raft analysis and half to prepare lipid
raft tissues for Western blot analysis. The hemicortices were
washedtwiceinice-coldphosphatebuﬀeredsaline(PBS)and
then transferred into a Tris-saline buﬀer supplemented with
a cocktail of protease and phosphatase inhibitors (50mM
Tris-HCl,150mMNaCl,5mMEDTA,andRocheComplete-
Mini (Roche Diagnostics Inc.) protease and phosphatase
inhibitor cocktail, pH 7.4). Crude tissue disruption was then
rapidlyachieved(at4◦C)usingasonicdismembrator(Fisher
ScientiﬁcModel100)followedbyabriefcentrifugation(4◦C,
1000×g,10minutes)topelletcellnucleiandunbrokencells.
The resultant supernatant was removed and Triton X-100
(Sigma Aldrich, USA) was added to the Tris-saline buﬀer to a
ﬁnal concentration of 1%. The supernatant membranes were
then incubated at 4◦C for 60 minutes in the Triton X-100
Tris-saline solution. After incubation, the supernatant solu-
tion was then added to a discontinuous gradient of 30% and
60% OptiPrep (Iodixanol, Sigma Aldrich, and U.S.A.) before
centrifugation at 200 000×gf o r1 6h o u r sa t4 ◦C. After cen-
trifugation, a detergent-resistant lipid band was evident in
the vertical solution column. Multiple fractions of 300μlv o l -
umeswerethenremovedfromtheverticalcentrifugationcol-
umn. Proteins werethen extracted fromthese fractionsusing
a proprietary ProteoExtract (EMD Biosciences) kit, accord-
ing to the manufacturer’s instructions. Isolated protein
pellets were then prepared for mass spectrometric analysis.
2.3. Mass Spectrometric Protein Analysis. Protein pellets
were dissolved into an ammonium bicarbonate buﬀer
(100mM, pH 8.5) and then reduced with dithiothreitol
(500mM: Pierce Biotechnology), alkylated with iodoac-
etamide (800mM: Sigma Aldrich) and then digested with
modiﬁed trypsin (5–10μg) (Promega) at 37
◦C for 17 hours.
Proteolysis was terminated by the addition of glacial acetic
acid. Tryptic peptides were then loaded onto a desaltingInternational Journal of Alzheimer’s Disease 3
column (360 ×200μm fused silica packed with 15cm of C18
beads (YMC ODS-AQ, Waters)), washed with 0.1% acetic
acid and eluted into sample tubes with 80% acetonitrile
in 0.1% acetic acid. Sample volume was reduced to usable
volumes under vacuum on a Savant SpeedVac. Samples
were then transferred onto a PicoFrit (75 × 100mm)
column packed with ProteoPep II C18, 300 ˚ A, 5μmp a r t i c l e s
(New Objective) connected to a nanoliquid chromatography
system (Dionex, Sunnyvale, CA) online with an LTQ ion trap
mass spectrometer (Thermo Finnigan, San Jose, CA). The
peptides were eluted using a linear gradient of 0–65% ace-
tonitrile over 90 minutes at a ﬂow rate of 250nl/min directly
into the mass spectrometer, which was operated to gener-
ate collision-induced dissociation spectra (data-dependent
MS/MS mode). The resultant tandem mass spectrometry
data were processed using the BioWorks suite, and multiple
collected spectra were used to interrogate the NCBI nonre-
dundant mouse and Swiss-Prot protein sequence databases,
using the computer algorithm SEQUEST to generate accu-
rate protein identities. Protein genpept accession identities
were then converted to Oﬃcial Gene Symbol terms using
NIAID-DAVID v. 6.7 (http://david.abcc.ncifcrf.gov/). The
statistical analysis and validation of the search results were
performed using MASCOT (Matrix Science). For protein
identiﬁcation, a maximum of three missed tryptic cleavages
was used, including ﬁxed modiﬁcation of carbamidomethy-
lationandvariablemodiﬁcationsofoxidizedmethionineand
N-terminalglutamineconversiontopyroglutamicacidinthe
search.Onlyproteinswithatleasttwovalidatedpeptidesand
a total score 25 and a conﬁdence of identiﬁcation of at least
95% were considered valid for reporting. Where required,
additional spectral counting was performed to determine
simplistic relative quantitation in conjunction with the
reported number of identiﬁed unambiguous peptides per
protein. Three lipid raft fraction samples (fractions 2, 3,
and 4) from each three control (nontransgenic gender/age
matched C57-BL6) or Alzheimer’s disease (3xTgAD) were
pooled and then run in an individual random order. Proteins
identiﬁed based on two unambiguous peptides that were
present in at least two out of the three individual animals
were employed for further expression pattern analysis.
2.4. Lipid Raft Band Quantiﬁcation. Digitized images of
centrifugal vertical ﬂuid columns were obtained using a
Canon Digital camera and were converted from Joint
Photographic Experts Group (JPG) ﬁles to a TIFF (Tagged
Image File Format) form using L-Process v. 2.2 (image
handling software: Fuji-Film). Image densitometry was then
performed using Fuji-Film Image Gauge v. 4.2. Lipid raft
band intensity was represented as a relative absorbance unit
(AU)valuewithbackground (B)subtractionpersquarepixel
(px2) (AU-B/px2).
2.5. Western Blotting Procedures. For the examination of
speciﬁc proteins in cortical cell samples (both lipid raft
and nonlipid raft), aliquots were removed from centrifugal
fractions from Section 2.2 and their protein concentration
was determined with a standard BCA protocol. Aliquot
samples for western blotting analysis were then mixed with
an equal volume of Laemmli sample buﬀer [26]. Samples
were resolved using one-dimensional gel electrophoresis
(SDS-PAGE), followed by electrotransfer to polyvinylened-
iﬂuoride (PVDF: PerkinElmer, Waltham, MA). PVDF mem-
branes were blocked for one hour at room temperature
in 4% nonfat milk (Santa Cruz; Santa Cruz, CA) before
application of speciﬁc primary antisera in the same nonfat
milk. The presence of primary antibody reactivity with
the PVDF membrane was detected by the application of a
1:5000 dilution of a species-speciﬁc alkaline phosphatase-
conjugated secondary antibody (Sigma, St. Louis, MO).
PVDF-bound immune complexes of secondary and primary
antibodies were subsequently detected using enzyme-linked
chemiﬂuorescence (ECF: GE Healthcare; Pittsburgh, PA).
Chemiﬂuorescent signals from the membranes were cap-
tured and quantiﬁed using a Typhoon 9410 phosphorimager
(GE Healthcare, Pittsburgh, PA). Speciﬁc primary antisera
used were obtained from the following sources: ﬂotillin-1,
proline-rich tyrosine kinase 2 (Pyk2), focal adhesion kinase
(FAK), G protein-coupled receptor kinase interactor-1 (GIT-
1),andpaxilinantibodieswereobtainedfromBDBioscience,
San Jose, CA; Janus kinase 2 (Jak2), v-Crk avian sarcoma
virus CT10 oncogene homolog (Crk), and insulin receptor
substrate-1 (IRS1) antibodies were obtained from Santa
Cruz Biotechnology Corporation, CA; caspase-7, FKBP12-
rapamycin complex-associated protein 1/mammalian target
of rapamycin (FRAP1/mTOR), and Fyn and IGF-1 receptor
beta antibodies were obtained from Cell Signaling Technol-
ogy, Danvers, MA); G protein-regulated inducer of neurite
outgrowth 2 (Grin2) antibody was obtained from Sigma
Aldrich. For the identiﬁcation of nonspeciﬁc total proteins
in each sample the highly sensitive protein dye, SYPRO Ruby
(Invitrogen Corporation) was employed. Fixed SDS-PAGE
gels were immersed in SYPRO-Ruby for 1 hour and then
washed in deionized water before scanning using a Typhoon
9410 phosphorimager (GE Healthcare, Pittsburgh, PA).
2.6. Bioinformatic Analyses. Protein identities were con-
verted to standard gene symbol nomenclature for simplicity
of usage with the batch conversion tool of NIH Bioinformat-
ics Resources DAVID v. 6.7 (http://david.abcc.ncifcrf.gov/).
Primary protein sets (containing consistently identiﬁed
lipid raft extract proteins) were organized into functional
signaling pathway groups and then analyzed for their diﬀer-
ential signiﬁcance of population of these canonical signaling
pathways. To compare the relative degree of association of
speciﬁc signaling pathways with the control or 3xTgAD
protein sets, the diﬀerence between the signaling pathways
“hybrid scores” was calculated (control subtracted from
3xTgAD). The magnitude of the “hybrid score” is indicative
of strength and signiﬁcance of association of the input
protein set with the speciﬁc signaling pathway. Signaling
pathway hybrid scores were generated using a process that
takes into account the signiﬁcant population and potential
activation of that pathway by multiplying the pathway
enrichment ratio (percentage of proteins in a designated
pathway that were also found in the experimental dataset)4 International Journal of Alzheimer’s Disease
and the probability (P) that the respective pathway is sig-
niﬁcantlyassociatedwiththeexperimentaldataset.However,
to create a simple numerical value, the hybrid pathway score
is calculated by multiplication of the ratio with the negative
log−10 of the P value. Each signaling pathway considered
was required to contain at least two unique proteins from
either control or 3xTgAD datasets and possess a P value
of ≤.05. Unbiased network analysis was also performed on
subsets of the primary protein sets that were speciﬁcally
limited to transmembrane receptor proteins. The networks
generated create predictions of the most likely functional
interactions between proteins in a complex dataset [27].
Networks are created to indicate the most signiﬁcant series
of molecular interactions. The networks with the highest
predictive “scores” possess the highest number of statistically
signiﬁcant “focus molecules”: “focus molecules” are proteins
that are present in the most statistically-likely predicted
functionalnetworkandarepresentintheinputexperimental
dataset. The network “score” is a numerical value used to
rank networks according to their degree of relevance to
the input dataset. The “score” accounts for the number
of experimental focus molecules (proteins) in the network
and its size, as well as the total number of proteins in the
Ingenuity Knowledge Base that could potentially be included
in the speciﬁc networks. The network “score”i sb a s e do n
the hypergeometric distribution and is calculated with the
right-tailed Fisher’s Exact Test. Speciﬁc scientiﬁc textual
associations between ﬁltered protein sets (transmembrane
receptor proteins IPA analysis) and Alzheimer’s disease pro-
cesseswerecreatedusinglatentsemanticindexing(LSI)algo-
rithms using GeneIndexer (Computable Genomix, Incorpo-
rated: https://www.computablegenomix.com/geneindexer).
GeneIndexer correlates the strength of association between
speciﬁc factors (proteins) in a dataset with a user-deﬁned
interrogation term. GeneIndexer employs a 2010 murine
or human database of over 1 × 106 scientiﬁc abstracts to
perform text-protein correlation analysis. LSI facilitates the
speciﬁc textual interrogation of an input dataset with a
speciﬁc term, that is, Alzheimer’s disease, to ascertain which
of the input dataset proteins are explicitly associated with
the interrogation term. Using LSI algorithms, not only is
the direct interrogation term used to analyze the input
datasetbutalsocloselycorrelatedadditionalterms,implicitly
associated with the user-deﬁned interrogation term, are also
employed in the search patterns. A latent semantic indexing
correlation score indicates the strength of association of
the interrogation term and the speciﬁc proteins in the
dataset. A highly relevant protein-term correlation yields a
large number of explicitly/implicitly associated proteins with
high LSI correlation scores. Therefore, a strong correlation
between the proteins in a dataset and a speciﬁc user-deﬁned
interrogation term yields a large number of correlated
proteins with high LSI correlation scores.
3.StatisticalAnalysis
Statistical analysis on multiple samples was performed using
a standard nonparametric two-tailed Student’s t-test using
95% conﬁdence limits. Analyses were computed using built-
in software in GraphPad Prism v. 3.0a (GraphPad Software
Inc., La Jolla, CA). Results are expressed as means ± SE.
P ≤ .05 was considered statistically signiﬁcant. For statistical
analysis using Ingenuity Pathway Analysis v. 8.5 of signaling
pathwaysandinteractionnetworkanalysis,Fisher’sExacttest
w a se m p l o y e dw i t haP ≤ .05 cutoﬀ. Network interaction
scores were generated using a right-tailed Fisher’s Exact Test.
4. Results
4.1. 3xTgAD Mice Demonstrate Impaired Learning and Mem-
ory Ability in the Morris Water Maze. Using the nonvisible
Morris water maze trial and 16-month-old male control
(C57-BL6) and 3xTgAD animals (n = 10 for both) we noted
that the 3xTgAD mice demonstrated a signiﬁcant reduction
in their ability to ﬁnd the location of the hidden platform
(Figure 1). The 3xTgAD mice demonstrated signiﬁcantly
longer escape latencies and distances traveled compared to
thecontrolmice,whilenotshowinganysigniﬁcantdiﬀerence
in calculated swim speed. Retention testing (three trials one
week after the initial training) of these animals (control and
3xTgAD) also demonstrated a reduced cognitive capacity of
the 3xTgAD mice compared to control (data not shown).
4.2. 3xTgAD Mice Demonstrate a Signiﬁcant Alteration
in Lipid Raft Density and Protein Marker Composition.
Employment of the lipid raft isolation process described in
the Methods section resulted in the clear visible isolation
of a detergent-resistant lipid layer comprising centrifugal
fractions 2–4 (Figure 1(a)). The lipid raft marker protein,
ﬂotillin-1, was demonstrated to be speciﬁcally enriched in
these centrifugal fractions (2–4) (Figure 2(a)). The visual
lipid density (absorbance units-background/square pixel) of
the raft layers was quantiﬁed using Fuji-Film Image Gauge.
Compared to control, both 8-month-old (Figure 2(c))a n d
16-month-old (Figure 2(d)) 3xTgAD-derived centrifugal
raft layers demonstrated a signiﬁcant (8 months old P =
.027, n = 3; 16 months old P = .031, n = 3) increase in
buoyant detergent-insoluble density. This 3xTgAD increase
in raft size, compared to control animals, demonstrated a
strong association with a signiﬁcant increase in expression
of ﬂotillin-1 in the raft fractions of 3xTgAD mice, especially
in centrifugal fraction 2 (Figure 2(e), P = .017, n = 3).
Equal levels of total protein (measured using BCA and also
SYPRO gel staining) were employed for each Western blot
of the raft extracts. Quantiﬁcation of fraction 2 was chosen,
as this reliably indicated the greatest enrichment of this lipid
raft marker. Similar quantitative alterations in expression of
ﬂotillin-1 between control and 3xTgAD mice were also seen
in the additional lipid raft centrifugal fractions, that is, 3
and 4. Qualitatively similar results, with respect to 3xTgAD
mouse lipid raft density and ﬂotillin-1 expression were noted
in parallel experiments carried out with age-matched female
mice. In addition we also noted a similar qualitative lipid raft
expression of ﬂotillin-1 trend in male human cortex tissue
(data not shown). These latter data and their signiﬁcanceInternational Journal of Alzheimer’s Disease 5
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Figure 1: Morris Water Maze testing of control and 3xTgAD mice. (a) Distance travelled (cm) in the nonvisible probe target results for
control (n = 10, blue bars) and 3xTgAD mice (n = 10, red bars) for 8 days of training. (b) Water maze escape latency (s) for days 1 to 8
of training in the nonvisible probe target. (c) Swim speed (cm/s) assessment of control and 3xTgAD animals during days 1–8 of training.
∗P<. 05; ∗∗P<. 01.
to our current data will be further addressed in subsequent
manuscripts.
4.3. Diﬀerential Protein Expression in Lipid Rafts Isolated
from 3xTgAD Mice Compared to Control Mice. Using an
un-biased proteomic analysis of replicate lipid raft extracts,
we were able to identify (from at least two individual
nonambiguous peptides) multiple proteins in both con-
t r o la n d3 x T g A Dc o r t i c a le x t r a c t s( c o n t r o l ,Appendix A;
3xTgAD, Appendix B). When comparing the relative diﬀer-
ences in lipid raft protein expression, only a small minority
(17%: Figure 3(a)) of identiﬁed proteins were substantively
identiﬁed in both control and 3xTgAD raft samples; however
manyofthesecommonproteinsidentiﬁedwerediﬀerentially
detected (see Supplementary Table 1 in Supplementary
Material available online at doi:10.4061/2010/604792). To
verify the relative diﬀerential expression of multiple proteins
in the control versus 3xTgAD lipid raft extracts, we also
performed multiple Western blot analyses of raft centrifugal
fraction-2 (F-2) samples. With loading of total equal protein
quantities (50μg: assessed in an unbiased manner with
SYPRO-Ruby: Figure 3(b)) of either control or 3xTgAD
F-2 samples, we assessed the relative diﬀerential expres-
sion of multiple proteins (Figures 3(c)–3(n)). From the
Western blot analysis it was consistently demonstrated that6 International Journal of Alzheimer’s Disease
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Figure 2: Quantiﬁcation of detergent-resistant lipid rafts. (a) The pictorial panel depicts an image of iodixanol-separated detergent resistant
membrane fractions (centered on red arrow), captured using a Nikon 3200 digital camera. The line diagram indicates the direction of
collection of centrifugal fractions 1–10, and the associated Western blot for ﬂotillin-1 demonstrates its enrichment in the raft fractions.
(b) Captured Joint Photographic Expert Group (JPG) images were converted to a Tagged Image File Format (TIFF) version and imported
to Image Gauge (v4.2) software and the speciﬁc area of interest (red box), that is, the detergent-resistant, ﬂotillin-1-rich lipid raft band
was quantiﬁed into absorbance units minus background absorbance per square pixel area ((AU-B)/px2)v a l u e s .( c )R e p r e s e n t a t i v es e to f
male 8-month-old control (1) and 3xTgAD (2) mice detergent-resistant membranes isolated from plasma membrane fractions separated
using an Iodixanol gradient. The associated histogram depicts mean ± s.e. (standard error) mean detergent-resistant membrane intensity
((AU-B)/px2) from at least three separate control and 3xTgAD mice (P = .033, nonpaired, two-tailed t-test). (d) Representative set of male
16-month-old control (1) and 3xTgAD (2) mice detergent resistant membranes isolated from plasma membrane fractions separated using
an Iodixanol gradient. The associated histogram depicts mean ± s.e. (standard error) mean detergent resistant membrane intensity ((AU-
B)/px2) from at least three separate C57-BL6 and 3xTgAD mice (P = .0224, non-paired, two-tailed t-test). (e) Representative ﬂotillin-1
Western blot for the lipid raft fraction series for 3xTgAD (red outline) or control (C57-BL6: blue outline) mice. The associated histogram
depicts mean ± s.e. (standard error) mean fraction 2 ﬂotillin expression intensity ((AU-B)/px2) from at least three separate C57-BL6 and
3xTgAD mice (P = .015, non-paired, two-tailed t-test).
diﬀerential qualitative protein detection in control versus
3xTgAD raft samples strongly correlated with diﬀerential
semiquantitative protein expression. Hence, the absence
of consistent MS-based detection of Pyk2 (Figure 3(d)),
Jak2 (Figure 3(f)), Fyn (Figure 3(h)), paxilin (Figure 3(i)),
IRS-1 (Figure 3(j)), caspase 7 (Figure 3(k)), mTOR/FRAP1
(Figure 3(l))andIGF-1R(Figure 3(n))incontrolraftsample
correlated to their signiﬁcantly lower expression in control
raft F-2 samples, compared to that in 3xTgAD samples.
Conversely, the absence of consistent MS-based detection of
FAK (Figure 3(c)), GIT-1 (Figure 3(e)), Crk (Figure 3(g)),
and Grin2 (Figure 3(m)), correlated to their signiﬁcantly
lower expression in 3xTgAD raft F-2 samples, compared to
that in control samples.International Journal of Alzheimer’s Disease 7
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Figure 3: Diﬀerential protein expression in control versus 3xTgAD lipid raft extracts. (a) Proportionately drawn Venn diagram analysis of
reliably identiﬁed proteins from control lipid rafts (blue line) and 3xTgAD rafts (red line). (b) Total protein loading control for centrifugal
fraction 2. A total of 50mg of fraction 2 protein was loaded and stained with SYPRO Ruby and scanned using a phosphorimager. (c)–(n).
Representative western blots from multiple expression analysis experiments for diﬀerential presentation of proteins in fraction 2 extracts
from control (blue) or 3xTgAD mice (red). Associated with each panel (c)–(n) the associated histograms represent the mean ± s.e. mean of
protein expression intensity (measured in ((AU-B)/px2)) from at least three separate experiments. ∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001. Protein
abbreviations are as follows. FAK: focal adhesion kinase; Pyk2: proline-rich tyrosine kinase 2; GIT-1: GRK interactor-1; Jak2: Janus kinase
2; Crk: v-Crk avian sarcoma virus CT10 oncogene homolog; Fyn: Fyn tyrosine kinase; IRS-1: insulin receptor substrate-1; casp 7: caspase 7;
mTOR: mammalian target of rapamycin; Grin2: G protein-regulated inducer of neurite outgrowth 2; IGF-1R: insulin-like growth factor-1
receptor.8 International Journal of Alzheimer’s Disease
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Figure 4: Functional pathway informatic clustering of control and 3xTgAD lipid raft proteins. (a) Subtractive representation of hybrid score
generation after clustering of lipid raft proteins from control and 3xTgAD animal rafts into cellular signaling pathways. The hybrid scores
were generated by multiplication of the protein enrichment ratio of the speciﬁc pathway with the negative log10 (−log10) of the probability of
that enrichment (see Section 2). The data is presented as a numerical value of the control pathway hybrid score subtracted from the 3xTgAD
pathway hybrid score. Pathways in which the score in 3xTgAD was greater than the control are denoted in red; pathways in which the control
hybrid score is greater than the 3xTgAD hybrid score are denoted in blue. A similar depiction format is employed for diﬀerential analysis of
control versus 3xTgAD Neuronal Function pathways (b), Energy Regulation/Metabolism pathways (c), and Stress Response pathways (d).
4.4. Functional Signaling Cluster Analysis of Control versus
3xTgAD Lipid Raft Proteomes. As our MS-based multidi-
mensional protein identiﬁcation process identiﬁed several
hundred proteins from each control or 3xTgAD lipid raft
sample, we employed a bioinformatic analysis process to
assess the relative functionalities of both the control versus
3xTgAD raft protein lists. As the majority of cellular
signaling processes are mediated and regulated by multiple
groups of proteins interacting with each other, we clustered,
in a statistically signiﬁcant manner, proteins in control
or 3xTgAD animal raft samples into functional signaling
groups.Toassesstherelativechangesinregulationofclassical
signaling pathways, we applied a subtractive approach for
the pathway “hybrid” scores (indicative of the “activity”
of the speciﬁc signaling pathway: calculated by signiﬁcant
expression enrichment ratio of proteins in that pathway
multiplied by the negative log10 (−log10) of the probability
of the pathway enrichment). For each speciﬁc common
signaling pathway, our mathematical approach subtracted
control pathway “hybrid” scores from the pathway “hybrid”
scores generated from the 3xTgAD protein set. Hence, a
positive result of this subtraction indicates a greater activity
ofthisfunctionalpathwayin3xTgADanimals,andanegative
score indicates a greater activity of this functional pathway
in the control animals. Analysis of pathways involved in
cellular signaling (Figure 4(a): proteins and scores in asso-
ciated Appendix C) demonstrated that pathways commonly
associated with cell stress responses were highly activated in
3xTgAD rafts, for example “p53 signaling”, “p38 mitogen-
activated protein kinase (MAPK) signaling”, and “stress-
activated protein kinase (SAPK)/JNK pathways”. In a stark
contrast, prosurvival synaptic connectivity and neurotrans-
missive pathways were more profoundly activated in the
controlmice,forexample,“tightjunctionsignaling”,“calcium
signaling”, “PTEN signaling”, and “Wnt/β-catenin signaling”.
To investigate the speciﬁc neuronal functional eﬀectsof these
disparate signaling activities, we next studied the signiﬁcant
clustering of raft proteins into neuron-functional path-
ways (Figure 4(b): Appendix D). As one would expect, the
3xTgAD mice raft protein clustering revealed a considerablyInternational Journal of Alzheimer’s Disease 9
greater (relative to control) activation of multiple neurode-
generative neuronal processes including: “amyloid process-
ing”,“ Amyotrophic lateral sclerosis”,“ Huntington’s disease sig-
naling”a n d“ Parkinson’s signaling”. In addition to the greater
activation of these degenerative processes, the 3xTgAD
mice also demonstrated profound changes in the signiﬁcant
clustering of proteins into cytoskeletal remodeling groups
(“actincytoskeleton signaling”, regulationof actin-based motil-
i t yb yR h o ’ ) compared to the control mice. In accordance
with our demonstration of the signiﬁcant diminution of
the learning and memory ability of the 3xTgAD mice, it
was striking to notice the profoundly greater activation of
neuron-functional pathways that control synaptic learning-
dependent processes (i.e., “synaptic long-term depression”,
“axonal guidance signaling”,and “synaptic long-term potenti-
ation”) in the control mice compared to the 3xTgAD mice.
Considerable evidence from multiple experimental studies
has recently underlined the importance of the regulation
of energy metabolism in controlling the aging process and
neurodegenerative disorders [28–30]. Upon inspection of
the relative diﬀerences in the activation of energy-regulatory
pathways created by clustering of control raft proteins versus
3xTgAD raft proteins, a profound functional distinction
was noted (Figure 4(c): Appendix E). In control animals
versus 3xTgAD, there was a considerably stronger activation
of energy-generating pathways connected to the use of
the primary metabolic substrate, that is, sugars (“amino
sugars metabolism”,“ glycolysis/gluconeogenesis”,a n d“ pentose
phosphate pathway”). In contrast, the energy regulatory
pathways that were more strongly associated with the
3xTgAD animals involved energy derivation from alternative
energy sources, for example, “synthesis and degradation
of ketone bodies”, “butanoate metabolism”, and “fatty acid
biosynthesis”. Many of the alterations in energy regulation
in aging and degenerative disorders are thought to be
associated with adaptive responses to the induction of
cellular stresses, potentially through toxic eﬀects of Aβ,N F T s
and accumulated oxidative damage [30]. When the raft
proteins from control and 3xTgAD mice were clustered into
functional stress response pathways, again a stark contrast
in the control- or 3xTgAD-associated pathways was demon-
strated (Figure 4(d): Appendix F). In the 3xTgAD mice
raft clustering it was noted that the association of energy-
associated stressful and neuronal damage-related pathways
(“PPARα/RXRα activation”,“ hypoxia signaling”,“ apoptosis
signaling”,a n d“ endoplasmic reticulum stress pathway”)w a s
considerably stronger than in the control mice. Indicating a
correlated connection between stress response capacity and
AD pathology, there was a considerably greater association
of the “Nrf2-mediated oxidative stress response pathway”
in control mice compared to the 3xTgAD. Therefore, the
3xTgAD mice may demonstrate excessive neuronal stress
and damage due to the attenuated activation of such stress
response pathways in lipid rafts of AD synapses.
4.5. Functional Receptor Signaling Cluster Analysis of
Control versus 3xTgAD Lipid Raft Proteomes. As one
of the most important functions of synaptic lipid rafts
is to congregate transmembrane or juxtamembrane
receptor systems [31], we next performed an in-depth
investigation of the signiﬁcant diﬀerential functional
clustering of receptor signaling pathways between control
and 3xTgAD rafts. Upon functional clustering of the
raft proteins into receptor signaling pathways, strong
diﬀerences in pathways association between control
a n d3 x T g A Dm i c ew e r en o t e d( Figure 5: Appendix G).
Some of the strongest diﬀerences were noted by the
considerably poorer activation of growth factor-related
signaling (“PDGF signaling”,“ EGF signaling”, and “FGF
signaling”), structural trans-synaptic receptor signaling
(“Neuregulin signaling” and “Ephrin receptor signaling”),
excitatory signaling (glutamate receptor signaling)a n d
neurodevelopmental signaling (Sonic hedgehog signaling)
pathways in the 3xTgAD mice, compared to the control
mice. The receptor signaling proﬁle of the 3xTgAD mice
demonstrated a more profound association compared to
control mice for pathways linked to inhibitory synaptic
signaling (“GABA receptor signaling”a n d“ Aryl hydrocarbon
receptor signaling”: [32]), amyloid processing (“Notch
signaling” and “Integrin signaling”: [33]), and neuronal
stress (glucocorticoid receptor signaling). Transmembrane
receptor signaling by systems including receptor tyrosine
kinases or G protein-coupled receptors (GPCRs) represents
one of the most important signaling mechanisms of
neuronal synaptic regulation [34]. However, the activation
of transmembrane receptor systems and the stimulation of
their intracellular signaling cascades, especially for GPCRs,
is now considered to be far more complex and intricate than
initially proposed by two-state receptor models [34, 35].
Much of this additional signaling diversity is thought to
arise from the additional complexity of receptor-accessory
scaﬀolding protein modiﬁcation of receptor signaling
[35]. To appreciate the multiple connections between
receptor (and GPCR in particular) activity and the presence
of neurophysiological deﬁcits in AD, we performed a
multidimensional analysis of the proteins present in control
or 3xTgAD mice. Using the novel, un-biased, bioinformatic
GeneIndexer latent semantic indexing (LSI) process
(https://www.computablegenomix.com/geneindexer.php),
explicit correlations can be made between protein/gene
factors from input datasets and their linkage (in over 1 ×106
curated scientiﬁc abstracts) to a speciﬁc interrogation
term, for example, Alzheimer’s. The semantic indexing
algorithms of GeneIndexer also allow for multidimensional
correlations to be measured for terms signiﬁcantly related
to the interrogation term, hence providing a ﬂexible,
intelligent query process. For the control and 3xTgAD
datasets, we employed multiple interrogation terms
targeted to demonstrate diﬀerences between control
and 3xTgAD datasets. Using the following interrogation
terms: Alzheimer’s, oxidation, neurodegeneration, synaptic
transmission, neurogenesis, scaﬀolding, and GPCR, we
demonstrated that, at a multidimensional interactive level,
there is minimal functional cross-over between control and
3xTgAD raft samples (Figure 6: Appendix H). Only proteins
that demonstrated explicit correlations (latent semantic
indexing score of ≥0.1) to at least two of the interrogation10 International Journal of Alzheimer’s Disease
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Figure 5: Functional receptor signaling pathway informatic clustering of control and 3xTgAD lipid raft proteins. Subtractive representation
of hybrid score generation after clustering of raft proteins from control and 3xTgAD animal rafts into receptor signaling pathways. The
data is presented as a numerical value of the control pathway hybrid score subtracted from the 3xTgAD pathway hybrid score. Pathways in
which the score in 3xTgAD was greater than the control are denoted in red; pathways in which the control hybrid score was greater than the
3xTgAD hybrid score are denoted in blue.
terms are denoted in the multidimensional heatmap
(Figure 6: Appendix H). Therefore, each of the proteins
identiﬁed in the heatmap are strongly correlated with
many of the connected interrogation terms and therefore
show potential synergistic activity. Analysis of identiﬁed
proteins in this manner, that is, selected speciﬁcally for
multidimensional neurological roles, allows for an un-
biased focusing on proteins that may possess keystone-like
functions in the molecular signaling networks involved in
neurodegeneration. With respect to speciﬁc interrogation
terms, a strong validation of the technique is demonstrated
by the fact that using the Alzheimer’s interrogation term, 47
3xTgAD-unique multidimensional proteins were indicated
while only 10 such multidimensional proteins were shown
in control rafts (Figure 6). Conﬁrming a strong role of
oxidative damage, 21 3xTgAD-unique multidimensional
proteins were present in the oxidation results while only
6 such control-unique were demonstrated. Interestingly
and perhaps suggestive of a potential future line of AD
research was the observation that considerably fewer
multidimensional 3xTgAD-unique proteins were associated
with the process of neurogenesis (15), compared to the 32
control-unique multidimensional proteins associated with
this neuroprotective mechanism. In accordance with the
important role of receptor systems in AD, we additionally
noted that more 3xTgAD-unique proteins were associated
with GPCRs (27) compared to control-unique GPCR-related
multidimensional proteins (16).
4.6. Functional Interaction Networks of Receptor Signaling
Proteins in Control versus 3xTgAD Lipid Raft Proteomes.
From our investigation of the multidimensional nature of
raft proteins with respect to neurodegenerative processes,
it is clear that there are many factors that are highly
likely to work together in complex and intricate functional
networks. To investigate the nature of the most statistically
likely functional network interactions, we employed IPA
network analysis of a receptor-ﬁltered (using IPA-knowledge
base data ﬁltering, IPA v. 8,5) subset of the control or
3xTgAD raft protein datasets (Tables 1 and 2, resp.). Using
these datasets, un-biased network analysis is able to predict
the most likely series of functional interactions (based on
empirically derived experimental evidence) that take place
between the receptor-associated raft proteins. The control
and 3xTgAD receptor-speciﬁc ﬁltered datasets demonstrated
a relatively minimal overlap, that is, 11.6% commonality,
indicating that substantial alterations of these proteins may
occurintheraftsof3xTgADanimals(Figure 7(a)).Themost
statistically likely interaction network that was predicted
to occur in control mice centered on neuroprotective and
neurotransmissive factors such as phosphoinositide-3-kinseInternational Journal of Alzheimer’s Disease 11
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Figure 6: Multidimensional protein latent semantic indexing (LSI) analysis of proteins extracted from control and 3xTgAD lipid rafts.
Proteins from the control or 3xTgAD extracted datasets that possessed an explicit latent semantic indexing (LSI, GeneIndexer, Computable
Genomix) score in at least two of the multiple GeneIndexer interrogation terms (Alzheimer’s, oxidation, neurodegeneration, synaptic
transmission, neurogenesis, scaﬀolding, and GPCR) are represented in a heatmap format. Proteins are identiﬁed on the left side of the
heatmap as an individual number (see Appendix H for key). The presence of a colored panel (3xTgAD, red: control, blue: 3xTgAD and
control: yellow) on the same lateral as the numbered protein denotes explicit textual correlation of that protein with the speciﬁc vertical
interrogation term.12 International Journal of Alzheimer’s Disease
Table 1: Receptor-speciﬁc protein list from lipid raft extracts from control animals. Primary protein lists of extracted lipid raft proteins were
ﬁltered for a speciﬁc receptor proﬁle using IPA v. 8.5.
Symbol Protein deﬁnition Location Protein type
Cd4 CD4 molecule Plasma membrane Transmembrane receptor
Celsr2 Cadherin, EGF LAG seven-pass G-type receptor 2 Plasma membrane G-protein coupled receptor
Celsr3 Cadherin, EGF LAG seven-pass G-type receptor 3 Plasma membrane G-protein coupled receptor
Chrm5 Cholinergic receptor, muscarinic 5 Plasma membrane G-protein coupled receptor
Chrnb3 Cholinergic receptor, nicotinic, beta 3 Plasma membrane Transmembrane receptor
Chrnb4 Cholinergic receptor, nicotinic, beta 4 Plasma membrane Transmembrane receptor
Chrng Cholinergic receptor, nicotinic, gamma Plasma membrane Transmembrane receptor
Cldn4 Claudin 4 Plasma membrane Transmembrane receptor
Clecsf6 C-type lectin domain family 4, member A Plasma membrane Transmembrane receptor
Cnr1 Cannabinoid receptor 1 (brain) Plasma membrane G-protein coupled receptor
Cntfr Ciliary neurotrophic factor receptor Plasma membrane Transmembrane receptor
Cxadr Coxsackie virus and adenovirus receptor Plasma membrane Transmembrane receptor
Dag1 Dystroglycan 1 (dystrophin-associated glycoprotein 1) Plasma membrane Transmembrane receptor
Ednrb Endothelin receptor type B Plasma membrane G-protein coupled receptor
Fshr Follicle stimulating hormone receptor Plasma membrane G-protein coupled receptor
Fzd9 Frizzled homolog 9 (Drosophila) Plasma membrane G-protein coupled receptor
Gabbr1 Gamma-aminobutyric acid (GABA) B receptor, 1 Plasma membrane G-protein coupled receptor
Gabrr3 Gamma-aminobutyric acid (GABA) receptor, rho 3 Plasma membrane Transmembrane receptor
Gcgr Glucagon receptor Plasma membrane G-protein coupled receptor
Gfra1 GDNF family receptor alpha 1 Plasma membrane Transmembrane receptor
Gfra3 GDNF family receptor alpha 3 Plasma membrane Transmembrane receptor
Gpr116 G protein-coupled receptor 116 Plasma membrane G-protein coupled receptor
Gpr141 G protein-coupled receptor 141 Plasma membrane G-protein coupled receptor
Gprc6a G protein-coupled receptor, family C, group 6, member A Plasma membrane G-protein coupled receptor
Grm4 Glutamate receptor, metabotropic 4 Plasma membrane G-protein coupled receptor
Grm5 Glutamate receptor, metabotropic 5 Plasma membrane G-protein coupled receptor
Cbp Opsin 1 (cone pigments), long-wave-sensitive Plasma membrane G-protein coupled receptor
Oprd1 Opioid receptor, delta 1 Plasma membrane G-protein coupled receptor
Osmr Oncostatin M receptor Plasma membrane Transmembrane receptor
Prom2 Prominin 2 Plasma membrane Transmembrane receptor
Prph2 Peripherin 2 (retinal degeneration, slow) Plasma membrane Transmembrane receptor
Ptger2 Prostaglandin E receptor 2 (subtype EP2), 53kda Plasma membrane G-protein coupled receptor
Pthr2 Parathyroid hormone 2 receptor Plasma membrane G-protein coupled receptor
Sfrp4 Secreted frizzled-related protein 4 Plasma membrane Transmembrane receptor
Smo Smoothened homolog (Drosophila) Plasma membrane G-protein coupled receptor
Sstr2 Somatostatin receptor 2 Plasma membrane G-protein coupled receptor
Tacr1 Tachykinin receptor 1 Plasma membrane G-protein coupled receptor
Tas2r41 Taste receptor, type 2, member 41 Plasma membrane G-protein coupled receptor
Thbd Thrombomodulin Plasma membrane Transmembrane receptor
Tlr3 Toll-like receptor 3 Plasma membrane Transmembrane receptor
Tlr4 Toll-like receptor 4 Plasma membrane Transmembrane receptor
Tlr5 Toll-like receptor 5 Plasma membrane Transmembrane receptor
Tlr6 Toll-like receptor 6 Plasma membrane Transmembrane receptor
Tlr9 Toll-like receptor 9 Plasma membrane Transmembrane receptor
Tshr Thyroid stimulating hormone receptor Plasma membrane G-protein coupled receptor
Unc5b Unc-5 homolog B (C. Elegans) Plasma membrane Transmembrane receptor
Vipr2 Vasoactive intestinal peptide receptor 2 Plasma membrane G-protein coupled receptorInternational Journal of Alzheimer’s Disease 13
Table 2: Receptor-speciﬁc protein list from lipid raft extracts from 3xTgAD animals. Primary protein lists of extracted lipid raft proteins were
ﬁltered for a speciﬁc receptor proﬁle using IPA v. 8.5.
Symbol Protein deﬁnition Location Protein type
Adcyap1r1 Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I Plasma membrane G-protein coupled receptor
Cd36 CD36 molecule (thrombospondin receptor) Plasma membrane Transmembrane receptor
Cd86 CD86 molecule Plasma membrane Transmembrane receptor
Cnr1 Cannabinoid receptor 1 (brain) Plasma membrane G-protein coupled receptor
Cxadr Coxsackie virus and adenovirus receptor Plasma membrane Transmembrane receptor
Gabbr1 Gamma-aminobutyric acid (GABA) B receptor, 1 Plasma membrane G-protein coupled receptor
Gpr1 G protein-coupled receptor 1 Plasma membrane G-protein coupled receptor
Gpr141 G protein-coupled receptor 141 Plasma membrane G-protein coupled receptor
Gpr56 G protein-coupled receptor 56 Plasma membrane G-protein coupled receptor
Htr2c 5-hydroxytryptamine (serotonin) receptor 2C Plasma membrane G-protein coupled receptor
Htr4 5-hydroxytryptamine (serotonin) receptor 4 Plasma membrane G-protein coupled receptor
Igf1r Insulin-like growth factor 1 receptor Plasma membrane Transmembrane receptor
Igf2r Insulin-like growth factor 2 receptor Plasma membrane Transmembrane receptor
Il1r2 Interleukin 1 receptor, type II Plasma membrane Transmembrane receptor
Il1rapl1 Interleukin 1 receptor accessory protein-like 1 Plasma membrane Transmembrane receptor
Lifr Leukemia inhibitory factor receptor alpha Plasma membrane Transmembrane receptor
Lphn1 Latrophilin 1 Plasma membrane G-protein coupled receptor
Lphn2 Latrophilin 2 Plasma membrane G-protein coupled receptor
Lrpap1 Low density lipoprotein receptor-related protein associated protein 1 Plasma membrane Transmembrane receptor
Npr2 Natriuretic peptide receptor B/guanylate cyclase B Plasma membrane G-protein coupled receptor
Npy5r Neuropeptide Y receptor Y5 Plasma membrane G-protein coupled receptor
Omg Oligodendrocyte myelin glycoprotein Plasma membrane G-protein coupled receptor
Cbp Opsin 1 (cone pigments), long-wave-sensitive Plasma membrane G-protein coupled receptor
Ptch1 Patched homolog 1 (Drosophila) Plasma membrane Transmembrane receptor
Pthr2 Parathyroid hormone 2 receptor Plasma membrane G-protein coupled receptor
Robo1 Roundabout, axon guidance receptor, homolog 1 (Drosophila) Plasma membrane Transmembrane receptor
Lgr7 Relaxin/insulin-like family peptide receptor 1 Plasma membrane G-protein coupled receptor
Tlr5 Toll-like receptor 5 Plasma membrane Transmembrane receptor
Tnfrsf14 Tumor necrosis factor receptor superfamily, member 14 Plasma membrane Transmembrane receptor
Tshr Thyroid stimulating hormone receptor Plasma membrane G-protein coupled receptor
(PI3K), Akt-1, muscarinic GPCRs (Chrm5), and glutamate
receptors (Grm5) (Figure 7(a): Appendix I). In contrast, the
highest statistically scoring network from 3xTgAD receptor-
speciﬁc proteins was centered on lipid-regulating factors
and stress-related factors including: p38 MAPK; Jnk (c-
jun N-terminal kinase), Lrpap1 (low-density lipoprotein
receptor-related protein associated protein 1); LDL (low
density lipoprotein), and NF-κB( Figure 7(b): Appendix J).
Therefore, at the level of functional interaction of receptor-
related proteins in the lipid rafts, it is clear that these
membrane microdomains are a strong functional locus
of this degenerative disease. Reinforcing this AD-relevant
microcosm eﬀect in the lipid rafts we analyzed, using latent
semantic indexing (LSI) interrogation of these receptor-
speciﬁc datasets (Table 2—control; Appendix I-3xTgAD),
the Alzheimer’s disease correlation of these receptor-speciﬁc
proteins. In Figure 8, we demonstrate that almost twice
as many proteins in the 3xTgAD dataset (21) explicitly
correlated with the interrogation term Alzheimer’s disease
compared to the proteins in the control dataset (11). The
degree of correlation of the interrogation term (Alzheimer’s)
to each speciﬁc protein is indicated by the LSI score.
In Figure 8(b) the cumulated LSI score for the 3xTgAD
Alzheimer’s-related proteins was 2.92 while for the control
proteins only 1.21 (Figure 8(b)), demonstrating that a much
stronger correlation of receptor-associated proteins existed
for the proteins in 3xTgAD rafts, compared to control.
Upon comparison of the phylogenetic relationships of the
receptor-speciﬁc proteins that form the most likely func-
tional networks (from Figure 7(b)), it is clear that for the
control-set proteins only three of these in this network are
highly correlated to reports of Alzheimer’s disease (27.2%:
Figure 8(c)) while the most coherent interaction network of
3xTgAD raft proteins possessed a much higher percentage
of Alzheimer’s disease-related proteins (62%: Figure 8(d)).
Therefore, this suggests that one of the important patholog-
ical loci of AD could be the disruption of interactivity of
receptor-associated proteins in the lipid raft microdomains14 International Journal of Alzheimer’s Disease
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Figure 7: Receptor-restricted control and 3xTgAD network interaction analysis. (a) Proportionally drawn Venn diagram depicting the
relative distribution between control or 3xTgAD raft samples of receptor-speciﬁc proteins ﬁltered using IPA version 8.5 (control ﬁltered
protein list, Table 1; 3xTgAD ﬁltered protein list, Table 2). (b) The highest scoring protein interaction network generated from IPA Network
analysis (network scores and focus molecules are listed in Appendix I) of the receptor-speciﬁc control dataset. (c) The highest scoring
protein interaction network generated from IPA Network analysis (network scores and focus molecules are listed in Appendix I)o ft h e
receptor-speciﬁc 3xTgAD dataset (Appendix J). A full description of the nature of interactions based on the connecting lines can be found at
thefollowingwebpagelinkedtotheIPAanalysismodule(https://analysis.ingenuity.com/pa/info/help/help.htm#ipa help.htm).Dashedlines
representindirectgeneinteractionswhilesolidlinesrepresentempiricallymeasureddirectinteractions.Thetwohighestsigniﬁcantlyscoring
networks (B—control, C—3xTgAD) are based on the highest percentage of the network occupation by speciﬁc proteins (focus molecules)
from the input receptor-speciﬁc datasets.
and that such a ﬁnding can be uncovered in a completely un-
biased informatic format from extremely large and diﬃcult
to interpret datasets.
5. Discussion
Multiple informatic techniques were employed to investigate
and elucidate the nature of functional protein interactions
that occur diﬀerentially in the lipid raft microdomains of
controlversus3xTgADAlzheimer’sdiseasemice.Cognitively
impaired male 3xTgAD mice showed profound diﬀerences
in the protein constituents of lipid raft extracts compared
to age-matched control mice, that is, only 17% of raft
proteins were similar between the two groups of mice. Our
microdomain proteomic approach was able to speciﬁcally
assist in the identiﬁcation of altered proteins that are
highly characteristic of AD-related raft pathophysiology, for
example, the Src-family tyrosine kinase Fyn (Figure 3(h))
[19, 20].
Currently, biological scientists are often faced with com-
plex biological issues concerning the interpretation of their
resultsduetothedevelopmentoffacilemassdataacquisition
technologies, that is, extracting relevant and illuminating
information from large datasets is often extremely challeng-
ing. However, with the application of multiple, sequentialInternational Journal of Alzheimer’s Disease 15
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Figure 8:Alzheimer’sdiseasecorrelationofcontrolor3xTgADreceptor-speciﬁclipidraftproteins.(a)Thehistogramrepresentsthenumber
ofreceptor-speciﬁcraftproteins(Table 1:control,Table 2:3xTgAD)thatdemonstrateanexplicitLSIcorrelationtotheterm“Alzheimer’s”for
control(blue)or3xTgAD(red)extracts.(b)ThehistogramdepictsthecumulatedLSIcorrelationscoresfortheAlzheimer’s-relatedreceptor-
speciﬁc proteins identiﬁed in (a). panels (c) and (d) represent the phylogenetic dendrograms for the receptor-speciﬁc raft proteins linked
to the interrogation term “Alzheimer’s” from control (c) or 3xTgAD (d) datasets. The proteins highlighted in red or blue and indicated by
an arrow were speciﬁcally clustered into the highest scoring protein interaction networks for control (Figure 7(b)) or 3xTgAD (Figure 7(c))
samples.
un-biased informatic processes, we were able to identify
speciﬁc lipid raft involvement in altered pathways that
can control multiple degenerative mechanisms, for exam-
ple, attenuation of the Wnt/β-catenin signaling pathway,
profound reduction of the important Nrf2 stress response
pathway (Figure 4(d)), the loss of neurogenesis association,
and the important involvement of synaptic GPCR-systems
(Figure 6)i nt h e3 x T g A Dm i c e[ 36–38].
Elucidation of the crucial signaling relationships in this
degenerative disorder, and the identity of the proteins that
mediate them, could lead to the more rational development
of novel therapeutics for Alzheimer’s disease. Using our
informatic receptor-targeted approach, we were also able
to reinforce the validity of our discovery process by also
identifying the importance of energy-related insulin/insulin-
like growth factor (IGF) signaling in AD (Figures 3(j),
3(n), 5,a n d8(d)) that has recently become more widely
appreciated by other researchers [39–42]. In addition to
IGF receptor activity, we noted a potential implication of
the presynaptic latrophilins (lphn) in AD pathophysiology
(Figure 8(d)). These unique receptors form the high aﬃnity
target of α-latrotoxin and may be able to integrate presynap-
ticcalciumregulationwithanabilitytopotentiallyphysically
interact with the postsynaptic neuron [43]. Another receptor
signaling system that our analysis revealed to possess a
potential role in AD is the Sonic Hedgehog (Shh) systems
(Figures5and8(d)).WithaspeciﬁccorrelationtoADpatho-
physiology, it has been demonstrated that Shh can act in a
synergisticmannerwithnervegrowthfactortoactoncentral
nervous system cholinergic neurons [44], and cholinergic
insuﬃciency has been strongly associated with cognitive
decline and Alzheimer’s-related pathophysiology [45].16 International Journal of Alzheimer’s Disease
6. Conclusions
The combined use of broad range proteomic analysis, with
sequential multidimensional informatic analysis enables the
determination of important correlations between patho-
physiology and functional protein diﬀerences. Using discrete
proteomes, that is, lipid raft extracts, versus whole-cell/tissue
proteomes, facilitates an improved ability to understand
the complex interactivity between transmembrane receptor
protein systems in a disease setting. The appreciation and
clustering of protein datasets into coherent groups greatly
increases our capacity to focus upon potentially impor-
tant therapeutic target networks. The knowledge gained of
protein activity networks may greatly assist in the future
development of network-targeting therapeutics that possess
a multidimensional eﬃcacy at several interacting proteins.
Appendices
A.
Lipid raft-derived extracted proteins from control mouse
16-month-old cortical tissue. Speciﬁc proteins isolated from
control mouse cortex were identiﬁed with multidimensional
protein identiﬁcation technology (MudPIT) LC MS/MS.
Each protein was identiﬁed in at least two out of three
experimental replicate animals and from at least two isolated
peptides per protein. The following are the protein symbol
and its corresponding deﬁnitions.
Atm: ataxia telangiectasia mutated
Bcat1: branched chain aminotransferase 1, cytosolic
Bcl11a: B-cell CLL/lymphoma 11A (zinc ﬁnger pro-
tein)
Bnip1:BCL2/adenovirusE1B19kDainteractingpro-
tein 1
Brd2: bromodomain containing 2
Bteb1: Kruppel-like factor 9
Bzrap1: benzodiazepine receptor (peripheral) associ-
ated protein 1
C3: complement component 3
C5: complement component 5
Cacna1a: calcium channel, voltage-dependent, P/Q
type, alpha 1A subunit
Cacna1c: calcium channel, voltage-dependent, L
type, alpha 1C subunit
Cacna2d2: calcium channel, voltage-dependent,
alpha 2/delta subunit 2
Cadps: Ca++-dependent secretion activator
Calb1: calbindin 1, 28kDa
Calb2: calbindin 2
Calm2: calmodulin 2 (phosphorylase kinase, delta)
Camkk1: calcium/calmodulin-dependent protein
kinase kinase 1, alpha
Camkk2: calcium/calmodulin-dependent protein
kinase kinase 2, beta
Cap1: CAP, adenylate cyclase-associated protein 1
(yeast)
Cast: calpastatin
Cat: catalase
Catsper2: cation channel, sperm associated 2
Cav1: caveolin 1, caveolae protein, 22kDa
Cblb: Cas-Br-M (murine) ecotropic retroviral trans-
forming sequence b
Cbp: opsin 1 (cone pigments), long-wave-sensitive
Cbr1: carbonyl reductase 1
Cbwd1: COBW domain containing 1
Cbx5: chromobox homolog 5 (HP1 alpha homolog,
Drosophila)
Ccbl1: cysteine conjugate-beta lyase, cytoplasmic
Ccin: calicin
Ccl28: chemokine (C-C motif) ligand 28
Ccl4: chemokine (C-C motif) ligand 4
ccnb1: cyclin B1
Ccnc: cyclin C
Cct2: chaperonin containing TCP1, subunit 2 (beta)
Cct3: chaperonin containing TCP1, subunit 3
(gamma)
Cct4: chaperonin containing TCP1, subunit 4 (delta)
Cct5: chaperonin containing TCP1, subunit 5
(epsilon)
Cct6a:chaperonincontainingTCP1,subunit6A(zeta
1)
Cd1: ribosomal protein L5
Cd151: CD151 molecule (Raph blood group)
Cd200: CD200 molecule
Cd276: CD276 molecule
Cd2ap: CD2-associated protein
Cd4: CD4 molecule
Cdc10: septin 7
Cdc25b: cell division cycle 25 homolog B (S. pombe)
Cdc42: cell division cycle 42 (GTP binding protein,
25kDa)
Cdc42bpa: CDC42 binding protein kinase alpha
(DMPK-like)
Cdc5l: CDC5 cell division cycle 5-like (S. pombe)
Cdh1: cadherin 1, type 1, E-cadherin (epithelial)
Cdh10: cadherin 10, type 2 (T2-cadherin)
Cdh2: cadherin 2, type 1, N-cadherin (neuronal)
Cdh4: cadherin 4, type 1, R-cadherin (retinal)International Journal of Alzheimer’s Disease 17
Cdk2: cyclin-dependent kinase 2
Cdk5rap2: CDK5 regulatory subunit associated pro-
tein 2
Cdk5rap3: CDK5 regulatory subunit associated pro-
tein 3
Cdk6: cyclin-dependent kinase 6
Cdk7: cyclin-dependent kinase 7
Cdkl2:cyclin-dependentkinase-like2(CDC2-related
kinase)
Cdkl3: cyclin-dependent kinase-like 3
Cdkn1b: cyclin-dependent kinase inhibitor 1B (p27,
Kip1)
Cds1: CDP-diacylglycerol synthase (phosphatidate
cytidylyltransferase) 1
Cdv1: intraﬂagellar transport 81 homolog (Chlamy-
domonas)
Cebpe: CCAAT/enhancer binding protein (C/EBP),
epsilon
Cebpz: CCAAT/enhancer binding protein (C/EBP),
zeta
Celsr2: cadherin, EGF LAG seven-pass G-type recep-
tor 2 (ﬂamingo homolog, Drosophila)
Celsr3: cadherin, EGF LAG seven-pass G-type recep-
tor 3 (ﬂamingo homolog, Drosophila)
Cend1: cell cycle exit and neuronal diﬀerentiation 1
Cenpf: centromere protein F, 350/400ka (mitosin)
Centa1: ArfGAP with dual PH domains 1
Centg1: ArfGAP with GTPase domain, ankyrin
repeat and PH domain 2
Cep350: centrosomal protein 350kDa
Ces1: carboxylesterase 1 (monocyte/macrophage ser-
ine esterase 1)
Ces3: carboxylesterase 3
Cetn2: centrin, EF-hand protein, 2
Cetn3: centrin, EF-hand protein, 3 (CDC31 homo-
log, yeast)
Cfh: complement factor H
Cﬂ1: coﬁlin 1 (nonmuscle)
Chd3: chromodomain helicase DNA binding protein
3
Chd4: chromodomain helicase DNA binding protein
4
Chga: chromogranin A (parathyroid secretory pro-
tein 1)
Chl1: cell adhesion molecule with homology to
L1CAM (close homolog of L1)
Chmp1a: chromatin modifying protein 1A
Chn2: chimerin (chimaerin) 2
Chrm5: cholinergic receptor, muscarinic 5
Chrnb3: cholinergic receptor, nicotinic, beta 3
Chrnb4: cholinergic receptor, nicotinic, beta 4
Chrng: cholinergic receptor, nicotinic, gamma
Chst7: carbohydrate (N-acetylglucosamine 6-O) sul-
fotransferase 7
Chx10: visual system homeobox 2
Cirbp: cold inducible RNA binding protein
Cit: citron (rho-interacting, serine/threonine kinase
21)
Cktsf1b1: gremlin 1, cysteine knot superfamily, hom-
olog (Xenopus laevis)
Clasp2: cytoplasmic linker associated protein 2
Clcc1: chloride channel CLIC-like 1
Clcn7: chloride channel 7
Cldn1: claudin 1
Cldn19: claudin 19
Cldn4: claudin 4
CLEC10A: C-type lectin domain family 10, member
A
Clecsf6: C-type lectin domain family 4, member A
Clic4: chloride intracellular channel 4
CLIP3: CAP-GLY domain containing linker protein 3
Clpb:ClpBcaseinolyticpeptidaseBhomolog(E.coli)
Clstn1: calsyntenin 1
Cltb: clathrin, light chain (Lcb)
Cndp2: CNDP dipeptidase 2 (metallopeptidase M20
family)
Cnga1: cyclic nucleotide gated channel alpha 1
Cnga4: cyclic nucleotide gated channel alpha 4
Cnksr2: connector enhancer of kinase suppressor of
Ras 2
Cnot6: CCR4-NOT transcription complex, subunit 6
Cnp: 2 ,3 -cyclic nucleotide 3  phosphodiesterase
Cnr1: cannabinoid receptor 1 (brain)
Cntfr: ciliary neurotrophic factor receptor
Cntn1: contactin 1
Cog3: component of oligomeric golgi complex 3
Colm: gliomedin
Copa: coatomer protein complex, subunit alpha
Copb1: coatomer protein complex, subunit beta 1
COPB2: coatomer protein complex, subunit beta 2
(beta prime)
Cops4: COP9 constitutive photomorphogenic hom-
olog subunit 4 (Arabidopsis)18 International Journal of Alzheimer’s Disease
Cops8: COP9 constitutive photomorphogenic hom-
olog subunit 8 (Arabidopsis)
Coro1a: coronin, actin binding protein, 1A
Coro7: coronin 7
Cp: ceruloplasmin (ferroxidase)
Cpe: carboxypeptidase E
Cplx1: complexin 1
Cpt1a: carnitine palmitoyltransferase 1A (liver)
Cpt2: carnitine palmitoyltransferase 2
Crabp2: cellular retinoic acid binding protein 2
Crhbp: corticotropin releasing hormone binding
protein
Crip2: cysteine-rich protein 2
Crk: v-crk sarcoma virus CT10 oncogene homolog
(avian)
Crkl: v-crk sarcoma virus CT10 oncogene homolog
(avian)-like
Crmp1: collapsin response mediator protein 1
Crnkl1: crooked neck pre-mRNA splicing factor-like
1 (Drosophila)
Crp: C-reactive protein, pentraxin-related
Cry1: cryptochrome 1 (photolyase-like)
Crygc: crystallin, gamma C
Crygs: crystallin, gamma S
Crym: crystallin, mu
Cs: citrate synthase
Csf1: colony stimulating factor 1 (macrophage)
Csnk1e: casein kinase 1, epsilon
Csnk1g2: casein kinase 1, gamma 2
Csnk2a1: casein kinase 2, alpha 1 polypeptide
Csnk2b: casein kinase 2, beta polypeptide
Cspg2: versican
Cspg3: neurocan
Cspg5: chondroitin sulfate proteoglycan 5 (neurogly-
can C)
Cspg6: structural maintenance of chromosomes 3
Cst6: cystatin E/M
Cstb: cystatin B (steﬁn B)
Ctf1: cardiotrophin 1
Cthrc1: collagen triple helix repeat containing 1
Ctla4: cytotoxic T-lymphocyte-associated protein 4
Ctnnb1: catenin (cadherin-associated protein), beta
1, 88kDa
Ctnnd2: catenin (cadherin-associated protein), delta
2 (neural plakophilin-related arm-repeat protein)
Ctrb: chymotrypsinogen B1
Ctrl: chymotrypsin-like
Ctsd: cathepsin D
Cttn: cortactin
Cttnbp2: cortactin binding protein 2
Cul1: cullin 1
Cul5: cullin 5
Cuta: cutA divalent cation tolerance homolog (E.
coli)
Cutl1: cut-like homeobox 1
CX3CL1: chemokine (C-X3-C motif) ligand 1
Cxadr: coxsackie virus and adenovirus receptor
Cxcl2: chemokine (C-X-C motif) ligand 2
Cyb5: cytochrome b5 type A (microsomal)
Cyb5b: cytochrome b5 type B (outer mitochondrial
membrane)
Cyb5r1: cytochrome b5 reductase 1
Cybb: cytochrome b-245, beta polypeptide
Cyln2: CAP-GLY domain containing linker protein 2
Cyp2s1: cytochromeP450,family2,subfamilyS,pol-
ypeptide 1
Cyr61: cysteine-rich, angiogenic inducer, 61
Dab2:disabledhomolog2,mitogen-responsivephos-
phoprotein (Drosophila)
Dab2ip: DAB2 interacting protein
Dad1: defender against cell death 1
Dag1: dystroglycan 1 (dystrophin-associated glyco-
protein 1)
Dap: death-associated protein
Dapk3: death-associated protein kinase 3
Dbc1: deleted in bladder cancer 1
DBH: dopamine beta-hydroxylase (dopamine beta-
monooxygenase)
Dbn1: drebrin 1
Dbndd2: dysbindin (dystrobrevin binding protein 1)
domain containing 2
Dbnl: drebrin-like
Dcd: dermcidin
Dci: dodecenoyl-Coenzyme A delta isomerase (3,2
trans-enoyl-Coenzyme A isomerase)
Dclk2: doublecortin-like kinase 2
Dclre1c: DNA cross-link repair 1C (PSO2 homolog,
S. cerevisiae)
Dctn2: dynactin 2 (p50)
Ddah2: dimethylarginine dimethylaminohydrolase 2
Ddb1: damage-speciﬁc DNA binding protein 1,
127kDaInternational Journal of Alzheimer’s Disease 19
Ddn: dendrin
Ddost: dolichyl-diphosphooligosaccharide-protein
glycosyltransferase
Ddr2: discoidin domain receptor tyrosine kinase 2
Ddt: D-dopachrome tautomerase
Ddx1: DEAD (Asp-Glu-Ala-Asp) box polypeptide 1
Ddx17: DEAD (Asp-Glu-Ala-Asp) box polypeptide
17
Ddx47: DEAD (Asp-Glu-Ala-Asp) box polypeptide
47
Ddx5: DEAD (Asp-Glu-Ala-Asp) box polypeptide 5
Decr1: 2,4-dienoyl CoA reductase 1, mitochondrial
Des: desmin
Dgcr14: DiGeorge syndrome critical region gene 14
Dgkb: diacylglycerol kinase, beta 90kDa
Dgkg: diacylglycerol kinase, gamma 90kDa
Dhcr7: 7-dehydrocholesterol reductase
Dhodh: dihydroorotate dehydrogenase
Dhrs8: hydroxysteroid (17-beta) dehydrogenase 11
Dhx16: DEAH (Asp-Glu-Ala-His) box polypeptide
16
Dhx30: DEAH (Asp-Glu-Ala-His) box polypeptide
30
Dia1: cytochrome b5 reductase 3
Dio1: deiodinase, iodothyronine, type I
Disc1: disrupted in schizophrenia 1
Dkc1: dyskeratosis congenita 1, dyskerin
Dlat: dihydrolipoamide S-acetyltransferase
Dlc1: deleted in liver cancer 1
Dld: dihydrolipoamide dehydrogenase
Dlgap1: discs, large (Drosophila) homolog-associat-
ed protein 1
Dlgap2: discs, large (Drosophila) homolog-associat-
ed protein 2
Dlgap4: discs, large (Drosophila) homolog-associat-
ed protein 4
Dll1: delta-like 1 (Drosophila)
Dll3: delta-like 3 (Drosophila)
Dlx5: distal-less homeobox 5
Dmd: dystrophin
Dmn: synemin, intermediate ﬁlament protein
Dmrt1: doublesex and mab-3 related transcription
factor 1
Dnah6: dynein, axonemal, heavy chain 6
Dnaja2: DnaJ (Hsp40) homolog, subfamily A, mem-
ber 2
Dnch1: dynein, cytoplasmic 1, heavy chain 1
Dncl2a: dynein, light chain, roadblock-type 1
Dntt: deoxynucleotidyltransferase, terminal
Dock9: dedicator of cytokinesis 9
Dpp3: dipeptidyl-peptidase 3
Dpyd: dihydropyrimidine dehydrogenase
Dpysl3: dihydropyrimidinase-like 3
Dpysl4: dihydropyrimidinase-like 4
Drd1ip: calcyon neuron-speciﬁc vesicular protein
Drg1: developmentally regulated GTP binding pro-
tein 1
Drpla: atrophin 1
Dscam: Down syndrome cell adhesion molecule
Dscr1l1: regulator of calcineurin 2
Dtnb: dystrobrevin, beta
Duox1: dual oxidase 1
Dusp12: dual speciﬁcity phosphatase 12
Dusp2: dual speciﬁcity phosphatase 2
Dvl1: dishevelled, dsh homolog 1 (Drosophila)
Dync1h1: dynein, cytoplasmic 1, heavy chain 1
Dync1li2: dynein, cytoplasmic 1, light intermediate
chain 2
Dyx1c1: dyslexia susceptibility 1 candidate 1
Eaf2: ELL associated factor 2
Ecel1: endothelin converting enzyme-like 1
Echdc1: enoyl Coenzyme A hydratase domain con-
taining 1
Ecm1: extracellular matrix protein 1
Ecm2: extracellular matrix protein 2, female organ
and adipocyte speciﬁc
Edf1: endothelial diﬀerentiation-related factor 1
Ednrb: endothelin receptor type B
Eef2: eukaryotic translation elongation factor 2
Efcbp1:N-terminalEF-handcalciumbindingprotein
1
Efemp2: EGF-containing ﬁbulin-like extracellular
matrix protein 2
Efnb1: ephrin-B1
Egf: epidermal growth factor (beta-urogastrone)
Egﬂ3: multiple EGF-like-domains 6
E g f r :e p i d e r m a lg r o w t hf a c t o rr e c e p t o r( e r y t h r o b -
lastic leukemia viral (v-erb-b) oncogene homolog,
avian)
Ehd2: EH-domain containing 2
Ehd4: EH-domain containing 4
Eif2c2: eukaryotic translation initiation factor 2C, 220 International Journal of Alzheimer’s Disease
Eif5b: eukaryotic translation initiation factor 5B
Elac2: elaC homolog 2 (E. coli)
Elavl3: ELAV (embryonic lethal, abnormal vision,
Drosophila)-like 3 (Hu antigen C)
ELK1: ELK1, member of ETS oncogene family
Elmo1: engulfment and cell motility 1
Emb: embigin homolog (mouse)
Emd: emerin
Eml5: echinoderm microtubule associated protein
like 5
Enah: enabled homolog (Drosophila)
Enc1: ectodermal-neural cortex (with BTB-like
domain)
Eno2: enolase 2 (gamma, neuronal)
Eno3: enolase 3 (beta, muscle)
Enpp2: ectonucleotide pyrophosphatase/phosphod-
iesterase 2
Enpp3: ectonucleotide pyrophosphatase/phosphod-
iesterase 3
Enpp5: ectonucleotide pyrophosphatase/phosphod-
iesterase 5 (putative function)
Ensa: endosulﬁne alpha
Entpd2: ectonucleoside triphosphate diphosphohy-
drolase 2
Entpd8: ectonucleoside triphosphate diphosphohy-
drolase 8
Epha3: EPH receptor A3
Epha5: EPH receptor A5
Epha7: EPH receptor A7
Ephb3: EPH receptor B3
Ephx1:epoxidehydrolase1,microsomal(xenobiotic)
Epn1: epsin 1
Eprs: glutamyl-prolyl-tRNA synthetase
Eps8l1: EPS8-like 1
Erap1: endoplasmic reticulum aminopeptidase 1
Erbb3: v-erb-b2 erythroblastic leukemia viral onco-
gene homolog 3 (avian)
Erbb4: v-erb-a erythroblastic leukemia viral onco-
gene homolog 4 (avian)
Ercc5: excision repair cross-complementing rodent
repair deﬁciency, complementation group 5
Erp29: endoplasmic reticulum protein 29
Esd: esterase D/formylglutathione hydrolase
Esr2: estrogen receptor 2 (ER beta)
Etfb: electron-transfer-ﬂavoprotein, beta polypeptide
Ets1: v-ets erythroblastosis virus E26 oncogene hom-
olog 1 (avian)
Evl: Enah/Vasp-like
Exoc5: exocyst complex component 5
Exoc7: exocyst complex component 7
Ezr: ezrin
Fabp1: fatty acid binding protein 1, liver
Fabp2: fatty acid binding protein 2, intestinal
Fabp3: fatty acid binding protein 3, muscle and heart
(mammary-derived growth inhibitor)
Fabp4: fatty acid binding protein 4, adipocyte
Fabp7: fatty acid binding protein 7, brain
Fads1: fatty acid desaturase 1
Fads2: fatty acid desaturase 2
Faim: Fas apoptotic inhibitory molecule
Fancd2: Fanconi anemia, complementation group
D2
Faslg: Fas ligand (TNF superfamily, member 6)
Fasn: fatty acid synthase
Fat: FAT tumor suppressor homolog 1 (Drosophila)
Fat3: FAT tumor suppressor homolog 3 (Drosophila)
Fbn1: ﬁbrillin 1
Fbn2: ﬁbrillin 2
Fbxw11:F-boxandWDrepeatdomaincontaining11
Fetub: fetuin B
FGA: ﬁbrinogen alpha chain
Fgb: ﬁbrinogen beta chain
Fgf18: ﬁbroblast growth factor 18
Fgf23: ﬁbroblast growth factor 23
Fgfr1: ﬁbroblast growth factor receptor 1
Fgfr1op2: FGFR1 oncogene partner 2
Fgfr2: ﬁbroblast growth factor receptor 2
Fgfr3: ﬁbroblast growth factor receptor 3
Fhl1: four and a half LIM domains 1
Fignl1: ﬁdgetin-like 1
Fip1l1: FIP1 like 1 (S. cerevisiae)
Fkbp14: FK506 binding protein 14, 22kDa
Fkbp1b: FK506 binding protein 1B, 12.6kDa
Fkbp5: FK506 binding protein 5
Flg: ﬁlaggrin
Flii: ﬂightless I homolog (Drosophila)
Fmo3: ﬂavin containing monooxygenase 3
Fnta: farnesyltransferase, CAAX box, alpha
Fos: FBJ murine osteosarcoma viral oncogene homo-
log
Fpgt: fucose-1-phosphate guanylyltransferase
Freq: frequenin homolog (Drosophila)International Journal of Alzheimer’s Disease 21
Fshr: follicle stimulating hormone receptor
Fthfd: aldehyde dehydrogenase 1 family, member L1
Fuca1: fucosidase, alpha-L-1, tissue
fut10:fucosyltransferase10(alpha(1,3)fucosyltrans-
ferase)
Fxc1: fracture callus 1 homolog (rat)
Fxyd6: FXYD domain containing ion transport regu-
lator 6
Fzd9: frizzled homolog 9 (Drosophila)
Gaa: glucosidase, alpha; acid
Gabarap: GABA(A) receptor-associated protein
Gabarapl2: GABA(A) receptor-associated protein-
like 2
Gabbr1:gamma-aminobutyricacid(GABA)Brecep-
tor, 1
Gabra3: gamma-aminobutyric acid (GABA) A recep-
tor, alpha 3
Gabrg2:gamma-aminobutyricacid(GABA)Arecep-
tor, gamma 2
Gabrr3:gamma-aminobutyricacid(GABA)receptor,
rho 3
Gadd45a:growtharrestandDNA-damage-inducible,
alpha
Galc: galactosylceramidase
Galk1: galactokinase 1
Galt: galactose-1-phosphate uridylyltransferase
Gapdh: glyceraldehyde-3-phosphate dehydrogenase
Gars: glycyl-tRNA synthetase
Gas6: growth arrest-speciﬁc 6
Gas7: growth arrest-speciﬁc 7
Gata2: GATA binding protein 2
Gata3: GATA binding protein 3
GC: group-speciﬁc component (vitamin D binding
protein)
Gc: group-speciﬁc component (vitamin D binding
protein)
Gcgr: glucagon receptor
Gckr: glucokinase (hexokinase 4) regulator
Gclc: glutamate-cysteine ligase, catalytic subunit
Gcnt3: glucosaminyl (N-acetyl) transferase 3, mucin
type
Gdap2: ganglioside induced diﬀerentiation associat-
ed protein 2
Gdi1: GDP dissociation inhibitor 1
Gdi2: GDP dissociation inhibitor 2
Gfap: glial ﬁbrillary acidic protein
Gfpt2: glutamine-fructose-6-phosphate transami-
nase 2
Gfra1: GDNF family receptor alpha 1
Gfra3: GDNF family receptor alpha 3
Ggt1: gamma-glutamyltransferase 1
Ggtl3: gamma-glutamyltransferase 7
Ggtla1: gamma-glutamyltransferase 5
Ghitm: growth hormone inducible transmembrane
protein
Gif: gastric intrinsic factor (vitamin B synthesis)
Gipc1: GIPC PDZ domain containing family, mem-
ber 1
Git1: G protein-coupled receptor kinase interacting
ArfGAP 1
Gja1: gap junction protein, alpha 1, 43kDa
Gja10: gap junction protein, alpha 10, 62kDa
Gja4: gap junction protein, alpha 4, 37kDa
Gjb6: gap junction protein, beta 6, 30kDa
Gla: galactosidase, alpha
Gldc: glycine dehydrogenase (decarboxylating)
Glg1: golgi apparatus protein 1
Gli: GLI family zinc ﬁnger 1
Glo1: glyoxalase I
Glra2: glycine receptor, alpha 2
Glrx2: glutaredoxin 2
Glud1: glutamate dehydrogenase 1
Glul: glutamate-ammonia ligase (glutamine synthe-
tase)
Gm2a: GM2 ganglioside activator
Gmcl1: germ cell-less homolog 1 (Drosophila)
Gmfb: glia maturation factor, beta
Gmfg: glia maturation factor, gamma
Gmpr2: guanosine monophosphate reductase 2
Gng7: guanine nucleotide binding protein (G pro-
tein), gamma 7
Gnpat: glyceronephosphate O-acyltransferase
Gns: glucosamine (N-acetyl)-6-sulfatase
Golga2: golgi autoantigen, golgin subfamily a, 2
Golgb1: golgin B1, golgi integral membrane protein
Golph3: golgi phosphoprotein 3 (coat-protein)
Golph4: golgi integral membrane protein 4
Gosr2: golgi SNAP receptor complex member 2
Got1: glutamic-oxaloacetic transaminase 1, soluble
(aspartate aminotransferase 1)
Got2: glutamic-oxaloacetic transaminase 2, mito-
chondrial (aspartate aminotransferase 2)22 International Journal of Alzheimer’s Disease
Gpam: glycerol-3-phosphate acyltransferase, mito-
chondrial
Gpc2: glypican 2
Gpi: glucose phosphate isomerase
Gpm6a: glycoprotein M6A
Gpr116: G protein-coupled receptor 116
Gpr141: G protein-coupled receptor 141
Gprc6a: G protein-coupled receptor, family C, group
6, member A
Gpsm1:G-proteinsignalingmodulator1(AGS3-like,
C. elegans)
Gpt: glutamic-pyruvate transaminase (alanine ami-
notransferase)
Gramd1a: GRAM domain containing 1A
Grasp: GRP1 (general receptor for phosphoinositides
1)-associated scaﬀold protein
Grem1: gremlin 1, cysteine knot superfamily, homo-
log (Xenopus laevis)
Gria1: glutamate receptor, ionotropic, AMPA 1
Grid2: glutamate receptor, ionotropic, delta 2
Grik1: glutamate receptor, ionotropic, kainate 1
Grik4: glutamate receptor, ionotropic, kainate 4
Grin2a: glutamate receptor, ionotropic, N-methyl D-
aspartate 2A
Grin2b: glutamate receptor, ionotropic, N-methyl D-
aspartate 2B
Grip1: glutamate receptor interacting protein 1
Gripap1: GRIP1 associated protein 1
Grk4: G protein-coupled receptor kinase 4
Grk5: G protein-coupled receptor kinase 5
Grk6: G protein-coupled receptor kinase 6
Grm4: glutamate receptor, metabotropic 4
Grm5: glutamate receptor, metabotropic 5
Grpel1: GrpE-like 1, mitochondrial (E. coli)
Gstk1: glutathione S-transferase kappa 1
Gstm2: glutathione S-transferase mu 2 (muscle)
Gsto1: glutathione S-transferase omega 1
Gtf2ird1: GTF2I repeat domain containing 1
Gtpbp4: GTP binding protein 4
Gucy1a2: guanylate cyclase 1, soluble, alpha 2
Gucy1a3: guanylate cyclase 1, soluble, alpha 3
Gucy1b2: guanylate cyclase 1, soluble, beta 2
Gucy2d: guanylate cyclase 2D, membrane (retina-
speciﬁc)
Gulp1: GULP, engulfment adaptor PTB domain
containing 1
Haao: 3-hydroxyanthranilate 3,4-dioxygenase
Itpka: inositol 1,4,5-trisphosphate 3-kinase A
Khdrbs2: KH domain containing, RNA binding,
signal transduction associated 2
Kpnb1: karyopherin (importin) beta 1
Lamp2: lysosomal-associated membrane protein 2
Ncstn: nicastrin
Nedd4l: neural precursor cell expressed, develop-
mentally down-regulated 4-like
Nip7: nuclear import 7 homolog (S. cerevisiae)
Nnat: neuronatin
Nos1: nitric oxide synthase 1 (neuronal)
Nox1: NADPH oxidase 1
Npepps: aminopeptidase puromycin sensitive
Nr1h3: nuclear receptor subfamily 1, group H,
member 3
Nr1i2:nuclearreceptorsubfamily1,groupI,member
2
Nr6a1: nuclear receptor subfamily 6, group A, mem-
ber 1
Nrcam: neuronal cell adhesion molecule
Nrd1: nardilysin (N-arginine dibasic convertase)
Ntn1: netrin 1
Nucb2: nucleobindin 2
Nudc: nuclear distribution gene C homolog (A.
nidulans)
Nup35: nucleoporin 35kDa
Nup54: nucleoporin 54kDa
Nup98: nucleoporin 98kDa
Oaz1: ornithine decarboxylase antizyme 1
Ocrl: oculocerebrorenal syndrome of Lowe
Oit3: oncoprotein induced transcript 3
Olfm2: olfactomedin 2
Opa1: optic atrophy 1 (autosomal dominant)
Oplah: 5-oxoprolinase (ATP-hydrolysing)
Oprd1: opioid receptor, delta 1
Orc4l: origin recognition complex, subunit 4-like
(yeast)
Osmr: oncostatin M receptor
Oxr1: oxidation resistance 1
P2rx7: purinergic receptor P2X, ligand-gated ion
channel, 7
P4hb: prolyl 4-hydroxylase, beta polypeptide
Pa2g4: proliferation-associated 2G4, 38kDa
Pabpc4: poly(A) binding protein, cytoplasmic 4
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Pace4: proprotein convertase subtilisin/kexin type 6
Pacs1: phosphofurin acidic cluster sorting protein 1
Pafah1b2: platelet-activating factor acetylhydrolase,
isoform Ib, subunit 2 (30kDa)
Pafah1b3: platelet-activating factor acetylhydrolase,
isoform Ib, subunit 3 (29kDa)
Pak1: p21 protein (Cdc42/Rac)-activated kinase 1
Pak2: p21 protein (Cdc42/Rac)-activated kinase 2
Pak3: p21 protein (Cdc42/Rac)-activated kinase 3
Palm: paralemmin
Pamci: Ras association (RalGDS/AF-6) domain fam-
ily (N-terminal) member 9
Panx1: pannexin 1
Panx2: pannexin 2
Pard3: par-3 partitioning defective 3 homolog (C.
elegans)
Parg: poly (ADP-ribose) glycohydrolase
Park7: Parkinson disease (autosomal recessive, early
onset) 7
Pawr: PRKC, apoptosis, WT1, regulator
Pax3: paired box 3
Pbp: phosphatidylethanolamine binding protein 1
Pc: pyruvate carboxylase
Pcca: propionyl Coenzyme A carboxylase, alpha pol-
ypeptide
Pcdh21: protocadherin 21
Pcdh7: protocadherin 7
Pcdha3: protocadherin alpha 3
Pcdhb1: protocadherin beta 1
Pck1: phosphoenolpyruvate carboxykinase 1 (solu-
ble)
Pclo: piccolo (presynaptic cytomatrix protein)
Pcm1: pericentriolar material 1
Pcmt1: protein-L-isoaspartate (D-aspartate) O-
methyltransferase
PCNT: pericentrin
Pcnx: pecanex homolog (Drosophila)
Pcnxl3: pecanex-like 3 (Drosophila)
Pcsk1: proprotein convertase subtilisin/kexin type 1
Pcsk1n: proprotein convertase subtilisin/kexin type 1
inhibitor
Pcsk5: proprotein convertase subtilisin/kexin type 5
Pcyox1: prenylcysteine oxidase 1
Pcyt1b: phosphate cytidylyltransferase 1, choline,
beta
Pdap1: PDGFA associated protein 1
Pdc: phosducin
Pdcd2: programmed cell death 2
Pdcl: phosducin-like
Pde10a: phosphodiesterase 10A
Pde1a:phosphodiesterase1A,calmodulin-dependent
Pde1c:phosphodiesterase1C,calmodulin-dependent
70kDa
Pde4a: phosphodiesterase 4A, cAMP-speciﬁc (phos-
phodiesterase E2 dunce homolog, Drosophila)
Pde4b: phosphodiesterase 4B, cAMP-speciﬁc (phos-
phodiesterase E4 dunce homolog, Drosophila)
Pde4d: phosphodiesterase 4D, cAMP-speciﬁc (phos-
phodiesterase E3 dunce homolog, Drosophila)
Pde5a: phosphodiesterase 5A, cGMP-speciﬁc
Pde7a: phosphodiesterase 7A
Pde7b: phosphodiesterase 7B
Pdgfra: platelet-derived growth factor receptor, alpha
polypeptide
Pdhb: pyruvate dehydrogenase (lipoamide) beta
Pdia3: protein disulﬁde isomerase family A, member
3
Pdia4: protein disulﬁde isomerase family A, member
4
Pdk4: pyruvate dehydrogenase kinase, isozyme 4
Pdlim7: PDZ and LIM domain 7 (enigma)
Pds5b: PDS5, regulator of cohesion maintenance,
homolog B (S. cerevisiae)
Pdzd3: PDZ domain containing 3
Pepd: peptidase D
Per3: period homolog 3 (Drosophila)
Pex14: peroxisomal biogenesis factor 14
Pfkl: phosphofructokinase, liver
Pfkm: phosphofructokinase, muscle
Pfkp: phosphofructokinase, platelet
Pgam1: phosphoglycerate mutase 1 (brain)
PGAP1: post-GPI attachment to proteins 1
Pgd: phosphogluconate dehydrogenase
Pgf: placental growth factor
Pgk1: phosphoglycerate kinase 1
Pgm1: phosphoglucomutase 1
Pgr: progesterone receptor
Pgrmc1: progesterone receptor membrane compo-
nent 1
Phactr1: phosphatase and actin regulator 1
Phactr3: phosphatase and actin regulator 3
Phb: prohibitin24 International Journal of Alzheimer’s Disease
Phex: phosphate regulating endopeptidase homolog,
X-linked
Phgdh: phosphoglycerate dehydrogenase
Phip: pleckstrin homology domain interacting pro-
tein
Phtf1: putative homeodomain transcription factor 1
Phyhipl: phytanoyl-CoA 2-hydroxylase interacting
protein-like
Pi4ka: phosphatidylinositol 4-kinase, catalytic, alpha
Picalm: phosphatidylinositol binding clathrin assem-
bly protein
Pigq: phosphatidylinositol glycan anchor biosynthe-
sis, class Q
Pigs: phosphatidylinositol glycan anchor biosynthe-
sis, class S
Pik3cg: phosphoinositide-3-kinase, catalytic, gamma
polypeptide
Pip5k1a: phosphatidylinositol-4-phosphate 5-kinase,
type I, alpha
Pip5k1c: phosphatidylinositol-4-phosphate 5-kinase,
type I, gamma
Pip5k2a: phosphatidylinositol-5-phosphate 4-kinase,
type II, alpha
Pip5k2c: phosphatidylinositol-5-phosphate 4-kinase,
type II, gamma
Pipox: pipecolic acid oxidase
Pitpn: phosphatidylinositol transfer protein, alpha
Pkd1: polycystic kidney disease 1 (autosomal domi-
nant)
Pkia: protein kinase (cAMP-dependent, catalytic) in-
hibitor alpha
Pkm2: pyruvate kinase, muscle
Pla2g4c: phospholipase A2, group IVC (cytosolic,
calcium-independent)
Plaa: phospholipase A2-activating protein
Plau: plasminogen activator, urokinase
Plcb1: phospholipase C, beta 1 (phosphoinositide-
speciﬁc)
Plcl1: phospholipase C-like 1
Pld3: phospholipase D family, member 3
Plekha4: pleckstrin homology domain containing,
family A (phosphoinositide binding speciﬁc) mem-
ber 4
Plekhe1: PH domain and leucine rich repeat protein
phosphatase 1
Plekhm1: pleckstrin homology domain containing,
family M (with RUN domain) member 1
Plg: plasminogen
Plk1: polo-like kinase 1 (Drosophila)
Plrg1: pleiotropic regulator 1 (PRL1 homolog, Ara-
bidopsis)
Plunc: palate, lung and nasal epithelium associated
Plvap: plasmalemma vesicle associated protein
Plxnb2: plexin B2
Pmpca: peptidase (mitochondrial processing) alpha
Pmvk: phosphomevalonate kinase
Pnliprp2: pancreatic lipase-related protein 2
Pnma1: paraneoplastic antigen MA1
Pno1: partner of NOB1 homolog (S. cerevisiae)
Pnpla2: patatin-like phospholipase domain contain-
ing 2
Pofut1: protein O-fucosyltransferase 1
Pon2: paraoxonase 2
Pon3: paraoxonase 3
Pop7: processing of precursor 7, ribonuclease P/MRP
subunit (S. cerevisiae)
Por: P450 (cytochrome) oxidoreductase
Pou2f2: POU class 2 homeobox 2
Ppﬁa3: protein tyrosine phosphatase, receptor type, f
polypeptide (PTPRF), interacting protein, alpha 3
Ppgb: cathepsin A
Ppib: peptidylprolyl isomerase B (cyclophilin B)
Ppid: peptidylprolyl isomerase D
Ppil3: peptidylprolyl isomerase (cyclophilin)-like 3
Ppm2c: pyruvate dehydrogenase phosphatase cat-
alytic subunit 1
Ppp1r10: protein phosphatase 1, regulatory (inhibi-
tor) subunit 10
Ppp1r14b: protein phosphatase 1, regulatory (inhibi-
tor) subunit 14B
Ppp1r14d: protein phosphatase 1, regulatory (inhibi-
tor) subunit 14D
Ppp1r1a: protein phosphatase 1, regulatory (inhibi-
tor) subunit 1A
Ppp1r7:proteinphosphatase1,regulatory(inhibitor)
subunit 7
Ppp1r8:proteinphosphatase1,regulatory(inhibitor)
subunit 8
Ppp1r9a: protein phosphatase 1, regulatory (inhibi-
tor) subunit 9A
Ppp1r9b: protein phosphatase 1, regulatory (inhibi-
tor) subunit 9B
Ppp2cb: protein phosphatase 2 (formerly 2A), cat-
alytic subunit, beta isoform
Ppp2r1a: protein phosphatase 2 (formerly 2A), regu-
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Ppp2r1b: protein phosphatase 2 (formerly 2A), regu-
latory subunit A, beta isoform
Ppp2r2a: protein phosphatase 2 (formerly 2A), regu-
latory subunit B, alpha isoform
PPP2R2B: protein phosphatase 2 (formerly 2A),
regulatory subunit B, beta isoform
Ppp2r5e: protein phosphatase 2, regulatory subunit
B’, epsilon isoform
Ppp3cc: protein phosphatase 3 (formerly 2B), cat-
alytic subunit, gamma isoform
Ppp5c: protein phosphatase 5, catalytic subunit
Prdm4: PR domain containing 4
Prdx1: peroxiredoxin 1
Prep: prolyl endopeptidase
Prf1: perforin 1 (pore forming protein)
Prkaa2: protein kinase, AMP-activated, alpha 2 cat-
alytic subunit
Prkaca: protein kinase, cAMP-dependent, catalytic,
alpha
prkar1a: protein kinase, cAMP-dependent, regula-
tory, type I, alpha (tissue speciﬁc extinguisher 1)
Prkar1a: protein kinase, cAMP-dependent, regula-
tory, type I, alpha (tissue speciﬁc extinguisher 1)
Prkar2a: protein kinase, cAMP-dependent, regula-
tory, type II, alpha
Prkar2b: protein kinase, cAMP-dependent, regula-
tory, type II, beta
Prkca: protein kinase C, alpha
Prkcb1: protein kinase C, beta
Prkci: protein kinase C, iota
Prkcm: protein kinase D1
PRKCQ: protein kinase C, theta
Prkcz: protein kinase C, zeta
Prkwnk1: WNK lysine deﬁcient protein kinase 1
Prmt3: protein arginine methyltransferase 3
Prnp: prion protein
Prom2: prominin 2
Prph2: peripherin 2 (retinal degeneration, slow)
Prpsap1: phosphoribosyl pyrophosphate synthetase-
associated protein 1
Prpsap2: phosphoribosyl pyrophosphate synthetase-
associated protein 2
Prr3: proline rich 3
Prrx2: paired related homeobox 2
Prrxl1: dorsal root ganglia homeobox
Prss1: protease, serine, 1 (trypsin 1)
Prss12: protease, serine, 12 (neurotrypsin, motopsin)
Prss15: lon peptidase 1, mitochondrial
Prtg: protogenin homolog (Gallus gallus)
Prx: periaxin
Psat1: phosphoserine aminotransferase 1
Psd: pleckstrin and Sec7 domain containing
Psd4: pleckstrin and Sec7 domain containing 4
Psmc1: proteasome (prosome, macropain) 26S sub-
unit, ATPase, 1
Psmc3: proteasome (prosome, macropain) 26S sub-
unit, ATPase, 3
Psmc5: proteasome (prosome, macropain) 26S sub-
unit, ATPase, 5
Psmd1: proteasome (prosome, macropain) 26S sub-
unit, non-ATPase, 1
Psme1: proteasome (prosome, macropain) activator
subunit 1 (PA28 alpha)
Psme2: proteasome (prosome, macropain) activator
subunit 2 (PA28 beta)
Psme3: proteasome (prosome, macropain) activator
subunit 3 (PA28 gamma; Ki)
Psph: phosphoserine phosphatase
Ptbp1: polypyrimidine tract binding protein 1
Ptbp2: polypyrimidine tract binding protein 2
Ptger2: prostaglandin E receptor 2 (subtype EP2),
53kDa
Ptgis: prostaglandin I2 (prostacyclin) synthase
Ptgs1: prostaglandin-endoperoxide synthase 1
(prostaglandin G/H synthase and cyclooxygenase)
Pth: parathyroid hormone
Pthr2: parathyroid hormone 2 receptor
Ptk2: PTK2 protein tyrosine kinase 2
Ptn: pleiotrophin
Ptov1: prostate tumor overexpressed 1
Ptp4a1: protein tyrosine phosphatase type IVA,
member 1
Ptpn11: protein tyrosine phosphatase, non-receptor
type 11
Rnmt: RNA (guanine-7-) methyltransferase
Rraga: Ras-related GTP binding A
Rtn4: reticulon 4
Ryr3: ryanodine receptor 3
Sca1: ataxin 1
Sca10: ataxin 10
Scfd1: sec1 family domain containing 1
Scgb3a2: secretoglobin, family 3A, member 2
Scn1a: sodium channel, voltage-gated, type I, alpha
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Scn2a1:sodium channel, voltage-gated,type II,alpha
subunit
Scp2: sterol carrier protein 2
Sdad1: SDA1 domain containing 1
Sdc2: syndecan 2
Sdcbp: syndecan binding protein (syntenin)
Sdfr1: neuroplastin
Sdha: succinate dehydrogenase complex, subunit A,
ﬂavoprotein (Fp)
Sec11l3: SEC11 homolog C (S. cerevisiae)
Sec31l1: SEC31 homolog A (S. cerevisiae)
Sectm1: secreted and transmembrane 1
Sema6c: sema domain, transmembrane domain
(TM), and cytoplasmic domain, (semaphorin) 6C
Sephs1: selenophosphate synthetase 1
Serinc3: serine incorporator 3
Serpinb3:serpinpeptidaseinhibitor,cladeB(ovalbu-
min), member 3
Serpine2: serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1), member 2
Sez6: seizure related 6 homolog (mouse)
Sf3b1: splicing factor 3b, subunit 1, 155kDa
Sfpq: splicing factor proline/glutamine-rich
(polypyrimidine tract binding protein associated)
Sfrp4: secreted frizzled-related protein 4
Sfrs10: transformer 2 beta homolog (Drosophila)
Sfrs8: splicing factor, arginine/serine-rich 8
(suppressor-of-white-apricot homolog, Drosophila)
Sfrs9: splicing factor, arginine/serine-rich 9
Sftpb: surfactant protein B
Sfxn3: sideroﬂexin 3
Sfxn5: sideroﬂexin 5
Sgca: sarcoglycan, alpha (50kDa dystrophin-associ-
ated glycoprotein)
Sgtb: small glutamine-rich tetratricopeptide repeat
(TPR)-containing, beta
Sh2d4a: SH2 domain containing 4A
Sh3bp4: SH3-domain binding protein 4
Sh3bp5: SH3-domain binding protein 5 (BTK-asso-
ciated)
Sh3gl3: SH3-domain GRB2-like 3
Sh3glb2: SH3-domain GRB2-like endophilin B2
Shank1: SH3 and multiple ankyrin repeat domains 1
Shank2: SH3 and multiple ankyrin repeat domains 2
Shc1: SHC (Src homology 2 domain containing)
transforming protein 1
Shh: sonic hedgehog homolog (Drosophila)
Shoc2: soc-2 suppressor of clear homolog (C. ele-
gans)
Siat7A: ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 1
Sipa1: signal-induced proliferation-associated 1
Sipa1l2: signal-induced proliferation-associated 1
like 2
Sipa1l3: signal-induced proliferation-associated 1
like 3
Sirpa: signal-regulatory protein alpha
Sirt2: sirtuin (silent mating type information regula-
tion 2 homolog) 2 (S. cerevisiae)
Sirt5: sirtuin (silent mating type information regula-
tion 2 homolog) 5 (S. cerevisiae)
Slc11a2: solute carrier family 11 (proton-coupled
divalent metal ion transporters), member 2
Slc12a1: solute carrier family 12 (sodium/potassi-
um/chloride transporters), member 1
Slc12a5: solute carrier family 12 (potassium-chloride
transporter), member 5
Slco3a1: solute carrier organic anion transporter
family, member 3A1
Slit1: slit homolog 1 (Drosophila)
Slit2: slit homolog 2 (Drosophila)
Slit3: slit homolog 3 (Drosophila)
Slk: STE20-like kinase (yeast)
Slu7: SLU7 splicing factor homolog (S. cerevisiae)
Smad1: SMAD family member 1
Smarca2: SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily a,
member 2
Smc1l1: structural maintenance of chromosomes 1A
Smo: smoothened homolog (Drosophila)
Smoc1: SPARC related modular calcium binding 1
Smu1: smu-1 suppressor of mec-8 and unc-52 hom-
olog (C. elegans)
Sn: sialic acid binding Ig-like lectin 1, sialoadhesin
Snai1: snail homolog 1 (Drosophila)
Snai2: snail homolog 2 (Drosophila)
Snap23: synaptosomal-associated protein, 23kDa
Snap25: synaptosomal-associated protein, 25kDa
Snap91: synaptosomal-associated protein, 91kDa
homolog (mouse)
Snca: synuclein, alpha (non A4 component of amy-
loid precursor)
Sncb: synuclein, betaInternational Journal of Alzheimer’s Disease 27
Snd1: staphylococcal nuclease and tudor domain
containing 1
Snph: syntaphilin
Snrk: SNF related kinase
Snx17: sorting nexin 17
Snx25: sorting nexin 25
Snx3: sorting nexin 3
Soat1: sterol O-acyltransferase 1
Socs1: suppressor of cytokine signaling 1
SOD1: superoxide dismutase 1, soluble
Sod2: superoxide dismutase 2, mitochondrial
Sord: sorbitol dehydrogenase
Sox10: SRY (sex determining region Y)-box 10
Sp2: Sp2 transcription factor
Sparc: secreted protein, acidic, cysteine-rich
(osteonectin)
Spata20: spermatogenesis associated 20
Spint1: serine peptidase inhibitor, Kunitz type 1
Spp1: secreted phosphoprotein 1
Spsb4: splA/ryanodine receptor domain and SOCS
box containing 4
Sqle: squalene epoxidase
Src: v-src sarcoma (Schmidt-Ruppin A-2) viral onco-
gene homolog (avian)
Srd5a2: steroid-5-alpha-reductase, alpha polypeptide
2
Srebf1: sterol regulatory element binding transcrip-
tion factor 1
Srprb: signal recognition particle receptor, B subunit
Ssb: Sjogren syndrome antigen B (autoantigen La)
Ssr4: signal sequence receptor, delta (translocon-as-
sociated protein delta)
Ssrp1: structure speciﬁc recognition protein 1
Sstr2: somatostatin receptor 2
Ssx2ip: synovial sarcoma, X breakpoint 2 interacting
protein
St14: suppression of tumorigenicity 14 (colon carci-
noma)
St18: suppression of tumorigenicity 18 (breast carci-
noma) (zinc ﬁnger protein)
St3gal1: ST3 beta-galactoside alpha-2,3-sialyltrans-
ferase 1
St6gal2: ST6 beta-galactosamide alpha-2,6-sialyl-
transferase 2
St7: suppression of tumorigenicity 7
St7l: suppression of tumorigenicity 7 like
Star: steroidogenic acute regulatory protein
Stard3nl: STARD3 N-terminal like
Stat1:signaltransducerandactivatoroftranscription
1, 91kDa
Stat3:signaltransducerandactivatoroftranscription
3 (acute-phase response factor)
Stau1: staufen, RNA binding protein, homolog 1
(Drosophila)
Stch: heat shock protein 70kDa family, member 13
Ste: sulfotransferase family 1E, estrogen-preferring,
member 1
Stim2: stromal interaction molecule 2
Stip1: stress-induced-phosphoprotein 1
Stk10: serine/threonine kinase 10
Stk11: serine/threonine kinase 11
Stmn1: stathmin 1
Stmn2: stathmin-like 2
Stmn3: stathmin-like 3
Stmn4: stathmin-like 4
Stnl: eukaryotic translation elongation factor 1 alpha
2
Stom: stomatin
Strbp: spermatid perinuclear RNA binding protein
Strn: striatin, calmodulin binding protein
Stx12: syntaxin 12
Stx1a: syntaxin 1A (brain)
Stx4a: syntaxin 4
Stx5a: syntaxin 5
Stx6: syntaxin 6
Stx8: syntaxin 8
Stxbp3: syntaxin binding protein 3
Stxbp5: syntaxin binding protein 5 (tomosyn)
Suclg1: succinate-CoA ligase, alpha subunit
Sult1a1: sulfotransferase family, cytosolic, 1A,
phenol-preferring, member 1
Sult1c1: sulfotransferase family, cytosolic, 1C, mem-
ber 2
Sult1c2: sulfotransferase family, cytosolic, 1C, mem-
ber 2
Sult1e1: sulfotransferase family 1E, estrogen-
preferring, member 1
Sult4a1: sulfotransferase family 4A, member 1
Supv3l1: suppressor of var1, 3-like 1 (S. cerevisiae)
Surf6: surfeit 6
Suv420h2: suppressor of variegation 4-20 homolog 2
(Drosophila)
Sv2a: synaptic vesicle glycoprotein 2A28 International Journal of Alzheimer’s Disease
Sv2b: synaptic vesicle glycoprotein 2B
Sycp1: synaptonemal complex protein 1
Sycp2: synaptonemal complex protein 2
Syn1: synapsin I
Syn2: synapsin II
Syn3: synapsin III
Syngap1: synaptic Ras GTPase activating protein 1
homolog (rat)
Synj1: synaptojanin 1
Synj2: synaptojanin 2
Synj2bp: synaptojanin 2 binding protein
Synpo: synaptopodin
Sypl: synaptophysin-like 1
Syt11: synaptotagmin XI
Syt12: synaptotagmin XII
Syt5: synaptotagmin V
Syt6: synaptotagmin VI
Syt8: synaptotagmin VIII
Tacc1: transforming, acidic coiled-coil containing
protein 1
Tacc2: transforming, acidic coiled-coil containing
protein 2
Tacr1: tachykinin receptor 1
Taf1c: TATA box binding protein (TBP)-associated
factor, RNA polymerase I, C, 110kDa
Taf9l: TAF9B RNA polymerase II, TATA box binding
protein (TBP)-associated factor, 31kDa
Tagln: transgelin
Tagln3: transgelin 3
Taldo1: transaldolase 1
Taok1: TAO kinase 1
Tapbp: TAP binding protein (tapasin)
Tars: threonyl-tRNA synthetase
Tas2r41: taste receptor, type 2, member 41
Tat: tyrosine aminotransferase
Tax1bp1: Tax1 (human T-cell leukemia virus type I)
binding protein 1
Tbc1d10b: TBC1 domain family, member 10B
Tbca: tubulin folding cofactor A
Tbx2: T-box 2
Tcirg1: T-cell, immune regulator 1, ATPase, H+
transporting, lysosomal V0 subunit A3
Tcn2: transcobalamin II; macrocytic anemia
Tcp1: t-complex 1
Tcra: T cell receptor alpha locus
Tdg: thymine-DNA glycosylase
Tdrd7: tudor domain containing 7
Tead1: TEA domain family member 1 (SV40 tran-
scriptional enhancer factor)
Tegt:transmembraneBAXinhibitormotifcontaining
6
Tg: thyroglobulin
Tgfb1: transforming growth factor, beta 1
Tgfbr3: transforming growth factor, beta receptor III
Tgm1: transglutaminase 1 (K polypeptide epidermal
type I, protein-glutamine-gamma-glutamyltransfer-
ase)
Tgm2: transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase)
Thbd: thrombomodulin
Thbs4: thrombospondin 4
Thpo: thrombopoietin
Thra: thyroid hormone receptor, alpha (erythrob-
lastic leukemia viral (v-erb-a) oncogene homolog,
avian)
Thrap3:thyroidhormonereceptorassociatedprotein
3
Thrb: thyroid hormone receptor, beta (erythroblastic
leukemia viral (v-erb-a) oncogene homolog 2, avian)
Thy1: Thy-1 cell surface antigen ¡list-item¿¡label/¿
Tigd3: tigger transposable element derived 3
Timm44: translocase of inner mitochondrial mem-
brane 44 homolog (yeast)
Timm8a: translocase of inner mitochondrial mem-
brane 8 homolog A (yeast)
Tinag: tubulointerstitial nephritis antigen
Tjp1: tight junction protein 1 (zona occludens 1)
Tjp2: tight junction protein 2 (zona occludens 2)
Tkt: transketolase
Tle3: transducin-like enhancer of split 3 (E(sp1)
homolog, Drosophila)
Tlr3: toll-like receptor 3
Tlr4: toll-like receptor 4
Tlr5: toll-like receptor 5
Tlr6: toll-like receptor 6
Tlr9: toll-like receptor 9
Tm4sf8: tetraspanin 3
Tm9sf2: transmembrane 9 superfamily member 2
Tm9sf3: transmembrane 9 superfamily member 3
Tmco1: transmembrane and coiled-coil domains 1
Tmeﬀ1: transmembrane protein with EGF-like and
two follistatin-like domains 1
Tmem27: transmembrane protein 27International Journal of Alzheimer’s Disease 29
Tmf1: TATA element modulatory factor 1
Tmpo: thymopoietin
Tmsb10: thymosin beta 10
Tnfaip1: tumor necrosis factor, alpha-induced pro-
tein 1 (endothelial)
Tnni1: troponin I type 1 (skeletal, slow)
Tnni2: troponin I type 2 (skeletal, fast)
Tnnt3: troponin T type 3 (skeletal, fast)
Tob1: transducer of ERBB2, 1
Tob2: transducer of ERBB2, 2
Tom1: target of myb1 (chicken)
Tor3a: torsin family 3, member A
Tpbg: trophoblast glycoprotein
Tpd52l2: tumor protein D52-like 2
Tph2: tryptophan hydroxylase 2
Tpm3: tropomyosin 3
Tpo: thyroid peroxidase
Tpst2: tyrosylprotein sulfotransferase 2
Tpt1: tumor protein, translationally-controlled 1
Tr4: nuclear receptor subfamily 2, group C, member
2
Traf3ip1: TNF receptor-associated factor 3 interact-
ing protein 1
Trak2: traﬃcking protein, kinesin binding 2
Trap1: TNF receptor-associated protein 1
Trib3: tribbles homolog 3 (Drosophila)
Trim13: tripartite motif-containing 13
Trim54: tripartite motif-containing 54
Trip10: thyroid hormone receptor interactor 10
Trpc2: transient receptor potential cation channel,
subfamily C, member 2 (pseudogene)
Trpc4: transient receptor potential cation channel,
subfamily C, member 4
Trpc5: transient receptor potential cation channel,
subfamily C, member 5
Trpc7: transient receptor potential cation channel,
subfamily C, member 7
Trpv1: transient receptor potential cation channel,
subfamily V, member 1
Trpv4: transient receptor potential cation channel,
subfamily V, member 4
Tsc1: tuberous sclerosis 1
Tsc2: tuberous sclerosis 2
Tsg101: tumor susceptibility gene 101
Tsga10: testis speciﬁc, 10
Tsga10ip: testis speciﬁc, 10 interacting protein
Tshr: thyroid stimulating hormone receptor
Tsn: translin
Tsnax: translin-associated factor X
Tst: thiosulfate sulfurtransferase (rhodanese)
Ttc1: tetratricopeptide repeat domain 1
Ttn: titin
Tub: tubby homolog (mouse)
Tuba1a: tubulin, alpha 1a
Tubb2b: tubulin, beta 2B
Tubb2c: tubulin, beta 2C
Tubb3: tubulin, beta 3
Tusc3: tumor suppressor candidate 3
Txn: thioredoxin
Txn2: thioredoxin 2
Txndc4: endoplasmic reticulum protein 44
Txnip: thioredoxin interacting protein
Txnl2: glutaredoxin 3
Txnrd1: thioredoxin reductase 1
Txnrd2: thioredoxin reductase 2
Ubc: ubiquitin C
Ube2e2: ubiquitin-conjugating enzyme E2E 2
(UBC4/5 homolog, yeast)
Ubl3: ubiquitin-like 3
Ubqln1: ubiquilin 1
Ubxd3: UBX domain protein 10
Uchl1:ubiquitincarboxyl-terminalesteraseL1(ubiq-
uitin thiolesterase)
Ucp1: uncoupling protein 1 (mitochondrial, proton
carrier)
Ucp2: uncoupling protein 2 (mitochondrial, proton
carrier)
Ugt1a1: UDP glucuronosyltransferase 1 family, poly-
peptide A1
Umod: uromodulin
Unc13a: unc-13 homolog A (C. elegans)
Unc13b: unc-13 homolog B (C. elegans)
Unc13c: unc-13 homolog C (C. elegans)
Unc5b: unc-5 homolog B (C. elegans)
Uqcrc2: ubiquinol-cytochrome c reductase core pro-
tein II
Uqcrfs1: ubiquinol-cytochrome c reductase, Rieske
iron-sulfur polypeptide 1
Uso1:USO1homolog,vesicledockingprotein(yeast)
Usp11: ubiquitin speciﬁc peptidase 11
Vamp1: vesicle-associated membrane protein 1
(synaptobrevin 1)30 International Journal of Alzheimer’s Disease
Vamp2: vesicle-associated membrane protein 2
(synaptobrevin 2)
Vamp3: vesicle-associated membrane protein 3 (cel-
lubrevin)
Vapa: VAMP (vesicle-associated membrane protein)-
associated protein A, 33kDa
Vapb: VAMP (vesicle-associated membrane protein)-
associated protein B and C
VCAN: versican
Vcan: versican
Vcp: valosin-containing protein
Vcpip1: valosin containing protein (p97)/p47 com-
plex interacting protein 1
Vdac1: voltage-dependent anion channel 1
Vdac2: voltage-dependent anion channel 2
Vegfa: vascular endothelial growth factor A
Vgcnl1: sodium leak channel, non-selective
Vgf: VGF nerve growth factor inducible
Vipr2: vasoactive intestinal peptide receptor 2
Vpreb1: pre-B lymphocyte 1
Vps33a: vacuolar protein sorting 33 homolog A (S.
cerevisiae)
Vps33b: vacuolar protein sorting 33 homolog B
(yeast)
Vps4a: vacuolar protein sorting 4 homolog A (S.
cerevisiae)
Vsnl1: visinin-like 1
Vtn: vitronectin
Wars: tryptophanyl-tRNA synthetase
Wbp2: WW domain binding protein 2
Wdr10: intraﬂagellar transport 122 homolog
(Chlamydomonas)
Wdr44: WD repeat domain 44
Wdr7: WD repeat domain 7
Wfs1: Wolfram syndrome 1 (wolframin)
Wif1: WNT inhibitory factor 1
Wipf1: WAS/WASL interacting protein family, mem-
ber 1
Wnk4: WNK lysine deﬁcient protein kinase 4
Wnt5a: wingless-type MMTV integration site family,
member 5A
Wnt7a: wingless-type MMTV integration site family,
member 7A
Xkr6: XK, Kell blood group complex subunit-related
family, member 6
Xpnpep2: X-prolyl aminopeptidase (aminopeptidase
P) 2, membrane-bound
Xpo1: exportin 1 (CRM1 homolog, yeast)
Xpo6: exportin 6
Xrcc1: X-ray repair complementing defective repair
in Chinese hamster cells 1
Xrcc5: X-ray repair complementing defective repair
in Chinese hamster cells 5
Xylt1: xylosyltransferase I
Yars2: tyrosyl-tRNA synthetase 2, mitochondrial
Yes1: v-yes-1 Yamaguchi sarcoma viral oncogene
homolog 1
Ykt6: YKT6 v-SNARE homolog (S. cerevisiae)
Ywhab: tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta polypeptide
Yy1: YY1 transcription factor
Znf382: zinc ﬁnger protein 382
Zranb1:zincﬁnger,RAN-bindingdomaincontaining
1
Zwint: ZW10 interactor.
B.
Lipid raft-derived extracted proteins from Alzheimer’s dis-
ease (3xTgAD) mouse 16-month-old cortical tissue. Speciﬁc
proteins isolated from 3xTgAD mouse cortex were identiﬁed
with multidimensional protein identiﬁcation technology
(MudPIT) LC MS/MS. Each protein was identiﬁed in at least
two out of three experimental replicate animals and from at
least two isolated peptides per protein. The following are the
protein symbol and its corresponding deﬁnition.
Abca1: ATP-binding cassette, sub-family A (ABC1),
member 1
ABCA7: ATP-binding cassette, sub-family A (ABC1),
member 7
Abcb4: ATP-binding cassette, sub-family B (MDR/
TAP), member 4
Abcc1: ATP-binding cassette, sub-family C (CFTR/
MRP), member 1
Abcc2: ATP-binding cassette, sub-family C (CFTR/
MRP), member 2
Abcc4: ATP-binding cassette, sub-family C (CFTR/
MRP), member 4
Abi1: abl-interactor 1
Acadl: acyl-Coenzyme A dehydrogenase, long chain
Acat1: acetyl-Coenzyme A acetyltransferase 1
Acin1: apoptotic chromatin condensation inducer 1
Acmsd: aminocarboxymuconate semialdehyde de-
carboxylase
Acp2: acid phosphatase 2, lysosomal
Acta1: actin, alpha 1, skeletal muscleInternational Journal of Alzheimer’s Disease 31
Actb: actin, beta
Actn4: actinin, alpha 4
Acvr1: activin A receptor, type I
Adam2: ADAM metallopeptidase domain 2
Adam6: ADAM metallopeptidase domain 6 (pseudo-
gene)
Adcy1: adenylate cyclase 1 (brain)
Adcy5: adenylate cyclase 5
Adcy8: adenylate cyclase 8 (brain)
Adcyap1: adenylate cyclase activating polypeptide 1
(pituitary)
Adcyap1r1:adenylatecyclaseactivatingpolypeptide1
(pituitary) receptor type I
Add1: adducin 1 (alpha)
Add2: adducin 2 (beta)
Adrbk1: adrenergic, beta, receptor kinase 1
Aes: amino-terminal enhancer of split
Agpat1: 1-acylglycerol-3-phosphate O-acyltransfer-
ase 1 (lysophosphatidic acid acyltransferase, alpha)
Agpat4: 1-acylglycerol-3-phosphate O-acyltransfer-
ase 4 (lysophosphatidic acid acyltransferase, delta)
Agrn: agrin
Ahi1: Abelson helper integration site 1
Ahr: aryl hydrocarbon receptor
Ahrr: aryl-hydrocarbon receptor repressor
Ak3: adenylate kinase 3
Akap12: A kinase (PRKA) anchor protein 12
Akap3: A kinase (PRKA) anchor protein 3
Akap4: A kinase (PRKA) anchor protein 4
Akap9: A kinase (PRKA) anchor protein (yotiao) 9
Alad: aminolevulinate, delta-, dehydratase
Aldh1a3: aldehyde dehydrogenase 1 family, member
A3
Alox5: arachidonate 5-lipoxygenase
Ampd1: adenosine monophosphate deaminase 1
(isoform M)
Anxa3: annexin A3
Anxa6: annexin A6
Apex2: APEX nuclease (apurinic/apyrimidinic endo-
nuclease) 2
Apob: apolipoprotein B (including Ag(x) antigen)
Apod: apolipoprotein D
App: amyloid beta (A4) precursor protein
Aps: kallikrein-related peptidase 3
Aqp3: aquaporin 3 (Gill blood group)
Aqp4: aquaporin 4
Aqp8: aquaporin 8
Arf1: ADP-ribosylation factor 1
Arf4: ADP-ribosylation factor 4
Arf6: ADP-ribosylation factor 6
Arﬁp1: ADP-ribosylation factor interacting protein 1
Arhgap20: Rho GTPase activating protein 20
Arhgap8: Rho GTPase activating protein 8
Arhgdia: Rho GDP dissociation inhibitor (GDI)
alpha
Arhgef11: Rho guanine nucleotide exchange factor
(GEF) 11
Arhgef12: Rho guanine nucleotide exchange factor
(GEF) 12
Arhgef6: Rac/Cdc42 guanine nucleotide exchange
factor (GEF) 6
Arnt: aryl hydrocarbon receptor nuclear translocator
Arntl: aryl hydrocarbon receptor nuclear transloca-
tor-like
Arpp19: cAMP-regulated phosphoprotein, 19kDa
Ascc1: activating signal cointegrator 1 complex sub-
unit 1
Asz1: ankyrin repeat, SAM and basic leucine zipper
domain containing 1
Atcay: ataxia, cerebellar, Cayman type
Atf3: activating transcription factor 3
Atm: ataxia telangiectasia mutated
Atp1a1: ATPase, Na+/K+ transporting, alpha 1 poly-
peptide
Atp1a4: ATPase, Na+/K+ transporting, alpha 4 poly-
peptide
Atp1b1: ATPase, Na+/K+ transporting, beta 1 poly-
peptide
ATP2B1: ATPase, Ca++ transporting, plasma mem-
brane 1
Atp2b1: ATPase, Ca++ transporting, plasma mem-
brane 1
Atp2b2: ATPase, Ca++ transporting, plasma mem-
brane 2
Atp5a1: ATP synthase, H+ transporting, mitochon-
drial F1 complex, alpha subunit 1, cardiac muscle
Atp5b: ATP synthase, H+ transporting, mitochon-
drial F1 complex, beta polypeptide
Atp5f1: ATP synthase, H+ transporting, mitochon-
drial F0 complex, subunit B1
Atp5h: ATP synthase, H+ transporting, mitochon-
drial F0 complex, subunit d
Atp5i: ATP synthase, H+ transporting, mitochon-
drial F0 complex, subunit E32 International Journal of Alzheimer’s Disease
Atp5j: ATP synthase, H+ transporting, mitochon-
drial F0 complex, subunit F6
Atp6b2: ATPase, H+ transporting, lysosomal
56/58kDa, V1 subunit B2
Atp6l: ATPase, H+ transporting, lysosomal 16kDa,
V0 subunit c
Atp6v0a1: ATPase, H+ transporting, lysosomal V0
subunit a1
ATPBD1C: GPN-loop GTPase 3
Atxn3: ataxin 3
Avil: advillin
B3gat1: beta-1,3-glucuronyltransferase 1 (glucu-
ronosyltransferase P)
Bace1: beta-site APP-cleaving enzyme 1
Basp1: brain abundant, membrane attached signal
protein 1
Bat2: HLA-B associated transcript 2
Bat5: HLA-B associated transcript 5
Bax: BCL2-associated X protein
Bcl10: B-cell CLL/lymphoma 10
Begain: brain-enriched guanylate kinase-associated
homolog (rat)
Bmp6: bone morphogenetic protein 6
Bnip1:BCL2/adenovirusE1B19kDainteractingpro-
tein 1
Bnip3:BCL2/adenovirusE1B19kDainteractingpro-
tein 3
Bpnt1: 3 (2 ), 5 -bisphosphate nucleotidase 1
Brd2: bromodomain containing 2
Brd8: bromodomain containing 8
Bst1: bone marrow stromal cell antigen 1
B t g 2 :B T Gf a m i l y ,m e m b e r2
Bzrap1: benzodiazepine receptor (peripheral) associ-
ated protein 1
c3orf6: coiled-coil domain containing 50
C4a: complement component 4A (Rodgers blood
group)
c8b: complement component 8, beta polypeptide
Cabc1: chaperone, ABC1 activity of bc1 complex
homolog (S. pombe)
Cabin1: calcineurin binding protein 1
Cacna1g: calcium channel, voltage-dependent, T
type, alpha 1G subunit
Cacna2d1: calcium channel, voltage-dependent,
alpha 2/delta subunit 1
Cacna2d2: calcium channel, voltage-dependent,
alpha 2/delta subunit 2
Cacna2d3: calcium channel, voltage-dependent,
alpha 2/delta subunit 3
Cacnb2: calcium channel, voltage-dependent, beta 2
subunit
Calb1: calbindin 1, 28kDa
Calb2: calbindin 2
Cald1: caldesmon 1
calm2: calmodulin 2 (phosphorylase kinase, delta)
Calr: calreticulin
Camk2g: calcium/calmodulin-dependent protein
kinase II gamma
Camkk1: calcium/calmodulin-dependent protein
kinase kinase 1, alpha
Camkv: CaM kinase-like vesicle-associated
Canx: calnexin
Cap1: CAP, adenylate cyclase-associated protein 1
(yeast)
Capn1: calpain 1, (mu/l) large subunit
Capn5: calpain 5
Capn6: calpain 6
Capzb: capping protein (actin ﬁlament) muscle Z-
line, beta
Card9: caspase recruitment domain family, member
9
Carhsp1: calcium regulated heat stable protein 1,
24kDa
Caskin1: CASK interacting protein 1
Casp7:caspase7,apoptosis-relatedcysteinepeptidase
Cast: calpastatin
Cbp: opsin 1 (cone pigments), long-wave-sensitive
Cbx3: chromobox homolog 3 (HP1 gamma homo-
log, Drosophila)
Ccnd2: cyclin D2
Ccs: copper chaperone for superoxide dismutase
Cct2: chaperonin containing TCP1, subunit 2 (beta)
Cd2ap: CD2-associated protein
Cd36: CD36 molecule (thrombospondin receptor)
Cd86: CD86 molecule
Cdc25b: cell division cycle 25 homolog B (S. pombe)
Cdc42: cell division cycle 42 (GTP binding protein,
25kDa)
Cdc5l: CDC5 cell division cycle 5-like (S. pombe)
Cdh1: cadherin 1, type 1, E-cadherin (epithelial)
Cdh10: cadherin 10, type 2 (T2-cadherin)
Cdh13: cadherin 13, H-cadherin (heart)
Cdh2: cadherin 2, type 1, N-cadherin (neuronal)International Journal of Alzheimer’s Disease 33
Cdk5rap2: CDK5 regulatory subunit associated pro-
tein 2
Cdkn1b: cyclin-dependent kinase inhibitor 1B (p27,
Kip1)
Cds1: CDP-diacylglycerol synthase (phosphatidate
cytidylyltransferase) 1
Cdv1: intraﬂagellar transport 81 homolog (Chlamy-
domonas)
Cebp: CCAAT/enhancer binding protein (C/EBP),
alpha
Cend1: cell cycle exit and neuronal diﬀerentiation 1
Cenpc1: centromere protein C 1
Cenpi: centromere protein I
Centa1: ArfGAP with dual PH domains 1
Ces1: carboxylesterase 1 (monocyte/macrophage ser-
ine esterase 1)
Cetn2: centrin, EF-hand protein, 2
Cfd: complement factor D (adipsin)
Cﬂ1: coﬁlin 1 (nonmuscle)
Cftr: cystic ﬁbrosis transmembrane conductance reg-
ulator (ATP-binding cassette sub-family C, member
7)
Chgb: chromogranin B (secretogranin 1)
Chka: choline kinase alpha
Chm: choroideremia (Rab escort protein 1)
Chst10: carbohydrate sulfotransferase 10
Chx10: visual system homeobox 2
Cktsf1b1: gremlin 1, cysteine knot superfamily, hom-
olog (Xenopus laevis)
Clcf1: cardiotrophin-like cytokine factor 1
Cldn18: claudin 18
Clic4: chloride intracellular channel 4
Clip3: CAP-GLY domain containing linker protein 3
Clta: clathrin, light chain (Lca)
Cltb: clathrin, light chain (Lcb)
Cltc: clathrin, heavy chain (Hc)
Clu: clusterin
Cnga1: cyclic nucleotide gated channel alpha 1
Cngb1: cyclic nucleotide gated channel beta 1
Cnot4: CCR4-NOT transcription complex, subunit 4
Cnr1: cannabinoid receptor 1 (brain)
Col5a3: collagen, type V, alpha 3
Copb1: coatomer protein complex, subunit beta 1
Cops4: COP9 constitutive photomorphogenic hom-
olog subunit 4 (Arabidopsis)
Coro1a: coronin, actin binding protein, 1A
Cp: ceruloplasmin (ferroxidase)
Cpa2: carboxypeptidase A2 (pancreatic)
Cpt2: carnitine palmitoyltransferase 2
Creb1: cAMP responsive element binding protein 1
Crhbp: corticotropin releasing hormone binding
protein
Crip2: cysteine-rich protein 2
Cript: cysteine-rich PDZ-binding protein
Crmp1: collapsin response mediator protein 1
Cry2: cryptochrome 2 (photolyase-like)
Csf1: colony stimulating factor 1 (macrophage)
Csh1: chorionic somatomammotropin hormone 1
(placental lactogen)
Csnk1e: casein kinase 1, epsilon
Csnk1g1: casein kinase 1, gamma 1
Csnk1g3: casein kinase 1, gamma 3
Cspg6: structural maintenance of chromosomes 3
Cst6: cystatin E/M
Cstb: cystatin B (steﬁn B)
Ctnnb1: catenin (cadherin-associated protein), beta
1, 88kDa
Cttn: cortactin
Cugbp2: CUG triplet repeat, RNA binding protein 2
Cul5: cullin 5
Cutl1: cut-like homeobox 1
Cxadr: coxsackie virus and adenovirus receptor
Cxcl10: chemokine (C-X-C motif) ligand 10
Cyb5r4: cytochrome b5 reductase 4
Cyln2: CAP-GLY domain containing linker protein 2
Cyp19a1: cytochrome P450, family 19, subfamily A,
polypeptide 1
Cyp1a1: cytochrome P450, family 1, subfamily A,
polypeptide 1
Cyp4x1: cytochrome P450, family 4, subfamily X,
polypeptide 1
Dab2ip: DAB2 interacting protein
Dbn1: drebrin 1
Dctn1: dynactin 1 (p150, glued homolog, Drosophi-
la)
Dctn2: dynactin 2 (p50)
Dctn4: dynactin 4 (p62)
Dcxr: dicarbonyl/L-xylulose reductase
Ddah2: dimethylarginine dimethylaminohydrolase 2
Ddb1: damage-speciﬁc DNA binding protein 1,
127kDa
Ddt: D-dopachrome tautomerase34 International Journal of Alzheimer’s Disease
Ddx1: DEAD (Asp-Glu-Ala-Asp) box polypeptide 1
Ddx19: DEAD (Asp-Glu-Ala-As) box polypeptide
19B
Ddx27: DEAD (Asp-Glu-Ala-Asp) box polypeptide
27
Ddx5: DEAD (Asp-Glu-Ala-Asp) box polypeptide 5
Dedd: death eﬀector domain containing
Degs1: degenerative spermatocyte homolog 1, lipid
desaturase (Drosophila)
Des: desmin
Dgkg: diacylglycerol kinase, gamma 90kDa
Dhcr7: 7-dehydrocholesterol reductase
Dhodh: dihydroorotate dehydrogenase
Dhx40: DEAH (Asp-Glu-Ala-His) box polypeptide
40
Dia1: cytochrome b5 reductase 3
Disc1: disrupted in schizophrenia 1
Dkc1: dyskeratosis congenita 1, dyskerin
Dlat: dihydrolipoamide S-acetyltransferase
Dlc1: deleted in liver cancer 1
Dlgap2: discs, large (Drosophila) homolog-associat-
ed protein 2
Dlgap4: discs, large (Drosophila) homolog-associat-
ed protein 4
Dll1: delta-like 1 (Drosophila)
Dnah7: dynein, axonemal, heavy chain 7
Dnah9: dynein, axonemal, heavy chain 9
Dnajc5: DnaJ (Hsp40) homolog, subfamily C, mem-
ber 5
Dnch1: dynein, cytoplasmic 1, heavy chain 1
Dnch2: dynein, cytoplasmic 2, heavy chain 1
Dnm1: dynamin 1
Dnmt1: DNA (cytosine-5-)-methyltransferase 1
Dnmt3a: DNA (cytosine-5-)-methyltransferase 3
alpha
Dntt: deoxynucleotidyltransferase, terminal
Dpp3: dipeptidyl-peptidase 3
Dpp6: dipeptidyl-peptidase 6
Dpyd: dihydropyrimidine dehydrogenase
Drd1ip: calcyon neuron-speciﬁc vesicular protein
Drg1: developmentally regulated GTP binding pro-
tein 1
Dtnb: dystrobrevin, beta
Dtnbp1: dystrobrevin binding protein 1
Duox1: dual oxidase 1
Dvl1: dishevelled, dsh homolog 1 (Drosophila)
Dyx1c1: dyslexia susceptibility 1 candidate 1
Eaf2: ELL associated factor 2
Echs1: enoyl Coenzyme A hydratase, short chain, 1,
mitochondrial
Eef1g: eukaryotic translation elongation factor 1
gamma
Eef2: eukaryotic translation elongation factor 2
Eef2k: eukaryotic elongation factor-2 kinase
Efemp2: EGF-containing ﬁbulin-like extracellular
matrix protein 2
E g f r :e p i d e r m a lg r o w t hf a c t o rr e c e p t o r( e r y t h r o b -
lastic leukemia viral (v-erb-b) oncogene homolog,
avian)
Eif2ak3: eukaryotic translation initiation factor 2-
alpha kinase 3
Eif2b1: eukaryotic translation initiation factor 2B,
subunit 1 alpha, 26kDa
Eif2c2: eukaryotic translation initiation factor 2C, 2
Eif2s2: eukaryotic translation initiation factor 2,
subunit 2 beta, 38kDa
eif4a1: eukaryotic translation initiation factor 4A,
isoform 1
Elavl3: ELAV (embryonic lethal, abnormal vision,
Drosophila)-like 3 (Hu antigen C)
ELK1: ELK1, member of ETS oncogene family
Emd: emerin
Eno2: enolase 2 (gamma, neuronal)
Enpp2: ectonucleotide pyrophosphatase/phosphod-
iesterase 2
Entpd8: ectonucleoside triphosphate diphosphohy-
drolase 8
Ephx2: epoxide hydrolase 2, cytoplasmic
Epn1: epsin 1
Erp29: endoplasmic reticulum protein 29
Esd: esterase D/formylglutathione hydrolase
Espn: espin
Esrrb: estrogen-related receptor beta
Etfa: electron-transfer-ﬂavoprotein, alpha polypep-
tide
Etfb: electron-transfer-ﬂavoprotein, beta polypeptide
Exoc7: exocyst complex component 7
Ezr: ezrin
F5: coagulation factor V (proaccelerin, labile factor)
Fabp1: fatty acid binding protein 1, liver
Fancd2: Fanconi anemia, complementation group
D2
Fat: FAT tumor suppressor homolog 1 (Drosophila)International Journal of Alzheimer’s Disease 35
Fat2: FAT tumor suppressor homolog 2 (Drosophila)
Fat3: FAT tumor suppressor homolog 3 (Drosophila)
Fbn1: ﬁbrillin 1
Fdps: farnesyl diphosphate synthase
Fgfr1op2: FGFR1 oncogene partner 2
Filip1: ﬁlamin A interacting protein 1
Fkbp1b: FK506 binding protein 1B, 12.6 kDa
Flg: ﬁlaggrin
Flot1: ﬂotillin 1
Flot2: ﬂotillin 2
Fosl1: FOS-like antigen 1
Fosl2: FOS-like antigen 2
Fpgt: fucose-1-phosphate guanylyltransferase
Frap1: mechanistic target of rapamycin (serine/thre-
onine kinase)
Freq: frequenin homolog (Drosophila)
Fyn: FYN oncogene related to SRC, FGR, YES
Gaa: glucosidase, alpha; acid
Gabbr1:gamma-aminobutyricacid(GABA)Brecep-
tor, 1
Gabra3: gamma-aminobutyric acid (GABA) A recep-
tor, alpha 3
Gabre: gamma-aminobutyric acid (GABA) A recep-
tor, epsilon
Gadd45a:growtharrestandDNA-damage-inducible,
alpha
Galc: galactosylceramidase
Galk1: galactokinase 1
Galnt10:UDP-N-acetyl-alpha-D-galactosamine:pol-
ypeptide N-acetylgalactosaminyltransferase 10
Gars: glycyl-tRNA synthetase
Gas7: growth arrest-speciﬁc 7
Gc: group-speciﬁc component (vitamin D binding
protein)
Gdi1: GDP dissociation inhibitor 1
Gdi2: GDP dissociation inhibitor 2
Gfap: glial ﬁbrillary acidic protein
Gif: gastric intrinsic factor (vitamin B synthesis)
Gjb2: gap junction protein, beta 2, 26kDa
Gla: galactosidase, alpha
Gldc: glycine dehydrogenase (decarboxylating)
Glra2: glycine receptor, alpha 2
Glut3: solute carrier family 2 (facilitated glucose
transporter), member 3
Gmcl1: germ cell-less homolog 1 (Drosophila)
Gmfb: glia maturation factor, beta
Gna11: guanine nucleotide binding protein (G pro-
tein), alpha 11 (Gq class)
Gnai1: guanine nucleotide binding protein (G pro-
tein), alpha inhibiting activity polypeptide 1
Gnai2: guanine nucleotide binding protein (G pro-
tein), alpha inhibiting activity polypeptide 2
Gnao1: guanine nucleotide binding protein (G pro-
tein), alpha activating activity polypeptide O
Gnaq: guanine nucleotide binding protein (G pro-
tein), q polypeptide
Gnaz: guanine nucleotide binding protein (G pro-
tein), alpha z polypeptide
Gnb2l1: guanine nucleotide binding protein (G pro-
tein), beta polypeptide 2-like 1
Gnl3: guanine nucleotide binding protein-like 3
(nucleolar)
Gnpat: glyceronephosphate O-acyltransferase
Gpi: glucose phosphate isomerase
Gpm6a: glycoprotein M6A
Gpr1: G protein-coupled receptor 1
Gpr141: G protein-coupled receptor 141
Gpr56: G protein-coupled receptor 56
Gpsm1:G-proteinsignalingmodulator1(AGS3-like,
C. elegans)
Gpt2: glutamic pyruvate transaminase (alanine ami-
notransferase) 2
Grin1: glutamate receptor, ionotropic, N-methyl D-
aspartate 1
Grpel1: GrpE-like 1, mitochondrial (E. coli)
Gstm2: glutathione S-transferase mu 2 (muscle)
Gstm3: glutathione S-transferase mu 3 (brain)
Gucy2d: guanylate cyclase 2D, membrane (retina-
speciﬁc)
Gucy2f: guanylate cyclase 2F, retinal
H1f0: H1 histone family, member 0
H1f4: histone cluster 1, H1e
H2afy: H2A histone family, member Y
Haao: 3-hydroxyanthranilate 3,4-dioxygenase
Hap1: huntingtin-associated protein 1
Hapln3: hyaluronan and proteoglycan link protein 3
Hbld2: iron-sulfur cluster assembly 1 homolog (S.
cerevisiae)
Hck: hemopoietic cell kinase
Hcn1: hyperpolarization activated cyclic nucleotide-
gated potassium channel 1
Hdac6: histone deacetylase 6
Hdgf: hepatoma-derived growth factor (high-
mobility group protein 1-like)36 International Journal of Alzheimer’s Disease
Hdlbp: high density lipoprotein binding protein
Hey1: hairy/enhancer-of-split related with YRPW
motif 1
Hgf:hepatocytegrowthfactor(hepapoietinA;scatter
factor)
Hip1r: huntingtin interacting protein 1 related
Hivep1: human immunodeﬁciency virus type I
enhancer binding protein 1
Hk1: hexokinase 1
Hmga2: high mobility group AT-hook 2
Hmgcr: 3-hydroxy-3-methylglutaryl-Coenzyme A
reductase
Hmgcs1: 3-hydroxy-3-methylglutaryl-Coenzyme A
synthase 1 (soluble)
Hmgn3: high mobility group nucleosomal binding
domain 3
Hn1: hematological and neurological expressed 1
Hnf4a: hepatocyte nuclear factor 4, alpha
Hnmt: histamine N-methyltransferase
Hnrnph1: heterogeneous nuclear ribonucleoprotein
H1 (H)
Hnrpa1: heterogeneous nuclear ribonucleoprotein
A1
Hnrpk: heterogeneous nuclear ribonucleoprotein K
Hnrpu: heterogeneous nuclear ribonucleoprotein U
(scaﬀold attachment factor A)
hook3: hook homolog 3 (Drosophila)
Hps5: Hermansky-Pudlak syndrome 5
Hpse: heparanase
Hras1: v-Ha-ras Harvey rat sarcoma viral oncogene
homolog
Hsd11b2: hydroxysteroid (11-beta) dehydrogenase 2
Hsd17B1: hydroxysteroid (17-beta) dehydrogenase 1
Hsf1: heat shock transcription factor 1
Hsp90ab1: heat shock protein 90kDa alpha (cytoso-
lic), class B member 1
Hspa14: heat shock 70kDa protein 14
Hspe1: heat shock 10kDa protein 1 (chaperonin 10)
Htr2c: 5-hydroxytryptamine (serotonin) receptor 2C
Htr3a: 5-hydroxytryptamine (serotonin) receptor 3A
Htr4: 5-hydroxytryptamine (serotonin) receptor 4
Hyou1: hypoxia up-regulated 1
Id2: inhibitor of DNA binding 2, dominant negative
helix-loop-helix protein
Idh1: isocitrate dehydrogenase 1 (NADP+), soluble
Igf1r: insulin-like growth factor 1 receptor
Igf2r: insulin-like growth factor 2 receptor
Ikbkap: inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase complex-associated pro-
tein
IL1b: interleukin 1, beta
Il1r2: interleukin 1 receptor, type II
Il1rapl1: interleukin 1 receptor accessory protein-like
1
Il6: interleukin 6 (interferon, beta 2)
Ilf3: interleukin enhancer binding factor 3, 90kDa
Inhbc: inhibin, beta C
Inpp4a: inositol polyphosphate-4-phosphatase, type
I, 107kDa
Inpp4b: inositol polyphosphate-4-phosphatase, type
II, 105kDa
Inpp5d: inositol polyphosphate-5-phosphatase,
145kDa
Irs1: insulin receptor substrate 1
Irs2: insulin receptor substrate 2
Isg20: interferon stimulated exonuclease gene 20kDa
Itga6: integrin, alpha 6
Itm2c: integral membrane protein 2C
Itpr2: inositol 1,4,5-triphosphate receptor, type 2
Itpr3: inositol 1,4,5-triphosphate receptor, type 3
Ivl: involucrin
Jag1: jagged 1 (Alagille syndrome)
Jak1: Janus kinase 1
Jak2: Janus kinase 2
J u n b :j u nBp r o t o - o n c o g e n e
Kalrn: kalirin, RhoGEF kinase
Katna1: katanin p60 (ATPase-containing) subunit A
1
Kcnh1: potassium voltage-gated channel, subfamily
H( e a g - r e l a t e d ) ,m e m b e r1
Kcnh2: potassium voltage-gated channel, subfamily
H( e a g - r e l a t e d ) ,m e m b e r2
Kcnk2: potassium channel, subfamily K, member 2
Kcns1: potassium voltage-gated channel, delayed-
rectiﬁer, subfamily S, member 1
Kcns3: potassium voltage-gated channel, delayed-
rectiﬁer, subfamily S, member 3
Kcnt1: potassium channel, subfamily T, member 1
Kif5a: kinesin family member 5A
Klc1: kinesin light chain 1
Klhl12: kelch-like 12 (Drosophila)
Kpnb1: karyopherin (importin) beta 1
Kras: v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homologInternational Journal of Alzheimer’s Disease 37
Lama5: laminin, alpha 5
Lancl1: LanC lantibiotic synthetase component C-
like 1 (bacterial)
Lars: leucyl-tRNA synthetase
Lbp: lipopolysaccharide binding protein
Lcmt1: leucine carboxyl methyltransferase 1
Letm1: leucine zipper-EF-hand containing trans-
membrane protein 1
Lgi1: leucine-rich, glioma inactivated 1
Lgr7: relaxin/insulin-like family peptide receptor 1
Lhfpl4: lipoma HMGIC fusion partner-like 4
Lhx3: LIM homeobox 3
Lifr: leukemia inhibitory factor receptor alpha
Lin10: chromosome 16 open reading frame 70
LMO7: LIM domain 7
Lphn1: latrophilin 1
Lphn2: latrophilin 2
Lpin1: lipin 1
Lrpap1: low density lipoprotein receptor-related pro-
tein associated protein 1
Lsamp: limbic system-associated membrane protein
Ltbp1: latent transforming growth factor beta bind-
ing protein 1
Luzp1: leucine zipper protein 1
Ly6g5b: lymphocyte antigen 6 complex, locus G5B
Lyar: Ly1 antibody reactive homolog (mouse)
LYL1: lymphoblastic leukemia derived sequence 1
Lyst: lysosomal traﬃcking regulator
Lzic:leucinezipperandCTNNBIP1domaincontain-
ing
M6pr: mannose-6-phosphate receptor (cation
dependent)
Magi3: membrane associated guanylate kinase, WW
and PDZ domain containing 3
Maoa: monoamine oxidase A
Map1lc3a: microtubule-associated protein 1 light
chain 3 alpha
Map2: microtubule-associated protein 2
Map3k7ip2: mitogen-activated protein kinase kinase
kinase 7 interacting protein 2
Map4: microtubule-associated protein 4
Mapk1: mitogen-activated protein kinase 1
Mapkapk2: mitogen-activated protein kinase-acti-
vated protein kinase 2
Mark1: MAP/microtubule aﬃnity-regulating kinase
1
Mark3: MAP/microtubule aﬃnity-regulating kinase
3
Matr3: matrin 3
Mcm7: minichromosome maintenance complex
component 7
Mdga2: MAM domain containing glycosylphos-
phatidylinositol anchor 2
Mdh1: malate dehydrogenase 1, NAD (soluble)
Mecp2: methyl CpG binding protein 2 (Rett syn-
drome)
Mfap3: microﬁbrillar-associated protein 3
Mgat1:mannosyl(alpha-1,3-)-glycoproteinbeta-1,2-
N-acetylglucosaminyltransferase
Mgat5:mannosyl(alpha-1,6-)-glycoproteinbeta-1,6-
N-acetyl-glucosaminyltransferase
Mid1: midline 1 (Opitz/BBB syndrome)
Mkln1: muskelin 1, intracellular mediator containing
kelch motifs
Mkrn2: makorin ring ﬁnger protein 2
Mlp: MARCKS-like 1
Mmp10: matrix metallopeptidase 10 (stromelysin 2)
Mnat1: m´ enage ` a trois homolog 1, cyclin H assembly
factor (Xenopus laevis)
Mpdz: multiple PDZ domain protein
Mpi: mannose phosphate isomerase
Mpo: myeloperoxidase
mpp7: membrane protein, palmitoylated 7 (MAGUK
p55 subfamily member 7)
mre11:MRE11meioticrecombination11homologA
(S. cerevisiae)
Mrpl38: mitochondrial ribosomal protein L38
Mrpl9: mitochondrial ribosomal protein L9
Mrps9: mitochondrial ribosomal protein S9
Msn: moesin
Mtap: methylthioadenosine phosphorylase
Mtdh: metadherin
Mtmr3: myotubularin-related protein 3
Mtr: 5-methyltetrahydrofolate-homocysteine meth-
yltransferase
Mtus1: microtubule-associated tumor suppressor 1
Mx1: myxovirus (inﬂuenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
Mybpc1: myosin binding protein C, slow type
myc: v-myc myelocytomatosis viral oncogene homo-
log (avian)
Mycbpap: MYCBP associated protein
Myh10: myosin, heavy chain 10, nonmuscle38 International Journal of Alzheimer’s Disease
Myh6: myosin, heavy chain 6, cardiac muscle, alpha
Myh9: myosin, heavy chain 9, nonmuscle
Myo1a: myosin IA
Myo1e: myosin IE
Myo5a: myosin VA (heavy chain 12, myoxin)
Myo5b: myosin VB
Myo7a: myosin VIIA
Myo9a: myosin IXA
Myom1: myomesin 1, 185kDa
Nab1: NGFI-A binding protein 1 (EGR1 binding
protein 1)
Nab2: NGFI-A binding protein 2 (EGR1 binding
protein 2)
Naca: nascent polypeptide-associated complex alpha
subunit
Naglu: N-acetylglucosaminidase, alpha-
Nap1l3: nucleosome assembly protein 1-like 3
Napepld: N-acyl phosphatidylethanolamine phos-
pholipase D
Nasp: nuclear autoantigenic sperm protein (histone-
binding)
Ncam1: neural cell adhesion molecule 1
Ncam2: neural cell adhesion molecule 2
Ncdn: neurochondrin
Ncl: nucleolin
Ncstn: nicastrin
Ndel1:nudEnucleardistributiongeneEhomolog(A.
nidulans)-like 1
Ndufa9: NADH dehydrogenase (ubiquinone) 1 alpha
s u b c o m p l e x ,9 ,3 9k D a
Ndufc2: NADH dehydrogenase (ubiquinone) 1, sub-
complex unknown, 2, 14.5kDa
Ndufs1: NADH dehydrogenase (ubiquinone) Fe-S
protein 1, 75kDa (NADH-coenzyme Q reductase)
Ndufs6: NADH dehydrogenase (ubiquinone) Fe-S
protein 6, 13kDa (NADH-coenzyme Q reductase)
Ndufs7: NADH dehydrogenase (ubiquinone) Fe-S
protein 7, 20kDa (NADH-coenzyme Q reductase)
Nedd4: neural precursor cell expressed, developmen-
tally down-regulated 4
Nef3: neuroﬁlament, medium polypeptide
Nefh: neuroﬁlament, heavy polypeptide
Negr1: neuronal growth regulator 1
Nell1: NEL-like 1 (chicken)
Neo1: neogenin homolog 1 (chicken)
Nes: nestin
Nexn: nexilin (F actin binding protein)
Nf2: neuroﬁbromin 2 (merlin)
Nﬁx: nuclear factor I/X (CCAAT-binding transcrip-
tion factor)
Nfkb1: nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1
Ninj1: ninjurin 1
Nlgn2: neuroligin 2
Nlgn3: neuroligin 3
Nme2: non-metastatic cells 2, protein (NM23B)
expressed in
Nolc1: nucleolar and coiled-body phosphoprotein 1
Nos1: nitric oxide synthase 1 (neuronal)
Nos3: nitric oxide synthase 3 (endothelial cell)
Notch1: Notch homolog 1, translocation-associated
(Drosophila)
Notch2: Notch homolog 2 (Drosophila)
Notch4: Notch homolog 4 (Drosophila)
Npc2: Niemann-Pick disease, type C2
Npdc1: neural proliferation, diﬀerentiation and con-
trol, 1
Npepps: aminopeptidase puromycin sensitive
Npm1: nucleophosmin (nucleolar phosphoprotein
B23, numatrin)
Npr2: natriuretic peptide receptor B/guanylate
cyclase B (atrionatriuretic peptide receptor B)
Npvf: neuropeptide VF precursor
Npy5r: neuropeptide Y receptor Y5
Nr1i2:nuclearreceptorsubfamily1,groupI,member
2
Nr5a2: nuclear receptor subfamily 5, group A, mem-
ber 2
Nr6a1: nuclear receptor subfamily 6, group A, mem-
ber 1
Nras: neuroblastoma RAS viral (v-ras) oncogene
homolog
Nrbf2: nuclear receptor binding factor 2
Nrp2: neuropilin 2
Nsf: N-ethylmaleimide-sensitive factor
Ntrk2: neurotrophic tyrosine kinase, receptor, type 2
Nucb1: nucleobindin 1
Nucb2: nucleobindin 2
Nudc: nuclear distribution gene C homolog (A.
nidulans)
Nup88: nucleoporin 88kDa
Oas3: 2 -5 -oligoadenylate synthetase 3, 100kDa
Obscn: obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEFInternational Journal of Alzheimer’s Disease 39
Ociad1: OCIA domain containing 1
Odc1: ornithine decarboxylase 1
Odf2: outer dense ﬁber of sperm tails 2
Ogfr: opioid growth factor receptor
Olfm2: olfactomedin 2
Olfm3: olfactomedin 3
Omg: oligodendrocyte myelin glycoprotein
Optn: optineurin
Osbp: oxysterol binding protein
Oxr1: oxidation resistance 1
P4hb: prolyl 4-hydroxylase, beta polypeptide
Pabpc1: poly(A) binding protein, cytoplasmic 1
Pabpc4: poly(A) binding protein, cytoplasmic 4
(inducible form)
Padi2: peptidyl arginine deiminase, type II
Pak3: p21 protein (Cdc42/Rac)-activated kinase 3
Palm: paralemmin
Panx1: pannexin 1
Pard3: par-3 partitioning defective 3 homolog (C.
elegans)
Parg: poly (ADP-ribose) glycohydrolase
Park7: Parkinson disease (autosomal recessive, early
onset) 7
Pbp: phosphatidylethanolamine binding protein 1
Pcca: propionyl Coenzyme A carboxylase, alpha pol-
ypeptide
Pcdh21: protocadherin 21
Pcdha3: protocadherin alpha 3
Pcdhb1: protocadherin beta 1
Pcdhb10: protocadherin beta 10
Pcdhga12: protocadherin gamma subfamily A, 12
Pclo: piccolo (presynaptic cytomatrix protein)
Pcolce: procollagen C-endopeptidase enhancer
Pcsk1n: proprotein convertase subtilisin/kexin type 1
inhibitor
Pcsk5: proprotein convertase subtilisin/kexin type 5
Pcyox1: prenylcysteine oxidase 1
Pdap1: PDGFA associated protein 1
Pdcd4:programmedcelldeath4(neoplastictransfor-
mation inhibitor)
Pdcl: phosducin-like
Pde10a: phosphodiesterase 10A
Pde4b: phosphodiesterase 4B, cAMP-speciﬁc (phos-
phodiesterase E4 dunce homolog, Drosophila)
Pdlim7: PDZ and LIM domain 7 (enigma)
Pea15: phosphoprotein enriched in astrocytes 15
Pecr: peroxisomal trans-2-enoyl-CoA reductase
Per1: period homolog 1 (Drosophila)
Per3: period homolog 3 (Drosophila)
Pfkl: phosphofructokinase, liver
PGAP1: post-GPI attachment to proteins 1
Phactr3: phosphatase and actin regulator 3
Phb: prohibitin
Phka1: phosphorylase kinase, alpha 1 (muscle)
Phkg2: phosphorylase kinase, gamma 2 (testis)
Pi4ka: phosphatidylinositol 4-kinase, catalytic, alpha
Picalm: phosphatidylinositol binding clathrin assem-
bly protein
Pik3c3: phosphoinositide-3-kinase, class 3
Pik3cb: phosphoinositide-3-kinase, catalytic, beta
polypeptide
Pik3r2: phosphoinositide-3-kinase, regulatory sub-
unit 2 (beta)
Pim1: pim-1 oncogene
Pip5k2a: phosphatidylinositol-5-phosphate 4-kinase,
type II, alpha
Pitpnm1: phosphatidylinositol transfer protein,
membrane-associated 1
Pkia: protein kinase (cAMP-dependent, catalytic) in-
hibitor alpha
Pkm2: pyruvate kinase, muscle
Pla2g2a: phospholipase A2, group IIA (platelets,
synovial ﬂuid)
Plb1: phospholipase B1
Plcb4: phospholipase C, beta 4
Plcd4: phospholipase C, delta 4
Plec1: plectin 1, intermediate ﬁlament binding pro-
tein 500kDa
Plk1: polo-like kinase 1 (Drosophila)
Pnkp: polynucleotide kinase 3’-phosphatase
Pnma1: paraneoplastic antigen MA1
Ppara: peroxisome proliferator-activated receptor
alpha
Ppargc1b: peroxisome proliferator-activated receptor
gamma, coactivator 1 beta
ppﬁbp2: PTPRF interacting protein, binding protein
2 (liprin beta 2)
Ppia: peptidylprolyl isomerase A (cyclophilin A)
Ppm2c: pyruvate dehydrogenase phosphatase cat-
alytic subunit 1
Ppp1r14b: protein phosphatase 1, regulatory (inhibi-
tor) subunit 14B
Ppp1r1a: protein phosphatase 1, regulatory (inhibi-
tor) subunit 1A40 International Journal of Alzheimer’s Disease
Ppp1r9a: protein phosphatase 1, regulatory (inhibi-
tor) subunit 9A
Ppp2r1a: protein phosphatase 2 (formerly 2A), regu-
latory subunit A, alpha isoform
Ppp3cc: protein phosphatase 3 (formerly 2B), cat-
alytic subunit, gamma isoform
Pqlc1: PQ loop repeat containing 1
Prdx1: peroxiredoxin 1
Prdx6: peroxiredoxin 6
Prg3: proteoglycan 3
Prkaa2: protein kinase, AMP-activated, alpha 2 cat-
alytic subunit
Prkaca: protein kinase, cAMP-dependent, catalytic,
alpha
Prkar1a: protein kinase, cAMP-dependent, regula-
tory, type I, alpha (tissue speciﬁc extinguisher 1)
Prkar2a: protein kinase, cAMP-dependent, regula-
tory, type II, alpha
Prkcd: protein kinase C, delta
PRKCQ: protein kinase C, theta
Prkwnk1: WNK lysine deﬁcient protein kinase 1
Prlh: prolactin releasing hormone
Prmt3: protein arginine methyltransferase 3
Prpsap2: phosphoribosyl pyrophosphate synthetase-
associated protein 2
Prrx2: paired related homeobox 2
Prss12: protease, serine, 12 (neurotrypsin, motopsin)
Prss15: lon peptidase 1, mitochondrial
Prx: periaxin
Psap: prosaposin
Pscd2: cytohesin 2
Pscd3: cytohesin 3
Psg4: pregnancy speciﬁc beta-1-glycoprotein 4
Psma1: proteasome (prosome, macropain) subunit,
alpha type, 1
Psma2: proteasome (prosome, macropain) subunit,
alpha type, 2
Psmc4: proteasome (prosome, macropain) 26S sub-
unit, ATPase, 4
Psme2: proteasome (prosome, macropain) activator
subunit 2 (PA28 beta)
Ptbp1: polypyrimidine tract binding protein 1
Ptch1: patched homolog 1 (Drosophila)
Pth: parathyroid hormone
Pthr2: parathyroid hormone 2 receptor
Ptk2b: PTK2B protein tyrosine kinase 2 beta
Ptp4a1: protein tyrosine phosphatase type IVA,
member 1
Ptpn11: protein tyrosine phosphatase, non-receptor
type 11
Ptpn23: protein tyrosine phosphatase, non-receptor
type 23
Ptprj: protein tyrosine phosphatase, receptor type, J
Ptprr: protein tyrosine phosphatase, receptor type, R
Ptprv: protein tyrosine phosphatase, receptor type, V
(pseudogene)
Pxn: paxillin
Pygl: phosphorylase, glycogen, liver
Qscn6: quiescin Q6 sulfhydryl oxidase 1
Rab10: RAB10, member RAS oncogene family
Rab14: RAB14, member RAS oncogene family
Rab2: RAB2A, member RAS oncogene family
Rab21: RAB21, member RAS oncogene family
Rab35: RAB35, member RAS oncogene family
Rab3il1: RAB3A interacting protein (rabin3)-like 1
Rab4a: RAB4A, member RAS oncogene family
Rab5a: RAB5A, member RAS oncogene family
Rab7: RAB7A, member RAS oncogene family
Rab9: RAB9A, member RAS oncogene family
Rabac1: Rab acceptor 1 (prenylated)
Rabggta: Rab geranylgeranyltransferase, alpha sub-
unit
Rac1:ras-relatedC3botulinumtoxinsubstrate1(rho
family, small GTP binding protein Rac1)
Rala: v-ral simian leukemia viral oncogene homolog
A( r a sr e l a t e d )
RalB: v-ral simian leukemia viral oncogene homolog
B (ras related; GTP binding protein)
Ralb: v-ral simian leukemia viral oncogene homolog
B (ras related; GTP binding protein)
Raly: RNA binding protein, autoantigenic (hnRNP
associated with lethal yellow homolog (mouse))
RanGap1: Ran GTPase activating protein 1
Rap2b: RAP2B, member of RAS oncogene family
Rbbp6: retinoblastoma binding protein 6
Rbl2: retinoblastoma-like 2 (p130)
Rbm3: RNA binding motif (RNP1, RRM) protein 3
Rcn1: reticulocalbin 1, EF-hand calcium binding
domain
Rcvrn: recoverin
Rdh10: retinol dehydrogenase 10 (all-trans)
Rdx: radixin
Rest: RE1-silencing transcription factorInternational Journal of Alzheimer’s Disease 41
Rgs4: regulator of G-protein signaling 4
Rgs5: regulator of G-protein signaling 5
Rgs7: regulator of G-protein signaling 7
Rhoa: ras homolog gene family, member A
RhoB: ras homolog gene family, member B
Rhoj: ras homolog gene family, member J
Rims1: regulating synaptic membrane exocytosis 1
Rnasel: ribonuclease L (2 ,5 -oligoisoadenylate syn-
thetase-dependent)
Rnf36: tripartite motif-containing 69
Rnf40: ring ﬁnger protein 40
Robo1: roundabout, axon guidance receptor, homo-
log 1 (Drosophila)
Robo4: roundabout homolog 4, magic roundabout
(Drosophila)
Rock1: Rho-associated, coiled-coil containing pro-
tein kinase 1
Rock2: Rho-associated, coiled-coil containing pro-
tein kinase 2
rora: RAR-related orphan receptor A
Rpe65: retinal pigment epithelium-speciﬁc protein
65kDa
Rpl13: ribosomal protein L13
Rpl6: ribosomal protein L6
Rplp1: ribosomal protein, large, P1
Rpn2: ribophorin II
Rps15: ribosomal protein S15
Rps16: ribosomal protein S16
Rps6ka2: ribosomal protein S6 kinase, 90kDa, poly-
peptide 2
Rtcd1: RNA terminal phosphate cyclase domain 1
Rtkn: rhotekin
Rtn1: reticulon 1
Rtn3: reticulon 3
Rtn4: reticulon 4
Rtn4r: reticulon 4 receptor
Samsn1: SAM domain, SH3 domain and nuclear
localization signals 1
Sardh: sarcosine dehydrogenase
Sart1: squamous cell carcinoma antigen recognized
b yTc e l l s
Sbds: Shwachman-Bodian-Diamond syndrome
Sc4mol: sterol-C4-methyl oxidase-like
Sca10: ataxin 10
Scg2: secretogranin II (chromogranin C)
Scg3: secretogranin III
Scn1a: sodium channel, voltage-gated, type I, alpha
subunit
Scn2a1: sodium channel, voltage-gated,type II,alpha
subunit
Scn5a: sodium channel, voltage-gated, type V, alpha
subunit
Scn8a: sodium channel, voltage gated, type VIII,
alpha subunit
Scoc: short coiled-coil protein
Scp2: sterol carrier protein 2
SCYB11: chemokine (C-X-C motif) ligand 11
Scye1: aminoacyl tRNA synthetase complex-
interacting multifunctional protein 1
Sdfr1: neuroplastin
Sdpr: serum deprivation response
SH3gl1: SH3-domain GRB2-like 1
SH3glb1: SH3-domain GRB2-like endophilin B1
Shank1: SH3 and multiple ankyrin repeat domains 1
Sirpa: signal-regulatory protein alpha
Skiv2l2: superkiller viralicidic activity 2-like 2 (S.
cerevisiae)
Slc12a2: solute carrier family 12 (sodium/potassi-
um/chloride transporters), member 2
Slc12a9: solute carrier family 12 (potassium/chloride
transporters), member 9
Slc13a3: solute carrier family 13 (sodium-dependent
dicarboxylate transporter), member 3
Slc17a6: solute carrier family 17 (sodium-dependent
inorganic phosphate cotransporter), member 6
Slc1a1: solute carrier family 1 (neuronal/epithelial
high aﬃnity glutamate transporter, system Xag),
member 1
Slc26a4: solute carrier family 26, member 4
Slc27a5: solute carrier family 27 (fatty acid trans-
porter), member 5
Slc30a1: solute carrier family 30 (zinc transporter),
member 1
Slc44a4: solute carrier family 44, member 4
Slc5a1: solute carrier family 5 (sodium/glucose
cotransporter), member 1
Slc6a8: solute carrier family 6 (neurotransmitter
transporter, creatine), member 8
Slc8a1: solute carrier family 8 (sodium/calcium
exchanger), member 1
Smad4: SMAD family member 4
Smc1l1: structural maintenance of chromosomes 1A
Smoc1: SPARC related modular calcium binding 1
Snai2: snail homolog 2 (Drosophila)42 International Journal of Alzheimer’s Disease
Snap25: synaptosomal-associated protein, 25kDa
Snap91: synaptosomal-associated protein, 91kDa
homolog (mouse)
Snca: synuclein, alpha (non A4 component of amy-
loid precursor)
Sncb: synuclein, beta
Snx3: sorting nexin 3
Snx7: sorting nexin 7
sod1: superoxide dismutase 1, soluble
Sod2: superoxide dismutase 2, mitochondrial
Son: SON DNA binding protein
Sord: sorbitol dehydrogenase
Sox5: SRY (sex determining region Y)-box 5
Sp4: Sp4 transcription factor
Sp7: Sp7 transcription factor
Sqle: squalene epoxidase
Srfbp1: serum response factor binding protein 1
Sst: somatostatin
St6gal2: ST6 beta-galactosamide alpha-2,6-sialyl-
transferase 2
St7l: suppression of tumorigenicity 7 like
Stard3nl: STARD3 N-terminal like
Stat3:signaltransducerandactivatoroftranscription
3 (acute-phase response factor)
Stat5a: signal transducer and activator of transcrip-
tion 5A
Stip1: stress-induced-phosphoprotein 1
Stk2: NIMA (never in mitosis gene a)-related kinase
4
Stk22a: testis-speciﬁc serine kinase 1A pseudogene
Stmn1: stathmin 1
Stmn2: stathmin-like 2
Stmn4: stathmin-like 4
Strbp: spermatid perinuclear RNA binding protein
Stx1a: syntaxin 1A (brain)
Stx1b2: syntaxin 1B
Stx5: syntaxin 5
stxbp1: syntaxin binding protein 1
Stxbp3: syntaxin binding protein 3
Sulf1: sulfatase 1
Svop: SV2 related protein homolog (rat)
SYAP1:synapseassociatedprotein1,SAP47homolog
(Drosophila)
Sycp1: synaptonemal complex protein 1
Sycp2: synaptonemal complex protein 2
Synj2: synaptojanin 2
Syt3: synaptotagmin III
Syt4: synaptotagmin IV
Tacc2: transforming, acidic coiled-coil containing
protein 2
Tacc3: transforming, acidic coiled-coil containing
protein 3
Tbx2: T-box 2
Tceb3: transcription elongation factor B (SIII), poly-
peptide 3 (110kDa, elongin A)
Tcp1: t-complex 1
Tcp11: t-complex 11 homolog (mouse)
Tdg: thymine-DNA glycosylase
Tdrd7: tudor domain containing 7
Tesk2: testis-speciﬁc kinase 2
Tfrc: transferrin receptor (p90, CD71)
Tgfb1: transforming growth factor, beta 1
Thrap3:thyroidhormonereceptorassociatedprotein
3
Thrb: thyroid hormone receptor, beta (erythroblastic
leukemia viral (v-erb-a) oncogene homolog 2, avian)
Thy1: Thy-1 cell surface antigen
Tinag: tubulointerstitial nephritis antigen
Tkt: transketolase
Tle3: transducin-like enhancer of split 3 (E(sp1)
homolog, Drosophila)
Tlr5: toll-like receptor 5
Tm4sf8: tetraspanin 3
Tm9sf2: transmembrane 9 superfamily member 2
Tmeﬀ1: transmembrane protein with EGF-like and
two follistatin-like domains 1
Tmem17: transmembrane protein 17
Tmlhe: trimethyllysine hydroxylase, epsilon
Tmod2: tropomodulin 2 (neuronal)
Tmpo: thymopoietin
Tnfrsf14: tumor necrosis factor receptor superfamily,
member 14 (herpesvirus entry mediator)
Top1: topoisomerase (DNA) I
Tpd52l2: tumor protein D52-like 2
Tpm4: tropomyosin 4
Tra1: heat shock protein 90kDa beta (Grp94), mem-
ber 1
Traf4: TNF receptor-associated factor 4
Trib3: tribbles homolog 3 (Drosophila)
Trim10: tripartite motif-containing 10
Trim25: tripartite motif-containing 25
Trim50: tripartite motif-containing 50International Journal of Alzheimer’s Disease 43
Trpa1: transient receptor potential cation channel,
subfamily A, member 1
TrpV6: transient receptor potential cation channel,
subfamily V, member 6
Tsc1: tuberous sclerosis 1
Tsga10: testis speciﬁc, 10
Tshr: thyroid stimulating hormone receptor
Ttc1: tetratricopeptide repeat domain 1
Ttn: titin
Tub: tubby homolog (mouse)
Tubb: tubulin, beta
Tubb2: tubulin, beta 2A
Txn: thioredoxin
U2af2: U2 small nuclear RNA auxiliary factor 2
Ubc: ubiquitin C
Ube2l3: ubiquitin-conjugating enzyme E2L 3
Ubqln1: ubiquilin 1
Uchl1:ubiquitincarboxyl-terminalesteraseL1(ubiq-
uitin thiolesterase)
Ugcgl1: UDP-glucose glycoprotein glucosyltrans-
ferase 1
Uhrf1: ubiquitin-like with PHD and ring ﬁnger
domains 1
Unc13: unc-13 homolog B (C. elegans)
Unc13a: unc-13 homolog A (C. elegans)
Unc13d: unc-13 homolog D (C. elegans)
Uqcrfs1: ubiquinol-cytochrome c reductase, Rieske
iron-sulfur polypeptide 1
Usp14: ubiquitin speciﬁc peptidase 14 (tRNA-
guanine transglycosylase)
Usp15: ubiquitin speciﬁc peptidase 15
Vamp2: vesicle-associated membrane protein 2
(synaptobrevin 2)
Vangl2: vang-like 2 (van gogh, Drosophila)
Vapa: VAMP (vesicle-associated membrane protein)-
associated protein A, 33kDa
Vapb: VAMP (vesicle-associated membrane protein)-
associated protein B and C
Vav1: vav 1 guanine nucleotide exchange factor
Vcp: valosin-containing protein
Vdac2: voltage-dependent anion channel 2
Vegfa: vascular endothelial growth factor A
Vgf: VGF nerve growth factor inducible
Viaat: solute carrier family 32 (GABA vesicular
transporter), member 1
Vim: vimentin
Vldlr: very low density lipoprotein receptor
Vps4a: vacuolar protein sorting 4 homolog A (S.
cerevisiae)
Vps52: vacuolar protein sorting 52 homolog (S.
cerevisiae)
Vps54: vacuolar protein sorting 54 homolog (S.
cerevisiae)
Vsnl1: visinin-like 1
Vti1a: vesicle transport through interaction with t-
SNAREs homolog 1A (yeast)
Vtn: vitronectin
Wbp11: WW domain binding protein 11
Wbscr1: eukaryotic translation initiation factor 4H
Whsc2: Wolf-Hirschhorn syndrome candidate 2
Wif1: WNT inhibitory factor 1
Wnk4: WNK lysine deﬁcient protein kinase 4
Wrnip1: Werner helicase interacting protein 1
Xpo7: exportin 7
Xrcc5: X-ray repair complementing defective repair
in Chinese hamster cells 5
Ybx1: Y box binding protein 1
yes1: v-yes-1 Yamaguchi sarcoma viral oncogene
homolog 1
Ywhah: tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide
Ywhaq: tyrosine 3-monooxygenase/tryptophan 5-
monooxygenaseactivationprotein,thetapolypeptide
Zbtb7a: zinc ﬁnger and BTB domain containing 7A
Zeb1: zinc ﬁnger E-box binding homeobox 1
Zfhx2: zinc ﬁnger homeobox 2
Zfp57: zinc ﬁnger protein 57 homolog (mouse)
Zmynd19: zinc ﬁnger, MYND-type containing 19
Znf219: zinc ﬁnger protein 219
Znf291:S-phasecyclinA-associatedproteinintheER
Znf292: zinc ﬁnger protein 292
Znf382: zinc ﬁnger protein 382.
C.
Cellularsignalingpathwayclustersofextractedproteinsfrom
primary cortical tissue. Speciﬁc cellular signaling pathway
clusters generated in an un-biased manner using Ingenuity
Pathway Analysis (v. 8.5). The relative score generated for
the degree of pathway population by proteins from the
respective input sets (control or 3xTgAD) is shown in bold.
T h ef o l l o w i n ga r ed i ﬀerent types of signaling pathways.
C.1. ERK/MAPK Signaling (Enrichment Ratio∗ −log10(p)).44 International Journal of Alzheimer’s Disease
Control Protein (1.32502). PPP2R2A, CRK, PPP1R14B,
DUSP2, PTK2, SHC1, PAK1, PPP1R10, PPP1R7, PIK3CG,
STAT1, PRKCA, ETS1, SRC, PAK2, YWHAB, CRKL,
PRKAR2A, STAT3, PLA2G4C, FOS, PPP2CB, PPP2R1A,
PRKAR2B, PRKCI, PAK3, PPP2R2B, PRKACA, PPP2R5E,
ELK1, PPP2R1B, PRKAR1A, PRKCB.
3xTgAD Protein (0.1537). PXN, YWHAH, PTK2B, RAC1,
PRKAR2A, PLA2G2A, STAT3, MYC, YWHAQ (includes
EG:10971), PPP2R1A, PAK3, PIK3C3, PRKCD, PRKACA,
PIK3CB, PIK3R2, ELK1, FYN, PRKAR1A.
C.2. Inositol Phosphate Metabolism (Enrichment Ratio∗
−log10(p)).
Control Protein (0.86424). PDIA3, OCRL, PAK1, PIK3CG,
P R K A A 2 ,P L C B 1 ,P L C L 1 ,P I 4 K A ,P M P C A ,A T M ,G R K 4 ,
PRKCQ, PAK2, CDK7, CDK6, PLK1, GRK5, ITPKA,
SYNJ2, PIP5K1A, PAK3, SYNJ1, PIP5K1C, GRK6, PIP4K2A,
PIP4K2C, CDK2.
3xTgAD Protein (0.15355). PLK1, INPP5D, SYNJ2,
INPP4A, INPP4B, INPP4B, PAK3, PIM1, PRKCD, PIK3C3,
PRKAA2, PIK3CB, PIK3R2, PIP4K2A, PLCD4, PI4KA,
ATM.
C.3. Wnt/β-Catenin Signaling (Enrichment Ratio∗
−log10(p)).
Control Protein (0.5609). PPP2R2A, SOX10, CSNK1E,
WIF1, WNT7A, TGFB1, SMO, CSNK2A1, CSNK2B,
CTNNB1, SRC, SFRP4, GJA1, CSNK1G2, DVL1, FZD9,
PPP2CB, CDH2, CDH1, PPP2R1A, PPP2R2B, TLE3,
PPP2R5E, UBC, PPP2R1B, WNT5A.
3xTgAD Protein (0.12772). CSNK1G1, CSNK1G3, DVL1,
ACVR1, APC, MYC, CSNK1E, PPP2R1A, CDH2, CDH1,
WIF1, TGFB1, GNAO1, TLE3, UBC, CTNNB1, SOX5
(includes EG:6660).
C.4. Calcium Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.33825). TRPC2, GRIN2A, TNNI2,
GRIA1, RCAN2, CALM2, CHRNB4, TRPC5, TNNT3,
RYR3, GRIK1, GRIN2B, PRKAR2A, TRPC4, PPP3CC,
TRPC7, CHRNG, PRKAR2B, TPM3, CAMKK1, PRKACA,
TNNI1, CHRNB3, CAMKK2, PRKAR1A.
3xTgAD Protein (0.110875). RAP2B, MYH10, CALR,
MYH6, ATP2B1, PRKAR2A, TPM4, PPP3CC, ATP2B2,
HDAC6, TRPV6, HTR3A, CAMKK1, PRKACA, MYH9,
SLC8A1, ACTA1, PRKAR1A.
C.5.TightJunctionSignaling(EnrichmentRatio∗ −log10(p)).
Control Protein (0.4147). TJP2, CDC42, TJP1, PPP2R2A,
CLDN19, VAPA, PRKAR2A, PRKCZ, FOS, PPP2CB,
PPP2R1A, PRKCI, PRKAR2B, CLDN4, CLDN1, TGFB1,
PPP2R2B, PRKACA, PPP2R5E, STX4, CTNNB1, PPP2R1B,
PRKAR1A.
3xTgAD Protein (0.24514). MYH10, MYH6, CDC42,
ACTB, HSF1, CLDN18, VAPA, RAC1, PRKAR2A, MPDZ,
PPP2R1A, TGFB1, RHOA, CEBPA, PRKACA, MYH9,
CTNNB1, ACTA1, PRKAR1A.
C.6. NF-κB Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.12096). PRKCQ, EGF, PRKCZ, TLR9,
TLR4, TLR5, PIK3CG, TLR6, PRKACA, CSNK2A1,
PDGFRA, TLR3, CSNK2B, PRKCB, EGFR.
3xTgAD Protein (0.0190128). IL1R2, TLR5, BCL10, PIK3C3,
PRKACA, IL1B, PIK3CB, PIK3R2, NFKB1, EGFR.
C.7. PTEN Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.1368). PTK2, SHC1, CDC42, PIK3CG,
CSNK2A1, PDGFRA, CSNK2B, CDKN1B, PRKCZ, FASLG,
EGFR.
3xTgAD Protein (0.1199). CDC42, YWHAH, RAC1,
PIK3CB, PIK3R2, CDKN1B, NFKB1, INPP5D, EGFR,
MAGI3.
C.8. SAPK/JNK Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.0544984). SHC1, CDC42, GADD45A,
CRKL, PIK3CG, CRK, ELK1, GNG7.
3xTgAD Protein (0.0717288). CDC42, GADD45A, IRS1,
PIK3C3, RAC1, PIK3CB, PIK3R2, ELK1, HNRNPK.
C.9. PI3K/AKT Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.15481). TSC1, PPP2R2A, YWHAB,
PRKCZ, PPP2CB, SHC1, PPP2R1A, PIK3CG, TSC2,
PPP2R2B, PPP2R5E, CDKN1B, CTNNB1, PPP2R1B.
3xTgAD Protein (0.19323). TSC1, JAK1, YWHAH, JAK2,
NOS3, INPP5D, YWHAQ (includes EG:10971), MTOR,
PPP2R1A, HSP90AB1, PIK3CB, PIK3R2, CDKN1B,
CTNNB1.
C.10. p38 MAPK Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.0630702). IL1R2, MYC, TGFB1,
MAP3K7IP2, IL1B, PLA2G2A, EEF2K, MAPKAPK2, ELK1.International Journal of Alzheimer’s Disease 45
C.11. p53 Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.037996). GADD45A, FASN, PIK3CG,
SNAI2, CTNNB1, CDK2, ATM, SERPINE2.
3xTgAD Protein (0.12075). CCND2, GADD45A, PIK3C3,
SNAI2, CABC1, PIK3CB, PIK3R2, BAX, CTNNB1, ATM.
C.12. JAK/Stat Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.051714). SHC1, SOCS1, PTPN11,
P I K 3 C G ,S T A T 3 ,S T A T 1 .
3xTgAD Protein (0.25857). STAT5A, MTOR, JAK1,
PTPN11, PIK3C3, PIK3CB, STAT3, PIK3R2, JAK2.
D.
Neuronal function pathway clusters of extracted proteins
from primary cortical tissue. Speciﬁc neuronal function
pathway clusters generated in an un-biased manner using
Ingenuity Pathway Analysis (v. 8.5). The relative score
generated for the degree of pathway population by proteins
from the respective input sets (control or 3xTgAD) is
shown in bold. The following are diﬀerent types of signaling
pathways.
D.1. Synaptic Long-Term Potentiation (Enrichment Ratio∗
−log10(p)).
Control Protein (1.27872). GRIN2B, GRIN2A, PRKCQ,
PPP1R1A, GRIA1, PRKAR2A, CALM2, CACNA1C,
PPP3CC, GRM4, PPP1R14B, PRKCZ, GRM5, PRKCI,
PRKAR2B, PPP1R10, PPP1R7, PPP1R14D, PRKACA,
PLCB1, PRKD1, PRKCA, PRKAR1A, PRKCB
3xTgAD Protein (0).
D.2. Axonal Guidance Signaling (Enrichment Ratio∗
−log10(p)).
Control Protein (0.69525). NOS1, GUCY1B2, PRKCQ,
GUCY1A3, GUCY2D, PPP2R2A, GRID2, GRIA1, GRM4,
PRKCZ, GRM5, PPP2CB, PPP2R1A, PRKCI, PPP2R2B,
RYR3, GUCY1A2, PLCB1, PPP2R5E, PPP2R1B, PRKD1,
PRKCA, PRKCB.
3xTgAD Protein (0.1918). NOS1, GUCY2D, GNAI1,
PLA2G2A, GNAZ, NOS3, PRDX6, GNAI2, PPP2R1A,
PRKCD, GNAO1, IGF1R, GUCY2F, ADCY8, NPR2.
D.3. Synaptic Long-Term Depression (Enrichment Ratio∗
−log10(p)).
Control Protein (0.47428). NOS1, GUCY1B2, PRKCQ,
GUCY1A3, GUCY2D, PPP2R2A, GRID2, GRIA1, GRM4,
PRKCZ, GRM5, PPP2CB, PPP2R1A, PRKCI, PPP2R2B,
RYR3, GUCY1A2, PLCB1, PPP2R5E, PPP2R1B, PRKD1,
PRKCA, PRKCB.
3xTgAD Protein (0.11112). NOS1, GUCY2D, GNAI1,
PLA2G2A, GNAZ, NOS3, PRDX6, GNAI2, PPP2R1A,
PRKCD, GNAO1, IGF1R, GUCY2F, ADCY8, NPR2.
D.4. Parkinson’s Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.168256). UCHL1, PARK7, SNCA.
3xTgAD Protein (0.18656). UCHL1, PARK7, SNCA.
D.5. Huntington’s Disease Signaling (Enrichment Ratio∗
−log10(p)).
Control Protein (0.20048). EGF, GNG7, PRKCZ, TGM2,
C T S D ,S H C 1 ,P I K 3 C G ,V A M P 3 ,P L C B 1 ,P R K D 1 ,P R K C A ,
EGFR, SDHA, GRIN2B, PRKCQ, YKT6, SH3GL3, STX1A,
S N A P 2 5 ,T A F 9 B ,G R M 5 ,P R K C I ,U B C ,G O S R 2 ,S N C A ,
PRKCB.
3xTgAD Protein (0.36179). VTI1A, HSPA14, REST,
GNB2L1, HDAC6, NSF, MTOR, PIK3C3, IGF1R, PIK3R2,
EGFR, CAPN5, CAPN6, CLTC, BAX, STX1A, SNAP25,
DNM1, DNAJC5, ATP5B, CAPN1, PRKCD, HAP1, DCTN1,
PIK3CB, UBC, SNCA, CASP7.
D.6. Regulation of Actin-Based Motility by Rho (Enrichment
Ratio∗ −log10(p)).
Control Protein (0.1476). PIP5K1A, WIPF1, PAK1, PAK2,
CDC42,CFL1,PAK3,PIP5K1C,PIP4K2A,PIP4K2C,PI4KA.
3xTgAD Protein (0.3243). CDC42, CFL1, ACTB, RAC1,
RHOJ, ROCK1, PAK3, RHOB, RHOA, ARHGDIA,
PIP4K2A, ACTA1, PI4KA.
D.7. Amyotrophic Lateral Sclerosis Signaling (Enrichment
Ratio∗ −log10(p)).
Control Protein (0.23184). NOS1, GRIN2B, GRIN2A,
SOD1, GRIA1, PGF, VEGFA, PAK1, GRIK4, PIK3CG, CAT,
GLUL, SSR4.
3xTgAD Protein (0.55955). NOS1, CAPN5, CAPN6, SOD1,
RAB5A,RAC1,NEFH,BAX,CCS,VEGFA,CAPN1,PIK3C3,
NEFM, PIK3CB, PIK3R2, CASP7.
D.8. Actin Cytoskeleton Signaling (Enrichment Ratio∗
−log10(p)).
Control Protein (0.0763861). PAK2, CFL1, CDC42, CRKL,
EGF, CRK, TTN, PTK2, SHC1, PAK1, PIP5K1A, PAK3,46 International Journal of Alzheimer’s Disease
PIP5K1C, FGF18, PIK3CG, EZR, FGF23, PIP4K2A,
PIP4K2C, GIT1.
3xTgAD Protein (0.44928). MYH10, MYH6, CDC42,
ROCK2, PIK3C3, EZR, PIK3R2, LBP, ACTA1, PXN,
A R H G E F 1 2 ,C F L 1 ,A C T B ,R A C 1 ,R D X ,A P C ,TT N ,R OC K 1 ,
PAK3, RHOA, ARHGEF6, MYH9, VAV1, PIK3CB, ACTN4,
PIP4K2A, MSN.
D.9. Amyloid Processing (Enrichment Ratio∗ −log10(p)).
Control Protein (0.20636). CSNK1E, PRKAR2B, CSNK2A,
PRKAR2A, PRKACA, NCSTN, CSNK2B, PRKAR1A.
3xTgAD Protein (0.66144). CSNK1E, CAPN5, CAPN6,
CAPN1, MARK1, PRKAR2A, PRKACA, NCSTN, BACE1,
APP, PRKAR1A.
E.
Energy regulation/Metabolism pathway clusters of extracted
proteins from primary cortical tissue. Speciﬁc energy reg-
ulation/metabolism pathway clusters generated in an un-
biasedmannerusingIngenuityPathwayAnalysis(v.8.5).The
relative score generated for the degree of pathway population
by proteins from the respective input sets (control or
3xTgAD) is shown in bold. The following are diﬀerent types
of signaling pathways.
E.1. Amino Sugars Metabolism (Enrichment Ratio∗
−log10(p)).
ControlProtein(0.61425). FMO3,PDE7A,PDE10A,GM2A,
CYB5R1, PDE4A, PDE4B, PDE1A, PDE4D, GFPT2, PDE1C,
PDE7B, GALK1, CYB5R3.
3xTgAD Protein (0.0471409). HK1, CYB5R4, PDE10A,
GALK1, CYB5R3, PDE4B.
E.2. Pentose Phosphate Pathway (Enrichment Ratio∗
−log10(p)).
Control Protein (0.48608). GPI, PGD, TKT, TALDO1, PRP-
SAP1, PGM1, PRPSAP2, PFKP, PFKL, PDHB, PFKM.
3xTgAD Protein (0.0245154). GPI, TKT, PRPSAP2, PFKL.
E.3. Glutamate Metabolism (Enrichment Ratio∗ −log10(p)).
Control Protein (0.31165). FMO3, GPT, GLUL, GCLC,
GLUD1, GOT1, GOT2, GFPT2, EPRS.
3xTgAD Protein (0).
E.4. Pantothenate and CoA Biosynthesis (Enrichment Ratio∗
−log10(p)).
Control Protein (0.34188). ENPP3, CRMP1, BCAT1, DPYD,
DPYSL3, ENPP5, ENPP2.
3xTgAD Protein (0.0348908). CRMP1, DPYD, ENPP2.
E.5. Glycolysis/Gluconeogenesis (Enrichment Ratio∗
−log10(p)).
Control Protein (0.28363). PKM2, PGK1, ENO3, ENO2,
GAPDH (includes EG:2597), PGM1, ALDH1L1, PFKP,
PFKL, PDHB, PFKM, GPI, GALK1, DLAT, PGAM1, DLD.
3xTgAD Protein (0.0610449). PKM2, HK1, ADH1A, GPI,
ALDH1A3, DLAT, GALK1, ENO2, PFKL, ACSL1.
E.6. Citrate Cycle (Enrichment Ratio∗ −log10(p)).
Control Protein (0.1581). SDHA, PC, CS, SUCLG1, DLD,
PCK1.
3xTgAD Protein (0).
E.7. Galactose Metabolism.
Control Protein (0.104958). GLA, GALT, GALK1, GAA,
PGM1, PFKP, PFKL, PFKM.
3xTgAD Protein (0.0486688). HK1, GLA, GALK1, GAA,
PFKL, AKR1B1.
E.8. Glycosphingolipid Biosynthesis—Globoseries (Enrichment
Ratio∗ −log10(p)).
Control Protein (0.0411384). GLA, ST3GAL1, GM2A.
3xTgAD Protein (0).
E.9. Glycosphingolipid Biosynthesis—Ganglioseries (Enrich-
ment Ratio∗ −log10(p)).
Control Protein (0.008832). ST3GAL1, GM2A.
3xTgAD Protein (0).
E.10.N-GlycanBiosynthesis(EnrichmentRatio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.015272). RPN2, ST6GAL2, MGAT5,
MGAT1.International Journal of Alzheimer’s Disease 47
E.11. Pentose and Glucuronate Interconversions (Enrichment
Ratio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.0184464). UCHL1, B3GAT1, HPSE,
DCXR, AKR1B1.
E.12. Fatty Acid Elongation in Mitochondria (Enrichment
Ratio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.0206016). ECHS1, PECR.
E.13. Glycerophospholipid Metabolism (Enrichment Ratio∗
−log10(p)).
ControlProtein(0.0232106). GPAM,PCYT1B,PLD3,CDS1,
PDIA3, GNPAT, DGKB, DGKG, PLCB1, PLCL1.
3xTgAD Protein (0.048204). AGPAT4, CDS1, GNPAT,
CHKA, AGPAT1, DGKG, PLA2G2A, CLCF1, PHKA1,
PLCD4, PRDX6.
E.14. Fatty Acid Biosynthesis (Enrichment Ratio∗
−log10(p)).
Control Protein (0).
3xTgAD Protein (0.0329256). ACACB, ACACA.
E.15. Purine Metabolism (Enrichment Ratio∗ −log10(p)).
Control Protein (0.08616). ENTPD8, PDE7A, PDE4A,
DNTT, PDE1A, PDE4D, PSMC5, PDE7B, VCP, DHX16,
ENPP2, PRPSAP2, PKM2, TJP2, GUCY1B2, GUCY1A3,
GUCY2D, PDE10A, ENPP5, PDE4B, PDE1C, ENPP3,
PSMC1, ENTPD2, PRPSAP1, GUCY1A2, PDE5A, DDX1,
GMPR2, PSMC3.
3xTgAD Protein (0.124932). MYH6, ENTPD8, NME2,
DNTT, WRNIP1, ABCC1, VCP, KATNA1, ATP5H (includes
EG:10476), ENPP2, PRPSAP2, ADCY8, ATP5F1, ATP5I,
ATP5J, PKM2, ATP1B1, GUCY2D, PDE10A, AMPD1,
ATP5A1, AK3, PSMC4, PDE4B, DDX19B, ATP5B, GUCY2F,
MYH9, DDX1, NPR2.
E.16. Pyruvate Metabolism (Enrichment Ratio∗ −log10(p)).
ControlProtein(0.0214935). PKM2,PC,DLA T ,DLD ,PCK1,
PDHB, GLO1.
3xTgAD Protein (0.070173). PKM2, ACACB, ALDH1A3,
DLAT, ACAT1, ACACA, MDH1, AKR1B1, ACSL1.
E.17. Butanoate Metabolism (Enrichment Ratio∗
−log10(p)).
Control Protein (0).
3xTgAD Protein (0.0523452). ECHS1, ALDH1A3, AACS,
ACAT1, MYO5B, DCXR, HMGCS1.
E.18. Synthesis and Degradation of Ketone Bodies (Enrichment
Ratio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.071505). ACAT1, HMGCS1.
F.
Cellular stress/damage pathway clusters of extracted pro-
teins from primary cortical tissue. Speciﬁc energy cellular
stress/damage pathway clusters generated in an un-biased
manner using Ingenuity Pathway Analysis (v. 8.5). The
relative score generated for the degree of pathway population
by proteins from the respective input sets (control or
3xTgAD) is shown in bold. The following are diﬀerent types
of signaling pathways.
F.1. NRF2-mediated Oxidative Stress Response (Enrichment
Ratio∗ −log10(p)).
Control Protein (0.44064). PRDX1, PPIB, GCLC, PRKCZ,
GSTM2, SOD2, PIK3CG, VCP, DNAJA2, TXN, FKBP5,
PRKD1, CBR1, PRKCA, GSTK1, SOD1, PRKCQ, TXNRD1,
GSTO1, FOS, PRKCI, ERP29, STIP1, CAT, PRKCB, EPHX1.
3xTgAD Protein (0.23751). USP14, SOD1, PRDX1, ACTB,
GSTM3 (includes EG:2947), JUNB, DNAJC5, GSTM2,
SOD2, ERP29, STIP1, PIK3C3, PRKCD, ABCC1, VCP,
PIK3CB, FOSL1, PIK3R2, TXN, EIF2AK3, ACTA1.
F.2. Ceramide Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0.15748). CTSD, PPP2CB, FOS, PPP2R1A,
PPP2R2A, PIK3CG, PPP2R2B, PPP2R5E, PPP2R1B.
3xTgAD Protein (0).
F.3. Glutathione Metabolism (Enrichment Ratio∗
−log10(p)).
Control Protein (0.094285). OPLAH, PGD, GSTM2, GGT5,
GCLC, GGT1, GSTO1, GSTK1, GGT7.
3xTgAD Protein (0).
F.4. LPS/IL-1 Mediated Inhibition of RXR Function (Enrich-
ment Ratio∗ −log10(p)).48 International Journal of Alzheimer’s Disease
Control Protein (0.19071). SULT1C2, FMO3, CPT1A,
CHST7, ALDH1L1, NR1H3, GSTO1, SULT4A1, GSTM2,
NR1I2, SREBF1, SULT1A1, CAT, CPT2, FABP4, XPO1,
FABP1, FABP7, SULT1E1, FABP3, GSTK1, TLR4, FABP2.
3xTgAD Protein (0.13872). PPARA, GSTM3 (includes
EG:2947), ABCA1, IL1R2, ABCC2, SLC27A5, GSTM2,
ALDH1A3, NR1I2, CPT2, ACSL4, FABP1, IL1B, NR5A2,
CHST10, LBP, ABCC4, HMGCS1, ACSL1, MAOA.
F.5. Fatty Acid Elongation in Mitochondria (Enrichment
Ratio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.0206016). ECHS1, PECR
F.6. Endoplasmic Reticulum Stress Pathway (Enrichment
Ratio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.047841). EIF2AK3, CASP7.
F.7. Apoptosis Signaling (Enrichment Ratio∗ −log10(p)).
Control Protein (0).
3xTgAD Protein (0.059156). ACIN1, ROCK1, CAPN5,
CAPN6, CAPN1, BAX, CASP7, PARP1.
F.8. Hypoxia Signaling (Enrichment Ratio∗ −log10(p)).
Control protein (0).
3xTgAD Protein (0.111983). VEGFA, P4HB, HSP90AB1,
UBE2L3, NOS3, UBC, ARNT, ATM.
F.9. PPARα/RXRα Activation (Enrichment Ratio∗
−log10(p)).
Control Protein (0.0315615). PDIA3, PRKAR2A, NR2C2,
SHC1, PRKAR2B, TGFB1, FASN, PRKACA, PLCB1, GOT2,
PLCL1, PRKCB, PRKCA, PRKAR1A.
3xTgAD Protein (0.14586). PPARA, ACVR1, PRKAR2A,
CD36, IL6, JAK2, ABCA1, IL1R2, ACADL, HSP90AB1,
TGFB1, IRS1, PRKACA, SMAD4, IL1B, ADCY8, PLCD4,
PRKAR1A.
G.
Receptor signaling pathway clusters of extracted proteins
from primary cortical tissue. Speciﬁc receptor signaling
pathway clusters generated in an un-biased manner using
Ingenuity Pathway Analysis (v. 8.5). The relative score
generated for the degree of pathway population by proteins
from the respective input sets (control or 3xTgAD) is
shown in bold. The following are diﬀerent types of signaling
pathways.
G.1. Dopamine Receptor Signaling.
Control Protein (0.65824). PPP2R2A, PRKAR2A,
PPP1R14B, PPP2CB, PPP2R1A, PRKAR2B, PPP1R10,
PPP1R14D, PPP1R7, PPP2R2B, PRKACA, FREQ, PPP2R5E,
PPP2R1B, PRKAR1A, CALY.
3xTgAD Protein (0.071199). PPP2R1A, FREQ, PRKAR2A,
PRKACA, ADCY8, CALY, MAOA, PRKAR1A.
G.2. PDGF Signaling.
Control Protein (0.73892). SRC, CRKL, CRK, STAT3, FOS,
SHC1, PIK3CG, CSNK2A1, PDGFRA, CAV1, CSNK2B,
ELK1, STAT1, PRKCB, PRKCA.
3xTgAD Protein (0.15738). MYC, JAK1, PIK3C3, STAT3,
PIK3R2, JAK2, ELK1, INPP5D.
G.3. EGF Signaling.
Control Protein (0.7956). SHC1, FOS, PIK3CG, CSNK2A1,
EGF, CSNK2B, STAT3, STAT1, ELK1, PRKCA, EGFR.
3xTgAD Protein (0.22499). JAK1, PIK3C3, PIK3CB, STAT3,
PIK3R2, ELK1, EGFR.
G.4. Neuregulin Signaling.
Control Protein (0.68068). SRC, PRKCQ, CRKL, EGF, CRK,
ERBB3, PRKCZ, SHC1, PRKCI, PTPN11, ERBB4, CDKN1B,
E L K 1 ,P R K D 1 ,P R K C B ,E G F R ,P R K C A .
3xTgAD Protein (0.1276). MYC, STAT5A, MTOR, PTPN11,
HSP90AB1, PRKCD, PIK3R2, CDKN1B, ELK1, EGFR.
G.5. Glutamate Receptor Signaling.
Control Protein (0.53342). GRM5, GRIN2B, GRIN2A,
GRIK4, GRIA1, GRID2, CALM2, GLUL, GRIP1, GRM4,
GNG7, GRIK1.
3xTgAD Protein (0).
G.6. Sonic Hedgehog Signaling.
Control Protein (0.73272). SHH, CCNB1, PRKAR2B,
PRKAR2A, PRKACA, SMO, GLI1, PRKAR1A.International Journal of Alzheimer’s Disease 49
3xTgAD Protein (0.20769). ADRBK1, PTCH1, PRKAR2A,
PRKACA, PRKAR1A.
G.7. TR/RXR Activation.
Control Protein (0.5481). UCP2, RCAN2, UCP1, THRA,
GRIP1, PFKP, PCK1, KLF9, SREBF1, DIO1, FASN, PIK3CG,
STRBP, THRB, FGA, SYT12.
3xTgAD Protein (0.0321142). MTOR, PIK3C3, STRBP,
ACACA, PIK3CB, PIK3R2, THRB.
G.8. Ephrin Receptor Signaling.
Control Protein (0.62472). GRIN2A, CDC42, EGF, CRK,
GNG7, PGF, VEGFA, PTK2, SHC1, PAK1, SDC2, PIK3CG,
EFNB1, EPHA7, GRIN2B, SRC, PAK2, CFL1, CRKL,
E P H A 3 ,S T A T 3 ,W I P F 1 ,S D C B P ,P T P N 1 1 ,P A K 3 ,E P H A 5 ,
EPHB3.
3xTgAD Protein (0.21037). FYN, PXN, CFL1, CDC42,
K A L R N ,G N B 2 L 1 ,G N A I 1 ,R A C 1 ,J A K 2 ,S T A T 3 ,G N A Z ,
ROCK1, VEGFA, GNAI2, ROCK2, ABI1, PTPN11, PAK3,
RHOA, GNAO1.
G.9. G-Protein Coupled Receptor Signaling.
Control Protein (0.3808). PDE7A, PDE4A, PDE1A, PDE4D,
SHC1, SYNGAP1, PDE7B, PIK3CG, PLCB1, PRKCA, SRC,
GRK4, EDNRB, PDE10A, PRKAR2A, PDE4B, STAT3,
GRM4, PDE1C, CHRM5, GRM5, OPRD1, PRKAR2B,
PRKACA, PRKCB, PRKAR1A.
3xTgAD Protein (0.13938). FYN, PTK2B, HTR4, ADRBK1,
PDE10A, RGS7, PRKAR2A, GNAI1, RGS4, STAT3, PDE4B,
GNAI2, HTR2C, PIK3C3, GNAO1, PRKACA, PIK3CB,
PIK3R2, ADCY8, PRKAR1A.
G.10. Chemokine Signaling.
Control Protein (0.23961). PTK2, NOX1, SRC, FOS, CCL4,
CFL1, PIK3CG, CALM2, PLCB1, PRKCA, PRKCB.
3xTgAD Protein (0.03232). ROCK2, GNAI2, CFL1, PTK2B,
RHOA, GNAI1.
G.11. Ceramide Signaling.
Control Protein (0.15748). CTSD, PPP2CB, FOS, PPP2R1A,
PPP2R2A,PIK3CG,PPP2R2B,PPP2R5E,PPP2R1B,PRKCZ.
3xTgAD protein (0).
G.12. FGF (Fibroblast Growth Factor) Signaling.
Control Protein (0.17423). FGFR3, PTPN11, FGF18, CRKL,
PIK3CG, FGFR1, FGF23, FGFR2, CRK, STAT3, PRKCA.
3xTgAD Protein (0.0667352). PTPN11, PIK3C3, HGF,
RAC1, PIK3CB, STAT3, PIK3R2, MAPKAPK2.
G.13. Toll-like Receptor Signaling.
Control Protein (0.1644). TLR4, FOS, TLR5, TLR6, TLR3,
ELK1, TLR9.
3xTgAD Protein (0.065562). PPARA, TLR5, MAP3K7IP2,
LBP, ELK1.
G.14. Nitric Oxide Signaling.
Control Protein (0.41157). GUCY1B2, GUCY1A3,
G U C Y 2 D ,C A L M 2 ,P R K A R 2 A ,P G F ,V E G F A ,P R K A R 2 B ,
PIK3CG, GUCY1A2, CAV1, PRKACA, PRKAR1A.
3xTgAD Protein (0.36801). VEGFA, HSP90AB1, GUCY2D,
PRKCD, PIK3C3, GUCY2F, PRKAR2A, PRKACA, PIK3CB,
PIK3R2, NOS3, PRKAR1A.
G.15. cAMP-Mediated Signaling.
Control Protein (0.39295). GRK4, SRC, CNGA4, PDE7A,
PDE10A, PRKAR2A, CALM2, PDE4A, PPP3CC, STAT3,
PDE4B, GRM4, PDE1A, PDE4D, CNGA1, PDE1C, CHRM5,
OPRD1, PRKAR2B, PDE7B, PRKACA, PKIA, PRKAR1A.
3xTgAD Protein (0.40848). AKAP12, HTR4, ADRBK1,
PDE10A, RGS7, PRKAR2A, GNAI1, RGS4, AKAP3,
PPP3CC, STAT3, PDE4B, CNGA1, GNAI2, AKAP4,
GNAO1, PRKACA, CNGB1, PKIA, ADCY8, AKAP9,
PRKAR1A.
G.16. TGF-β Signaling.
Control protein (0).
3xTgAD Protein (0.0236421). TGFB1, ACVR1, SMAD4,
HNF4A, UBC, INHBC.
G.17. Neurotrophin/TRK Signaling.
Control Protein (0.016851). SHC1, FOS, CDC42, PTPN11,
PIK3CG.
3xTgAD Protein (0.0440592). NTRK2, CDC42, PTPN11,
PIK3C3, PIK3CB, PIK3R2.
G.18. IGF-1 Signaling.50 International Journal of Alzheimer’s Disease
Control Protein (0.49715). PRKAR2A, PTK2, SHC1,
FOS, PRKAR2B, PTPN11, PIK3CG, PRKACA, CSNK2A1,
CSNK2B, ELK1, PRKAR1A.
3xTgAD Protein (0.52722). PXN, YWHAH, PRKAR2A,
NEDD4, YWHAQ, PTPN11, IRS1, PIK3C3, PRKACA,
IGF1R, IRS2, PIK3CB, PIK3R2, ELK1, PRKAR1A.
G.19. Serotonin Receptor Signaling.
Control protein (0).
3xTgAD Protein (0.059769). HTR2C, HTR4, HTR3A,
MAOA.
G.20. Glucocorticoid Receptor Signaling.
Control protein (0).
3xTgADProtein(0.066). STAT5A,JAK1,YWHAH,HSPA14,
RAC1, IL6, PPP3CC, STAT3, JAK2, NFKB1, MNAT1, IL1R2,
HSP90AB1, TGFB1, PIK3C3, CEBPA, PRKACA, SMAD4,
IL1B, PIK3CB, PIK3R2, ELK1.
G.21. Aryl Hydrocarbon Receptor Signaling.
Control Protein (0.1218). SRC, CDK6, ALDH1L1, GSTO1,
TGM2, CTSD, FOS, GSTM2, TGFB1, FASN, CDKN1B,
ESR2, CDK2, FASLG, ATM, GSTK1.
3xTgAD Protein (0.31125). CYP1A1, NFIX, GSTM3, IL6,
BAX, NFKB1, ARNT, MYC, AHRR, GSTM2, CCND2,
HSP90AB1, TGFB1, ALDH1A3, IL1B, CDKN1B, AHR,
MCM7, ATM.
G.22. Insulin Receptor Signaling.
Control Protein (0.28288). TSC1, TRIP10, CRKL,
PRKAR2A, CRK, VAMP2, PPP1R14B, PRKCZ, SHC1,
PRKCI, PPP1R10, PTPN11, PIK3CG, TSC2, PRKACA.
3xTgAD Protein (0.5056). TSC1, FYN, JAK1, PRKAR2A,
JAK2, VAMP2, INPP5D, MTOR, PTPN11, IRS1, PIK3C3,
PRKACA, EIF2B1, PIK3CB, IRS2, PIK3R2, PRKAR1A.
G.23. Notch Signaling.
Control Protein (0.0437248). DLL1, CNTN1, NCSTN,
DLL3.
3xTgAD Protein (0.30609). N O T C H 4 ,D L L 1 ,N O T C H 2 ,
NCSTN, JAG1, NOTCH1, HEY1.
G.24. GABA Receptor Signaling.
Control Protein (0.099214). GABRG2, UBQLN1, GABBR1,
GABARAP, UBC, GABRA3.
3xTgAD Protein (0.4216). DNM1, NSF, SLC32A1,
UBQLN1, GABBR1, MYO5B, GABRE, UBC, GABRA3.
G.25. VEGF Signaling.
Control Protein (0.0252652). VEGFA, PTK2, SHC1,
PIK3CG, PGF, PRKCA, PRKCB.
3xTgAD Protein (0.53464). EIF2S2, PXN, PTK2B, ACTB,
NOS3, ARNT, ROCK2, VEGFA, ROCK1, PIK3C3, EIF2B1,
PIK3CB, PIK3R2, ACTN4, ACTA1.
G.26. Integrin Signaling.
Control protein (0).
3xTgAD Protein (0.54604). RAP2B, FYN, RALA, CDC42,
TSPAN3, ARF6, RHOB, PIK3C3, ARF4, PIK3R2, ACTA1,
CAPN5, CAPN6, PXN, ACTB, RALB, RAC1, ITGA6, RHOJ.
H.
Heatmap Protein Position Key. The individual position
numbers are correlated to the speciﬁc multidimensional
proteins represented by colored blocks in Figure 6.T h e
following are the symbols of the proteins (the numbers
between brackets refer to the position).
(1) adcyap1: adenylate cyclase activating polypeptide 1
(pituitary)
(2) adcyap1r1: adenylate cyclase activating polypeptide 1
(pituitary) receptor type I
(3) hap1: huntingtin-associated protein 1
(4) htr4: 5-hydroxytryptamine (serotonin) receptor 4
(5) ntrk2: neurotrophic tyrosine kinase, receptor, type 2
(6) Kalrn: kalirin, RhoGEF kinase
(7) klc1: kinesin light chain 1
(8) adrbk1: adrenergic, beta, receptor kinase 1
(9) agrn: agrin
(10) apod: apolipoprotein D
(11) app: amyloid beta (A4) precursor protein
(12) arhgef11: Rho guanine nucleotide exchange factor
(GEF) 11
(13) arpp19: cAMP-regulated phosphoprotein, 19kDa
(14) bace1: beta-site APP-cleaving enzyme 1
(15) ccs: copper chaperone for superoxide dismutase
(16) chgb: chromogranin B (secretogranin 1)
(17) ﬂot1: ﬂotillin 1
(18) ﬂot2: ﬂotillin 2International Journal of Alzheimer’s Disease 51
(19) gnb2l1: guanine nucleotide binding protein (G pro-
tein), beta polypeptide 2-like 1
(20) hyou1: hypoxia up-regulated 1
(21) lphn1: latrophilin 1
(22) lphn2: latrophilin 2
(23) magi3: membrane associated guanylate kinase, WW
and PDZ domain containing 3
(24) nefh: neuroﬁlament, heavy polypeptide
(25) prdx6: peroxiredoxin 6
(26) pscd2: cytohesin 2
(27) rtn3: reticulon 3
(28) rtn4r: reticulon 4 receptor
(29) slc44a4: solute carrier family 44, member 4
(30) stxbp1: syntaxin binding protein 1
(31) abca1: ATP-binding cassette, sub-family A (ABC1),
member 1
(32) abi1: abl-interactor 1
(33) adcy1: adenylate cyclase 1 (brain)
(34) adcy5: adenylate cyclase 5
(35) akap9: A kinase (PRKA) anchor protein 9
(36) aldh1a3: aldehyde dehydrogenase 1 family, member
A3
(37) alox5: arachidonate 5-lipoxygenase
(38) arf6: ADP-ribosylation factor 6
(39) arhgef12: Rho guanine nucleotide exchange factor
(GEF) 12
(40) atcay: ataxia, cerebellar, Cayman type
(41) atp2b1: ATPase, Ca++ transporting, plasma mem-
brane 1
(42) atxn3: ataxin 3
(43) begain: brain-enriched guanylate kinase-associated
homolog (rat)
(44) cabc1: chaperone, ABC1 activity of bc1 complex
homolog (S. pombe)
(45) capn1: calpain 1, (mu/l) large subunit
(46) caskin1: CASK interacting protein 1
(47) casp7: caspase 7, apoptosis-related cysteine peptidase
(48) cd36: CD36 molecule (thrombospondin receptor)
(49) cfd: complement factor D (adipsin)
(50) clu: clusterin
(51) cpa2: carboxypeptidase A2 (pancreatic)
(52) cript: cysteine-rich PDZ-binding protein
(53) dpp6: dipeptidyl-peptidase 6
(54) espn: espin
(55) fdps: farnesyl diphosphate synthase
(56) ﬁlip1: ﬁlamin A interacting protein 1
(57) gna11: guanine nucleotide binding protein (G pro-
tein), alpha 11 (Gq class)
(58) gnai2: guanine nucleotide binding protein (G pro-
tein), alpha inhibiting activity polypeptide 2
(59) gnao1: guanine nucleotide binding protein (G pro-
tein), alpha activating activity polypeptide O
(60) gnaq: guanine nucleotide binding protein (G pro-
tein), q polypeptide
(61) gnaz: guanine nucleotide binding protein (G pro-
tein), alpha z polypeptide
(62) gpr56: G protein-coupled receptor 56
(63) hip1r: huntingtin interacting protein 1 related
(64) hmgcr: 3-hydroxy-3-methylglutaryl-Coenzyme A
reductase
(65) hsf1: heat shock transcription factor 1
(66) htr2c: 5-hydroxytryptamine (serotonin) receptor 2C
(67) itm2c: integral membrane protein 2C
(68) itpr3: inositol 1,4,5-triphosphate receptor, type 3
(69) lsamp: limbic system-associated membrane protein
(70) maoa: monoamine oxidase A
(71) map1lc3a: microtubule-associated protein 1 light
chain 3 alpha
(72) mapkapk2:mitogen-activatedproteinkinase-activat-
ed protein kinase 2
(73) mark1: MAP/microtubule aﬃnity-regulating kin-
ase 1
(74) mdga2: MAM domain containing glycosylphos-
phatidylinositol anchor 2
(75) mpdz: multiple PDZ domain protein
(76) mpo: myeloperoxidase
(77) mpp7: membrane protein, palmitoylated 7 (MAGUK
p55 subfamily member 7)
(78) ncam1: neural cell adhesion molecule 1
(79) ncam2: neural cell adhesion molecule 2
(80) ncdn: neurochondrin
(81) ndufs1: NADH dehydrogenase (ubiquinone) Fe-S
protein 1, 75kDa (NADH-coenzyme Q reductase)
(82) ndufs7: NADH dehydrogenase (ubiquinone) Fe-S
protein 7, 20kDa (NADH-coenzyme Q reductase)
(83) nes: nestin
(84) nlgn2: neuroligin 2
(85) nlgn3: neuroligin 3
(86) npc2: Niemann-Pick disease, type C2
(87) npdc1: neural proliferation, diﬀerentiation and con-
trol, 1
(88) npy5r: neuropeptide Y receptor Y5
(89) nsf: N-ethylmaleimide-sensitive factor52 International Journal of Alzheimer’s Disease
(90) padi2: peptidyl arginine deiminase, type II
(91) plcb4: phospholipase C, beta 4
(92) pxn: paxillin
(93) rab5a: RAB5A, member RAS oncogene family
(94) rgs4: regulator of G-protein signaling 4
(95) rgs7: regulator of G-protein signaling 7
(96) rims1: regulating synaptic membrane exocytosis 1
(97) rora: RAR-related orphan receptor A
(98) sh3gl1: SH3-domain GRB2-like 1
(99) sod2: superoxide dismutase 2, mitochondrial
(100) sst: somatostatin
(101) vldlr: very low density lipoprotein receptor
(102) camkk1: calcium/calmodulin-dependent protein
kinase kinase 1, alpha
(103) cacna2d2:calciumchannel,voltage-dependent,alpha
2/delta subunit 2
(104) vcp: valosin-containing protein
(105) stx1a: syntaxin 1A (brain)
(106) vgf: VGF nerve growth factor inducible
(107) calb2: calbindin 2
(108) prdx1: peroxiredoxin 1
(109) stmn2: stathmin-like 2
(110) vsnl1: visinin-like 1
(111) cdh2: cadherin 2, type 1, N-cadherin (neuronal)
(112) dbn1: drebrin 1
(113) oxr1: oxidation resistance 1
(114) gpsm1: G-protein signaling modulator 1 (AGS3-like,
C. elegans)
(115) gmfb: glia maturation factor, beta
(116) cd2ap: CD2-associated protein
(117) centa1: ArfGAP with dual PH domains 1
(118) ncstn: nicastrin
(119) pak3: p21 protein (Cdc42/Rac)-activated kinase 3
(120) sncb: synuclein, beta
(121) calb1: calbindin 1
(122) cnr1: cannabinoid receptor 1 (brain)
(123) disc1: disrupted in schizophrenia 1
(124) dlgap2: discs, large (Drosophila) homolog-associated
protein 2
(125) dlgap4: discs, large (Drosophila) homolog-associated
protein 4
(126) dtnb: dystrobrevin, beta
(127) dvl1: dishevelled, dsh homolog 1 (Drosophila)
(128) exoc7: exocyst complex component 7
(129) gabbr1: gamma-aminobutyric acid (GABA) B recep-
tor, 1
(130) panx1: pannexin 1
(131) pclo: piccolo (presynaptic cytomatrix protein)
(132) phactr3: phosphatase and actin regulator 3
(133) picalm: phosphatidylinositol binding clathrin assem-
bly protein
(134) shank1: SH3 and multiple ankyrin repeat domains 1
(135) snap91: synaptosomal-associated protein, 91kDa
homolog (mouse)
(136) stmn4: stathmin-like 4
(137) sod1: superoxide dismutase 1, soluble
(138) synj2: synaptojanin 2
(139) tub: tubby homolog (mouse)
(140) snca: synuclein, alpha (non A4 component of amy-
loid precursor)
(141) park7: Parkinson disease (autosomal recessive, early
onset) 7
(142) pcsk1n: proprotein convertase subtilisin/kexin type 1
inhibitor
(143) palm: Paralemmin
(144) vapb: VAMP (vesicle-associated membrane protein)-
associated protein B and C
(145) cttn: cortactin
(146) cacna1a: calcium channel, voltage-dependent, P/Q
type, alpha 1A subunit
(147) celsr3: cadherin, EGF LAG seven-pass G-type recep-
tor 3 (ﬂamingo homolog, Drosophila)
(148) chl1: cell adhesion molecule with homology to
L1CAM (close homolog of L1)
(149) chrm5: cholinergic receptor, muscarinic 5
(150) cnksr2: connector enhancer of kinase suppressor of
Ras 2
(151) cnp: 2 ,3 -cyclic nucleotide 3  phosphodiesterase
(152) cntfr: ciliary neurotrophic factor receptor
(153) cntn1: contactin 1
(154) cplx1: complexin 1
(155) dag1: dystroglycan 1 (dystrophin-associated glyco-
protein 1)
(156) dbndd2: dysbindin (dystrobrevin binding protein 1)
domain containing 2
(157) dbnl: drebrin-like
(158) dclk2: doublecortin-like kinase 2
(159) dlgap1: discs, large (Drosophila) homolog-associated
protein 1
(160) dscam: Down syndrome cell adhesion molecule
(161) ecel1: endothelin converting enzyme-like 1
(162) efnb1: ephrin-B1
(163) eml5: echinoderm microtubule associated protein
like 5International Journal of Alzheimer’s Disease 53
(164) epha3: EPH receptor A3
(165) epha5: EPH receptor A5
(166) epha7: EPH receptor A7
(167) ephb3: EPH receptor B3
(168) erbb4: v-erb-a erythroblastic leukemia viral onco-
gene homolog 4 (avian)
(169) evl: Enah/Vasp-like
(170) exoc5: exocyst complex component 5
(171) fzd9: frizzled homolog 9 (Drosophila)
(172) GABARAP: GABA(A) receptor-associated protein
(173) gabarapl2: GABA(A) receptor-associated protein-
like 2
(174) gabrr3: gamma-aminobutyric acid (GABA) A recep-
tor, alpha 3
(175) gcgr: glucagon receptor
(176) gng7: guanine nucleotide binding protein (G pro-
tein), gamma 7
(177) got1: glutamic-oxaloacetic transaminase 1, soluble
(aspartate aminotransferase 1)
(178) got2: glutamic-oxaloacetic transaminase 2, mito-
chondrial (aspartate aminotransferase 2)
(179) gprc6a: G protein-coupled receptor, family C, group
6, member A
(180) gria1: glutamate receptor, ionotropic, AMPA 1
(181) grid2: glutamate receptor, ionotropic, delta 2
(182) grik4: glutamate receptor, ionotropic, kainate 4
(183) grin2a: glutamate receptor, ionotropic, N-methyl D-
aspartate 2A
(184) grip1: glutamate receptor interacting protein 1
(185) gripap1: GRIP1 associated protein 1
(186) grk6: G protein-coupled receptor kinase 6
(187) opa1: optic atrophy 1 (autosomal dominant)
(188) pak1: p21 protein (Cdc42/Rac)-activated kinase 1
(189) pak2: p21 protein (Cdc42/Rac)-activated kinase 2
(190) pawr: PRKC, apoptosis, WT1, regulator
(191) phactr1: phosphatase and actin regulator 1
(192) pip5k1c: phosphatidylinositol-4-phosphate 5-kinase,
type I, gamma
(193) plcb1: phospholipase C, beta 1 (phosphoinositide-
speciﬁc)
(194) pld3: phospholipase D family, member 3
(195) ppﬁa3: protein tyrosine phosphatase, receptor type,
f polypeptide (PTPRF), interacting protein (liprin),
alpha 3
(196) ppid: peptidylprolyl isomerase D
(197) ppp2cb: protein phosphatase 2 (formerly 2A), cat-
alytic subunit, beta isoform
(198) ppp2r2a: protein phosphatase 2 (formerly 2A), regu-
latory subunit B, alpha isoform
(199) prkar2b: protein kinase, cAMP-dependent, regula-
tory, type II, beta
(200) prnp: prion protein
(201) ptk2: PTK2 protein tyrosine kinase 2
(202) ptn: pleiotrophin
(203) ryr3: ryanodine receptor 3
(204) sdcbp: syndecan binding protein (syntenin)
(205) sh3gl3: SH3-domain GRB2-like 3
(206) shank2: SH3 and multiple ankyrin repeat domains 2
(207) sirt2: sirtuin (silent mating type information regula-
tion 2 homolog) 2 (S. cerevisiae)
(208) smu1: smu-1 suppressor of mec-8 and unc-52 hom-
olog (C. elegans)
(209) soat1: sterol O-acyltransferase 1
(210) sstr2: somatostatin receptor 2
(211) ssx2ip: synovial sarcoma, X breakpoint 2 interacting
protein
(212) stau1: staufen, RNA binding protein, homolog 1
(Drosophila)
(213) stmn3: stathmin-like 3
(214) strn: striatin, calmodulin binding protein
(215) syn1: synapsin I
(216) syngap1: synaptic Ras GTPase activating protein 1
homolog (rat)
(217) synj2bp: synaptojanin 2 binding protein
(218) synpo: synaptopodin
(219) syt11: synaptotagmin XI
(220) trap1: TNF receptor-associated protein 1
(221) trpc2: transient receptor potential cation channel,
subfamily C, member 2 (pseudogene)
(222) trpc4: transient receptor potential cation channel,
subfamily C, member 4
(223) trpc5: transient receptor potential cation channel,
subfamily C, member 5
(224) wnt7a: wingless-type MMTV integration site family,
member 7A
(225) tuba1a: tubulin, alpha 1a
(226) vipr2: vasoactive intestinal peptide receptor 2
(227) trak2: traﬃcking protein, kinesin binding 2
(228) snx17: sorting nexin 17
(229) psd: pleckstrin and Sec7 domain containing
(230) ppp2r2b: protein phosphatase 2 (formerly 2A), regu-
latory subunit B, beta isoform
(231) ppp1r9b: protein phosphatase 1, regulatory (inhibi-
tor) subunit 9B54 International Journal of Alzheimer’s Disease
(232) grm5: glutamate receptor, metabotropic 5
(233) grk5: G protein-coupled receptor kinase 5
(234) grin2b: glutamate receptor, ionotropic, N-methyl D-
aspartate 2B
(235) grik1: glutamate receptor, ionotropic, kainate 1
(236) grasp: GRP1 (general receptor for phosphoinositides
1)-associated scaﬀold protein
(237) gipc1: GIPC PDZ domain containing family, mem-
ber 1
(238) dpysl4: dihydropyrimidinase-like 4
(239) dpysl3: dihydropyrimidinase-like 3
(240) dgkb: diacylglycerol kinase, beta 90kDa
(241) ddn: dendrin
(242) cit: citron (rho-interacting, serine/threonine kinase
21)
(243) grm4: glutamate receptor, metabotropic 4
(244) ctnnd2: catenin (cadherin-associated protein), delta
2 (neural plakophilin-related arm-repeat protein).
I.
Receptor-speciﬁc protein interaction networks in lipid raft
extracts from control animals. IPA-generated receptor-
speciﬁc protein lists from control lipid raft samples were
clustered into coherent functional interaction networks.
Focus molecules (BOLD in “molecules in network”) denote
the proteins that are present in the predicted reaction
network as well as the experimental input protein set.
T h ef o l l o w i n ga r ed i ﬀerent types of interaction net-
works.
(1) Control: cell signaling, nucleic acid metabolism,
small molecule biochemistry; score: 32; focus molecule: 15;
molecules in network: ADCY, Akt, Beta-Arrestin, CD4,
CHRM5, CNTFR,C r e b ,EDNRB, ERK1/2, FSHR, GABBR1,
GCGR, Gpcr, GPR3, GPR12, GPR20, GPR34, GPR65,
GPR161, GRM5, hCG, Mapk, OPRD1, OVGP1, P2RY6,
P2RY11, PDGF BB, PI3K, Pkc(s), PTGER2, SFRP4, SSTR2,
THBD, UNC5B, VIPR2.
(2) Control: infectious disease, antigen presentation,
antimicrobial response; score: 31; focus molecule: 15;
molecules in network: Ap1, CHRNB3, CHRNB4, CHRNG,
CLDN4, CNR1, CXADR, G alphai, Ifn, IFN Beta, IFN
TYPE 1, IgG, IKK (complex), IL-1R/TLR, IL12 (complex),
Il12 (family), Interferon alpha, IRAK, IRF, NFkB (complex),
NRG, OSMR,P 3 8M A P K ,SMO, TACR1, Tlr, TLR3, TLR4,
TLR5, TLR6, TLR9, TSHR, Ubiquitin.
(3) Control: cellular development tumor morphology, cell
death; score: 18; focus molecule: 10; molecules in net-
work: APOL5, ARR3, ARTN, ASB16, Cadherin (E,N,P,VE),
CELSR2, CELSR3, CTNNB1, CTNNβ-CDHE/N, DAG1,
EVX1, FZD9,G D N F ,GFRA1, GFRA3,G L T S C R 1 ,GPRC6A,
GRB2, GRM4, HRH4, KCNN1, OPN1LW, OPN1SW,
PALM2-AKAP2, PHACTR2, PRICKLE3, PTH2R,S A G ,
SEPN1, SHROOM2, SRC.
(4) Control: carbohydrate metabolism; score: 2; focus
molecule: 1; molecules in network: CLEC4A, IL13.
(5) Control: cell-to-cell signaling and interaction, nervous
system development and function; score: 2; focus molecule: 1;
molecules in network: PRPH2,R O M 1 .
(6) Control: protein synthesis, molecular transport, protein
traﬃcking; score: 2; focus molecule: 1; molecules in network:
GABRR3,P R K C Z ,S Q S T M 1 .
J.
Receptor-speciﬁc protein interaction networks in lipid raft
extracts from 3xTgAD animals. IPA-generated receptor-
speciﬁc protein lists from 3xTgAD lipid raft samples were
clustered into coherent functional interaction networks.
Focus molecules (BOLD in “molecules in network”) denote
the proteins that are present in the predicted reaction
network as well as the experimental input protein set.
T h ef o l l o w i n ga r ed i ﬀerent types of interaction net-
works.
(1)3xTgAD:metabolicdisease,endocrinesystemdisorders,
cell signaling; score: 45; focus molecule: 18; molecules in
network: ADCYAP1R1,A p 1 ,CD36, CD86, CNR1,C r e b ,
CREB-NFkB, CXADR, ERK, ERK1/2, GABBR1, GPR56,
hCG, HTR4, HTR2C, IGF1R, IGF2R, IgG, IL12 (complex),
IL1R2, Insulin, Jnk, LDL, LIFR, LRPAP1, Mapk, MIP1,
NFkB (complex), NPR2, OVGP1, P38 MAPK, Pkc(s), TLR5,
TNFRSF14, TSHR.
(2) 3xTgAD: cell signaling, nucleic acid metabolism,
small molecule biochemistry; score: 13; focus molecule: 7;
moleculesinnetwork:AATK,ABR,AKR1A1,BPI,CACNG5,
CRYM, cyclic AMP, CYP26B1, DHRS3, DLG4, GH1, His-
tone h3, HSD17B11, KCTD11, KIF3C, LAP3, LPHN1,
LPHN2, OPN1LW, OPN1SW, P2RY11, PTCH1, PTH2R,
RLN3, RN5S, ROBO1,R O S 1 ,RXFP1, RXFP2, SERPINB8,
TMEM49, TNF, USP3.
(3) 3xTgAD: cell signaling, cellular function and main-
tenance, molecular transport; score: 2; focus molecule: 1;
molecules in network: CFTR, FREQ, IL1RAPL1, MYD88.
(4) 3xTgAD: cell-to-cell signaling and interaction, cellular
function and maintenance, cellular movement; score: 2; focus
molecule: 1; molecules in network: GPR1, PAX3, PRDM5.
(5) 3xTgAD: behavior, digestive system development and
function, cell morphology; score: 2; focus molecule: 1;
molecules in network: NPY, NPY5R, PPY, PYY, SSB.
(6) 3xTgAD: cancer, reproductive system disease, gene
expression; score: 2; focus molecule: 1; molecules in network:
FOS, MIR103-1, MIR103-2, MIR107, MIRLET7G, MYC,
OMG, RHOA, RTN4R.
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